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Human Papillomavirus and its Impact on Vulnerable Populations
Harpriya Kaur, Ph.D.
University of Nebraska, 2016

Supervisor: Shinobu Watanabe-Galloway, Ph.D.

Human papillomavirus (HPV) is the most common sexually transmitted infection. The
infection is higher in certain racial/ethnic groups and those who are
immunocompromised including pregnant women. Because immune system is
suppressed during pregnancy, women are at higher risk of various types of infection
including HPV, a known risk factor for pregnancy complications. However, its role in
adverse pregnancy outcomes is unclear. Another high risk population is Northern Plain
American Indian. In the Northern Plains region, American Indian women have
significantly higher rate of HPV infection than white counterparts and are infected with
different types of HPVs than the general population. Because the prevalence of infection
with these HPV types are higher in American Indian population, the impact of HPV
vaccine on cervical cancer cases is expected to vary from other populations.
The objectives of this study were to explore the relationship between HPV infection and
adverse pregnancy outcomes and to estimate the number of cervical cancer cases
reduced by 9-valent vaccine among Northern Plains American Indian women. To
achieve these objectives, an analysis was conducted using Pregnancy Risk Assessment
and Monitoring System (PRAMS), in a population-based survey of pregnant women from
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2004 to 2011. In addition, a hospital-based data analysis was conducted on women who
delivered a live birth at Nebraska Medical Center between 2012 and 2014. HPV infection
was diagnosed on the basis of a Pap test report. PROC SURVEYLOGISTIC (or logistic)
procedures were used to examine the relationship between HPV infection and adverse
pregnancy outcomes such as low birth weight, preeclampsia, preterm birth, and
premature rupture of membrane. Additionally, to project the impact of 9-valent vaccine
on the American Indian population, a compartmental deterministic model was
developed. Our study found low prevalence of HPV infection among pregnant women.
Significant associations were found between HPV infection and adverse pregnancy
outcomes, including preeclampsia, preterm birth, and low birth weight. In addition, this
study found that the 9-valent vaccine is associated with a greater reduction of cervical
cancer cases among white women than among American Indian women. Overall, this
study fills various gaps in knowledge about the impact of HPV infection on two
vulnerable populations.
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CHAPTER 1
INTRODUCTION

1.1. Human Papillomavirus Overview
1.1.1 Discovery of HPV
Human papillomavirus (HPV) is a small (50–55 nm in diameter), nonenveloped,
double-stranded, circular DNA virus that infects the skin or mucosal epithelium.
Throughout evolution, diseases associated with HPV infection were well documented.
Greek and Roman physicians were well aware of skin and genital warts. In those days,
the term condyloma (a word of Greek origin), meaning “a round swelling around the
anus,” was used for genital warts.1 In 1842, an Italian physician, Rigoni-Stern, analyzed
the death certificates of individuals who died as a result of cancer in Verona during the
period 1760–1839. He found that deaths related to cervical cancer were rare among
virgins and nuns, as compared to married women or widows. This study indicated the
possible association of cervical cancer with sexually transmitted disease.1
Since ancient times, genital warts have been considered a result of sexual
promiscuity and have been regarded as infectious. However, their link to sexual behavior
was not firmly established until 1954. At the end of the 19th century, the infectious nature
of common warts was confirmed by Payne. Their infectiousness was also confirmed by
Heidingsfield, who described a prostitute who had developed condyloma lesions on her
tongue as a result of oral sex.2 In 1907, Ciuffo demonstrated the infectious nature of
human warts by using a cell filtrate of a common wart to transfer the infection. 3 This
experiment also established the viral nature of the responsible agent.
By the end of the 1960s, herpes simplex virus type 2 was thought to be the
cause of cervical cancer, but further studies failed to confirm it.4 The interest of
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researchers in HPV arose when HPV was visualized in HPV warts with the help of
electron microscopy. The role of HPV in the development of cervical cancer was
postulated and analyzed by Harald zur Hausen. In 1983–1984, the first HPV types, 16
and 18, were isolated from cancer biopsies of the cervix and were later cloned.5 In
2008, zur Hausen was awarded the Nobel Prize for Medicine, for the discovery of the
infectious etiology of cervical cancer.
1.1.2 High- and Low-Risk HPV Types
During the 1970s, the multiplicity of HPV types became apparent. The plurality of
HPV was established by a series of research studies by zur Hausen and his colleagues
as well as by Gerard Orth’s group in Paris. These researchers discovered the first four
HPV types in cutaneous warts and numbered them 1 through 4.6-8 Soon, serological
evidence was provided to support this plurality, because there seemed to be no link
between HPV types 1–4 and the HPV types found in condylomata accuminata, laryngeal
papillomas, or any of the malignant tumors tested.9 For the identification of new
papillomavirus types, the most conserved region within the genome, L1 ORF, is used. If
the DNA sequence of the L1 ORF differs by more than 10% from the closest types and
the complete genome is cloned, then a new papillomavirus is recognized.10 Differences
in homology ranging between 2% and 10% define a subtype, whereas those of less than
1% define a variant.11
More than 100 types of HPV have been identified, and 40 of those types infect
the genital tract.12 HPV types are categorized as high-risk and low-risk groups. High-risk
types are oncogenic and more persistent than low-risk types. High-risk types cause
cervical intraepithelial lesions and cancers of the cervix, anus, head and neck, penis,
and vulva. High-risk types currently include HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 69, 73, and 82. High-risk types 16 and 18 are responsible for 70% of
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cervical cancers. The remaining types are considered to be low risk because they do not
cause cancer. These low-risk types can cause skin warts, or condylomata acuminata, on
or around the genitals or anus. 13
1.1.3 Structure and life cycle of HPV
The HPV viral genome consists of approximately 8000 base pairs14 and is
organized into three regions: the early region I, which incorporates E1, E2, and E4-E7
and constitutes 50% of the genome; the late region (L), consisting of the L1 and L2
region, which forms 40% of the genome; and the genomic regulatory region, which
represents 10% of the genome.15 The early region is involved in the DNA replication (E1,
E2), transcription (E5), and cell transformation (E5, E6, and E7), while the late region
encodes structural proteins of the virion (Figure 1).16

4

Figure1 Structure of HPV. Adapted from Malik H, et al. 2013.17

The papillomavirus structure does not contain any enzymes, lipids, or
saccharides. The virus becomes inactivated at 70° Celsius, is stable at a pH of 3–7, and
is killed after 30 minutes if kept at a temperature above 50° Celsius. HPV is resistant to
solvents, acids, and X-rays.10 Because papillomaviruses initiate productive infections
only within stratified epithelia of the skin, oral cavity, and anogenital tract, they are
considered highly epitheliotropic. The life cycle of the virus is thought to begin when the
basal epithelium cells become infected, probably at the site of injury.
1.1.4 Life cycle of HPV
The life cycle of HPV (Figure 2) begins when infecting viral particles reach the
germinal cells in the basal layer through a small abrasion to the mucosa during sexual
intercourse.18 The virus starts binding and then undergoes a conformational relaxation
and enters the basal cell by endocytosis. This process of endocytosis takes about 2 to 4
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hours. As soon as the virus enters the basal cells, the protein envelope is decomposed,
and the viral DNA moves to the nucleus. Within the nucleus, the viral DNA exists in
episomes but is separate from the host DNA. This is usually linked with the presence of
low virus copy numbers and no cytological abnormalities.19
In the maturing squamous epithelium, viral assembly occurs as the virus
amplifies its DNA to high copy numbers and synthesizes capsid proteins.20 This in turn
results in the release of amplified virus from terminally differentiated squamous cells.
Next, the HPV early genes E6 and E7, which are required for malignant transformation,
are produced in both the lower and the upper layers of the epithelium. The HPV L1 and
L2 proteins form the viral capsid. These proteins are produced and assembled into
virions that stimulates the immune response and are released only in the terminally
differentiated outer epithelial layer.21 In very few scenarios, persistence, integration, and
transformation occur. Usually, in order to integrate into the host cell DNA, the HPV DNA
disrupts the E2 gene, enabling the circular genome to become linear. This disruption of
E2 gene results in cessation of viral synthesis and also activates the deregulation of E6
and E7. The E6 gene binds and degrades p53 while the E7 gene inactivates the
retinoblastoma gene. Retinoblastoma and p53 are both tumor suppressor genes, and
inactivation of these genes causes genetic instability, prevention of apoptosis, and
uncontrolled cellular proliferation, which may result in cancer.21
Unlike other infections, the life cycle of HPV is actually hidden from the host
immune system. There is no systemic response, no viremia, and no blood-borne phase.
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Figure 2. Life cycle of HPV. Adapted from Moody CA, et al., 2010 22

1.1.5 HPV Risk Factors
Sexual activity is one of the major risk factors for acquiring HPV infection. Having
multiple sex partners is associated with greater risk of infection. However, having sex
with only one partner does not entirely eliminate the risk of procuring the infection.23
Some of the other risk factors for HPV include co-infection with other sexually
transmitted diseases, smoking, and a weakened immune system. In addition, use of
hormonal contraceptives for longer duration is believed to be associated with increased
risk of infection.24
Age is another major risk factor, in that HPV infection is most common in
sexually active men and women who are 21-24 years old. Although this association
could be the result of risky behaviors among this age group, evidence indicates this
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association may have biological causes.23 Squamous cells are the most common type in
adults, whereas columnar and metaplastic cells are predominant in adolescents.
Neonates are born with an abrupt squamo-columnar junction present on the ectocervix.
At the time of puberty, the columnar epithelium gradually transforms into the squamous
epithelium. This process is known as squamous metaplasia. During this process, large
areas of transitional squamous, glandular, and metaplastic cells are formed, all of which
support HPV replication.25
1.1.6 Transmission of HPV
HPV is usually transmitted during sexual intercourse through contact with
infected cervical, vaginal, vulvar, penile, or anal epithelium. However, it can also be
transmitted through nonpenetrative sexual contact, such as oral-genital or digital-genital
contact.26 Inconsistent use of condoms also increases the risk of transmission of the
virus. However, condom use is only 70% effective in preventing the transmission of HPV
because there is still contact with genital skin.13
In addition to horizontal transmission, rarely vertical transmission of HPV from
mother to fetus can also occur.27 When transmitted vertically, HPV can cause juvenileonset recurrent respiratory papillomatosis and laryngeal papillomatosis in infants.28 A
study conducted by Tenti et al. investigated HPV type-specific concordance between
mother-infant pairs and observed that HPV types carried by HPV-positive newborns
were identical to those found in their mothers.29
1.1.7 Infectivity and Incubation
The probability of transmission of HPV infection per sexual act is independent of
the type of HPV and is quite high. A previous study found that genital warts are highly
infectious because of the high viral load, and up to 65% of sexual contacts develop an
infection.30 The incubation period of genital warts is usually 3 weeks to 8 months, with an
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average of 2.9 months.30 Longitudinal studies have indicated that most HPV infections
are transient and no longer detectable within 1–2 years.31 High-risk infections usually
persist longer than low-risk infections.31 In high-risk infections, HPV 16 seems to persist
longer than other types. This indicates that high-risk HPV would spread at a greater rate
than would low-risk HPV in populations with similar sexual patterns and
transmissibility.26
HPV infection can be in a latent, subclinical, or clinical phase. During the latent
phase, the infection is inactive, there are no noticeable symptoms, and the infected site
remains cytologically normal. In the subclinical phase, HPV infection is generally
transient, and colposcopically detectable lesions develop that are usually low-grade
cervical intraepithelial neoplasia (CIN)1.32 In most women the infection resolves by itself
because of cell-mediated immunity. About 10% to 15% of women whose infection does
not clear naturally remain HPV DNA positive and have persistent viral infection.23 There
is not yet a clear definition of persistence. However, follow-up strategies targeting
abnormalities lasting 1–2 years seem to distinguish infections and associated lesions
that put an individual at a greater risk of transient infections.33 A study conducted by
Moscicki et al. indicates that the risk of developing CIN3 is 14 times higher among
women who have had at least three positive tests for high-risk HPV, compared to
women with negative HPV test results.34 Older women generally have higher persistence
of HPV infection than younger women. One reason could be that the acquired infection
is less likely to clear naturally in older women.35 Additionally, this greater persistence
could be due to the gradual predominance of longer-duration infection from earlier
exposures, in comparison with more recent and more transient infection.35

9
1.2 HPV and Cancer
1.2.1 HPV and cervical cancer
Virtually all cervical cancers are caused by HPV infection.36 As mentioned earlier,
HPV types 16 and 18 are responsible for nearly 70% of cervical cancer cases. The
development of cervical cancer occurs in a series of four steps (Figure 1): HPV
transmission, viral persistence, progression of a clone of persistently infected cells to
pre-cancer, and invasion. Persistent HPV infection results in changes in the cervical
cytology of squamous epithelia that may progress to noninvasive CIN2/3 and, many
years later, to invasive cervical cancer.36
Natural History of Cervical Cancer

Figure 3: Steps in the development of cervical cancer. Adapted from Schiffman et al,2007.33
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HPV infection tends to cause cancer in areas known as the transformation zone.
In this zone, one type of epithelium contacts and gradually replaces another by
transforming itself through a process called metaplasia. Some examples of
transformation zones that are prone to HPV infection include the cervix, anus, and
tonsils. In the cervix, the transformation zone is the area of the columnar epithelium that
transforms into the squamous epithelium.23 The above process is comparatively inactive
in children but becomes quite active around puberty.
In all HPV-related cancers, the stage of malignancy is set when HPV DNA
integrates into the host cell genome. Viral oncoproteins E6 and E7 are released during
the process. These proteins further bind and degrade host tumor suppressor genes
TP53 and RB1.37 Although HPV infection can cause various types of cancers, it is a
primary concern for cervical cancer. Genotypes that cause cervical cancer include HPV
51 (alpha 5); HPV 56 and HPV 66 (alpha 6); HPV 18, HPV 39, HPV 45, and HPV 59
(alpha 7); and HPV 16, HPV 31, HPV 33, HPV 35, HPV 52, and HPV 58 (alpha 9).38 All
HPV genotypes that cause cervical cancer belong to the alpha genus.
Women who have a persistent infection of high-risk HPV types are at higher risk
of developing high-grade intraepithelial disease and invasive cervical cancer.39 High-risk
HPV DNA can be detected in nearly 99.7% of squamous cell carcinomas40 and in about
94% to 100% of cervical adenocarcinomas and adenosquamous carcinomas.41 Cervical
squamous cell carcinomas are the most common histological types of cervical cancer
that develop from pre-existing noninvasive squamous precursor lesions, also known as
cervical intraepithelial neoplasias (CINs) or squamous intraepithelial lesions (SILs).42
Lesions are histologically classified based on the atypia of epithelial cells that continue to
increase from the lower parabasal layers of squamous epithelium up to the whole
epithelium. CIN1 and SIL correspond to mild dysplasia, CIN2 to moderate dysplasia, and

11
CIN3 to severe dysplasia.42 CIN2 and CIN3 are at high risk of progression or of cancer
and are thus considered its precursor. The natural history of cervical carcinogenesis is
shown in Figure 4.

Figure 4: Natural history of cervical carcinogenesis. Adapted from Juckett G et al.,
2010.37
Adenocarcinoma in situ (ACIS) and adenocarcinoma of the cervix (AdCA) are
often not detected by Pap Smear, as they are located higher in the cervical canal and
consequently are less accessible to the brush. Because of this, it might be beneficial to
add testing for high-risk (HR)-HPV to the cervical cancer screening program in order to
detect ACIS and AdCA. 41
1.2.2 HPV and Penile Cancer
HPV plays an important role in the development of penile cancer. Although penile
cancer is uncommon in developed countries, the incidence is much higher in developing
countries such as Uganda (incidence, 4.4 per 100,000) or Paraguay (incidence, 4.2 per
100,000).43 There are several different histological types of penile carcinomas. Most of
the penile tumors are well-differentiated, keratinizing squamous cell carcinomas.
Verrucous carcinoma is the second most common tumor subtype, and its variants are
basaloid carcinoma and warty carcinoma. About 80% to 100% of basaloid and warty
penile cancers are HPV positive. However, only a small fraction of verrucous penile
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carcinomas are the result of HPV infection. Similar to cervical cancer, high-risk HPV
expresses oncoproteins E6 and E7, which bind to p53 and inactivate the tumor
suppressor protein Rb.44
The pre-cancerous penile condition is known as penile intraepithelial neoplasia
(PIN). Histologically, PIN is similar to CIN. However, the natural history of penile lesions
is unknown, and therefore there are no standard protocols for diagnosis or management
of penile cancer.45
1.2.3 HPV and Head and Neck Cancers
Head and neck cancer (HNC) is the fifth most common cancer worldwide
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and the

eighth most common cause of cancer mortality.47 HNC is a heterogeneous group of
cancers, including cancers of the lip, oral cavity, nose, paranasal sinuses, oropharynx,
nasopharynx, hypopharynx, larynx, salivary glands, and esophagus.48 Although tobacco
and alcohol are considered the two major risk factors for HNC49,5050 about 25% of HNCs
are associated with high-risk HPV. HPV-positive HNCs are usually less differentiated
and of basaloid type.51 Although laryngeal and hypopharyngeal cancers are associated
with smoking and alcohol consumption, oropharyngeal cancers involving tonsils, the
pharyngeal wall, and the tongue base are mostly associated with HPV infection.52,53 The
mechanisms of HPV oncogenesis in the oropharynx seems to be similar to those of
cervical cancer. The differences are related to the anatomic, cellular, and immune
environments. For instance, there is no transformation region in the oropharynx like that
in the uterine cervix, in which malpighian epithelium of the exocervix joins the
unistratified glandular epithelium of the enocervix, where most of the cancer develops. In
the oropharynx, the tonsil is the most commonly affected anatomical region. So far, the
exact mechanism of HPV infection in the nongenital region is unclear. However, easy
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access to tonsillar crypts that have a favorable microenvironment may be the reason for
the higher prevalence of HPV in this region.
1.2.4 HPV and Anal Cancer
Most of the anal squamous cell carcinomas are caused by HPV infection. Anal
carcinoma is a rare malignancy with an incidence of 0.3 to 0.8 per 100,000 among men
and 0.5 to 1.0 per 100,000 among women. However, since the 1970s there has been a
2% increase in the incidence of anal cancer in both men and women.54 The exact reason
for the increase is still unclear, but it may be the result of a change in sexual behavior.54
Overall, the incidence of anal cancer is usually higher among men having sex with men
and individuals who are immunosuppressed.55
Invasive anal carcinoma develops from anal intraepithelial neoplasia (AIN).
Similar to cervical intraepithelial neoplasia (CIN), AIN is classified into three categories:
AIN1, AIN2, and AIN3. In AIN1, the lower third of the epithelium is affected, while in
AIN2 and AIN3, two thirds of the epithelium and the entire epithelium, respectively, are
affected.
1.2.5 Risk Factors for HPV-Related Cancer
Tobacco Smoking
Smoking is one of the risk factors for HPV-related cancers. One possible
mechanism by which smoking may contribute to cervical carcinogenesis is that there is
direct exposure of DNA in the cervical epithelial cells to nicotine and cotinine.56,57
Another proposal is that exposure of DNA in cervical epithelial cells to metabolic
products resulting from reactions among other components of cigarettes, such as
aromatic polycyclic hydrocarbons and aromatic amines, may result in
carcinogenesis.56,57 Studies have demonstrated measurable amounts of cigarette
constituents and their metabolites such as benzopyrene,58 nicotine, and nicotine-derived
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nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone are found in cervical mucus
and DNA adducts in cervical tissues.59 HPV infection genome amplification is increased
by benzopyrene, which may in turn increase the probability of viral DNA integration into
the host genome, which is a crucial step in the development of cervical cancer.60
Additionally, aberrant HPV-induced methylation might be another mechanism of
smoking-related cervical carcinogenesis. In vitro studies in untransformed and
transformed cell lines have shown that there are changes in the expression of DNA
methyltransferases, DNMT1, DNMT3A, and DNMT3B, when the cell lines are exposed
to nicotine or tobacco smoke for a short period. Aberrant methylation of p16, a tumor
suppressor gene, is strongly associated with current smoking in women with squamouscell cervical cancers and high-grade CIN.61 Furthermore, tobacco smoking is believed to
facilitate the acquisition or persistence of an HPV infection through a reduced number of
Langerhans cells and CD4 lymphocytes,62,63 which are markers of local immune
response in the cervix.64,205
Immunosuppression
Previous studies have found that the prevalence of HPV infection is higher
among those with immunosuppression.65,66 T-helper cells are part of the defense
mechanism that acts against HPV-transformed cells. Individuals with
immunosuppression have a lower number of T-helper cells, predisposing them to HPV
infection. This is one of the major reasons that Human immunodeficiency virus (HIV)positive individuals, pregnant women, and organ transplant recipients are at greater risk
of HPV infection. Studies of HIV-positive women suggest that alteration in cell-mediated
immunity plays a vital role in the development and progression of CIN, specifically in
individuals with lower CD4+ T cell counts or with high HIV RNA plasma levels.67-69
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Use of Oral Contraceptives
There has been a long debate on the risk of cervical cancer among users of oral
contraceptives. A pooled analysis conducted by the International Agency for Research
on Cancer (IARC) to study the association between oral contraceptives and risk of
cervical cancer among HPV-positive women revealed no excess risk among women who
had used oral contraceptives for ≤5 years. However, the study found that the relative risk
of cervical cancer was 2.8 for those who had used oral contraceptives for 5–9 years and
4.0 for those who had used it for ≥10 years.70 It is believed that oral contraceptives favor
the progression of pre-cancerous lesions to cervical cancer.71
Parity
High parity has been associated with cervical cancer. The independent role of
high parity has been confirmed by case-control studies of cervical carcinoma.72-74 A
study conducted by IARC revealed that women with seven or more full-term pregnancies
had 4 times the risk of developing squamous-cell carcinomas, compared to nulliparous
women.74 Similarly, another study conducted in Costa Rica showed an increased risk of
HSIL/CC with increasing number of live births.75
During pregnancy, the level of estrogens and progesterone in blood increases
progressively.76 The change in blood hormone levels results in a change in the junction
between the squamous and columnar epithelium occurring during pregnancy. In early
pregnancy, eversion of columnar epithelium onto the ectocervix begins and is more
noticeable during the second and third trimesters. Since cervical ectopy increases with
number of full pregnancies, it is believed that high parity might increase the risk of
cervical carcinoma77 because it maintains the transformation zone on the exocervix for a
number of years, thus assisting the direct exposure to HPV.74
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1.2.6 Epidemiology of HPV and HPV-Related Cancers in the United States
HPV is the most common sexually transmitted infection and affects nearly 80% of
women at some point in their lives.78 In 2010, the prevalence of HPV among women in
age group 18-59 years was 42.7% in the United States.79 Although the prevalence of
HPV varies geographically, the prevalence of both low-risk and high-risk HPV is highest
in the age group of 21–24 years, compared to other age groups.79 Additionally, the
incidence of HPV infection is higher in certain racial/ ethnic groups. In the United States,
non-Hispanic blacks have the highest prevalence of HPV (63.1%), followed by Mexican
Americans (40.1%).79 Furthermore, a study showed an HPV prevalence of 50.8% among
women who had ≥3 lifetime partners. Moreover, the prevalence was found to be 74%
among women who had >2 sexual partners in the past year.79
HPV among Northern Plains American Indians
The Northern Plains region of the United States comprises Iowa, South Dakota,
North Dakota, Minnesota, and Nebraska. In the Northern Plains, American Indian
women have a significantly higher rate of HPV infection than their white counterparts
and are infected with different types of HPV than the general population.80 The incidence
rate among Northern Plains American Indians is 11.3 per 100,000, which is 1.7 times
higher than among non-Hispanic whites (7.5 per 100,000). 81
Despite the fact that cervical cancer is preventable, it is the leading cause of
cancer death among American Indian women. A study conducted by the Aberdeen Area
Indian Health Services reported an age-adjusted cervical cancer mortality rate of 15.6
per 100,000, five times the rate reported in the general U.S. population (3 per
100,000).82 There is also disparity in the cervical cancer survival rates among American
Indian women. In 2010, the 5-year survival rate for cervical cancer was reported to be
81% among American Indian women, compared to 84% among white women.83
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One of the major reasons for the disparity could be the higher prevalence of HPV
types other than HPV 16 and 18, which are not covered by the two established vaccines
(bivalent and quadrivalent). This explanation is supported by studies of infections among
American Indian women that showed a broad variety and different patterns of HPV
types, including a higher prevalence of mixed HPV infections.80,84
1.2.7 Burden of HPV-related cancers
Worldwide, cervical cancer is the fourth most common cancer in women and the
seventh overall.85 However, the majority of the burden of cervical cancer is in developing
nations. Cervical cancer is the most common cancer in women in Eastern and Middle
Africa.85 In 2012, there were an estimated 528,000 new cases and 266,000 deaths from
cervical cancer worldwide, accounting for 7.5% of all female cancer deaths.85 American
cancer society estimates that in 2016 about 12,990 new cases of invasive cervical
cancer will be diagnosed and 4120 women will die from cervical cancer.86
Annually, there are approximately 97,215 cases of HPV noncervical cancers
among men and women worldwide, including 50,780 cancers among men (13,485 anal
cancers, 26,775 oropharyngeal cancers, and 10,520 penile cancers) and 46,435 cancers
among women (14,787 anal cancers, 6,048 oropharyngeal cancers, and 25,600
vaginal/vulvar cancers).87,88

1.3. Impact of HPV on Pregnancy
1.3.1 HPV among pregnant women
Pregnancy is a known risk factor for new or recurrent HPV infections. 89 In the
state of pregnancy, the levels of progesterone are elevated, causing an increase in the
replication of HPV DNA. HPV infection can increase the rate of trophoblast cell death,
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which can further impair the extravillous trophoblast invasion into the maternal uterine
wall. This could result in placental dysfunction and other adverse pregnancy outcomes.90
HPV-related pregnancy outcomes
Adverse pregnancy outcomes that have been associated with bacterial or viral
infection include preeclampsia, premature rupture of membrane (PROM), preterm birth,
and low birth weight. However, little is known about their association with HPV infection.
Preeclampsia is characterized by high blood pressure and signs of damage to
other organ systems during pregnancy and is a major cause of maternal and fetal
mortality and morbidity.91 Preeclampsia generally begins after 20 weeks of pregnancy in
a woman whose blood pressure had been normal. It complicates about 3% to 6% of
pregnancies, and if left untreated, it can lead to serious and even fatal complications for
both the mother and the unborn baby.92 Although the exact mechanism of preeclampsia
is unknown, one suggested mechanism is defective placentation with reduced invasion
of fetal extravillous trophoblast cells, in addition to reduced remodeling of maternal
uteroplacental spiral arteries.93 Additionally, it is believed that systemic inflammation—as
illustrated by exaggerated leukocytosis, extensive platelet activation, and increased
complement activation in preeclampsia—plays a vital role in the development of
preeclampsia.94-96 It is widely accepted that cervicovaginal HPV infection causes chronic
inflammation that may result in detrimental pregnancy outcomes. However, its
association with preeclampsia is still elusive. Some of the known risk factors for
preeclampsia include pre-existing hypertension, diabetes, older age, multiple
pregnancies, and obesity.97
Another adverse pregnancy outcome that may be associated with HPV infection
is PROM, the rupture of fetal membrane before the onset of labor. It occurs in nearly 3%
of pregnancies and can lead to respiratory distress syndrome, neonatal sepsis, umbilical
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cord prolapse, placental abruption, and fetal death. It is a multifactorial disorder, but
infection is one of the major causes of membrane damage. One possible mechanism for
rupture as a result of infection is that the cytokines and metalloproteases (especially
matrix metalloproteinase [MMP]-2) released by an organism can degrade collagen and
also weaken the fetal membrane, resulting in membrane damage. Few studies have
examined the association of PROM and MMP with HPV infection. However, because
HPV in human invasive cervical carcinoma cell lines results in an increase in MMP-2
expression, HPV may play an important role in regulation of MMP.98
Preterm birth is one of the leading causes of infant death and occurs in about
12% of all pregnancies in the United States.99 Although the survival rate of preterm-birth
babies is high, they are at increased risk of neurodevelopmental impairments and
respiratory and other complications.100 Some of the risk factors for preterm birth include
maternal demographic characteristics such as low socioeconomic status, low and high
maternal ages, infection, nutritional status, and pregnancy history.100 Intrauterine
infections account for 25% to 40% of preterm births, but this may be an underestimate
since intrauterine infections can be difficult to detect with conventional techniques.
Intrauterine infections activate the innate immune response that is believed to lead to
preterm births.101-103 In addition to preterm birth, intrauterine infections can also result in
low birth weight, defined as less than 2500 grams. In the United States the prevalence of
low birth weight is 7.7%.104 Similar to preterm birth, the association of low birth weight
and HPV infection has not been examined.
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1.4. Prevention & Control of HPV
Cervical cancer and other HPV-related cancers are a burden on the health care
system, yet they are preventable. The probability of acquiring HPV infection can be
lowered with the help of HPV vaccines, regular HPV testing, and screening.
1.4.1 Pap test and HPV testing
Papanicolaou (Pap) test
The U.S. Preventive Services Task Force (USPSTF) recommends that women
in the age group of 21 to 65 years be screened with a Pap smear test every three years.
Pap test results are reported as normal, inconclusive, or conclusive. The test results are
considered normal if no abnormal cells are detected in the cervix but are considered
inconclusive if atypical squamous cells are detected. These cells are divided into two
categories: atypical squamous cells of undetermined significance (ASCUS) and atypical
squamous cells for which high-grade squamous intraepithelial lesions cannot be
excluded (ASC-H). An ASCUS designation means that the squamous cells do not
appear to be completely normal, but it is unclear what the cell changes indicate. ASCUS
is similar to the ASC-H designation, except that ASC-H indicates a possibly higher risk of
precancerous lesions. The changes could be the result of HPV infection or any other
infection.
HPV testing
HPV testing is used to identify high-risk HPV types in the cervical cells. Since HPV
cannot be cultured, HPV test depends on the detection of viral nucleic acids in the
infected tissue. Most tests are based on direct hybridization or DNA-based amplification
techniques.105 In women 30 years and older, HPV testing has been shown to be more
sensitive than Pap testing for the detection of cervical interstitial neoplasia (CIN) grade
2/3+.106,107 Various HPV tests have been approved for screening purposes. For example,
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Hybrid Capture 2 is currently the only US FDA approved HPV test. It is a signal-amplified
hybridization microplate-based assay.108,109 Most tests detect the DNA of high-risk HPV;
however, one test detects the RNA of high-risk HPV. Currently the HPV test is only for
women; there is no HPV test for men.
1.4.2 Screening guidelines
Women who want to increase the screening interval should be screened with
both a combination of cytology (Pap smear) and HPV testing every five years. The
USPSTF recommends against screening for cervical cancer in women younger than age
21.110 The reason for that is that women in their 20s who are sexually active are much
more likely to have HPV infection that will clear off on its own. Currently, there is no
recommended testing for HPV in pregnant women.111
1.4.3 HPV Vaccines
There are currently three types of Food and Drug Administration (FDA)-approved
HPV vaccines recommended for preteen males and females aged 11 or 12 years
through 26 years.112 All three vaccines consist of recombinant noninfectious virus-like
particles (VLPs) formed by the HPV L1 capsid protein. The three vaccines that protect
against certain types of HPV are Gardasil, Cervarix, and Gardasil 9. Whereas Cervarix is
approved only for females, Gardasil can be given to both male and females. Gardasil is
a quadrivalent vaccine that protects against HPV 6, 11, 16, and 18. Cervarix is bivalent
and protects against two types of HPV: 16 and 18.112 In US Gardasil was the only
vaccine available from 2006 to late 2009.113
Mechanism of Action of Gardasil
Each Gardasil dose of 120 mg antigenic protein load comprises L1 VLPs specific
to HPV 16 and 18 as well as genital warts. The recombinant vaccine is synthesized in
Saccharomyces cerevisiae, and each 0.5 ml of Gardasil dose contains aluminum
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hydroxy phosphate sulfate and polysorbate-80. Gardasil is a prophylactic vaccine. It
induces high initial serum HPV-type specific antibodies.114,114 The antibodies prevent
endocytosis into the epithelial cells, thus neutralizing the infecting HPV virion. There are
two ways by which antibodies can reach the denuded basement membrane: via a
constant transude from the dermal capillary network up through the intact basement
membrane or via an exudate that is triggered by tissue injury to the cervical epithelium,
exposing the basement membrane to HPV virions. To neutralize infective type-specific
virions by any method, high antibody titers are necessary.114
Mechanism of Action of Cervarix vaccine
Cervarix is an AS04 adjuvant vaccine that contains recombinant L1 protein, the major
antigenic protein of capsid and HPV types 16 and 18.115 Each 0.5-ml dose consists of 20
micrograms of HPV type 16 L1 protein, 20 micrograms of HPV type 18 L1 protein, 50
micrograms of the 3-O-desacyl-4’-monophosphoryl lipid A, and 0.5 mg of aluminum
hydroxide. The efficacy of L1 VLP vaccine may be facilitated by the development of IgG
neutralizing antibodies directed against HPV-L1 capsid protein, produced as a result of
vaccination.115
Both Gardasil and Cervarix vaccines are given intramuscularly in a series of
three doses (scheduled for 0, 1 to 2, and 6 months) and are 90% to 100% effective
against the respective HPV types.116,117 Gardasil and Cervarix were approved by the
FDA in 2006 and 2009, respectively. In 2014, the FDA approved the Gardasil 9 vaccine
by Merck, which consists of high-risk HPV types (HPV 31, 33, 45, 52, and 58) in addition
to the pre-existing types in the Gardasil vaccine. Gardasil 9 included five additional types
of HPV that are believed to account for nearly 20% or more of cervical cancer cases.118
Because these other types of HPV are more prevalent in the American Indian population
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than in other populations, it is beneficial to study the impact of the 9-valent vaccine in
that population.
1.4.4 HPV treatment
If a woman is found to have an abnormal Pap test result and a positive HPV test
result, colposcopy (use of an instrument called a colposcope to examine the vagina and
the cervix) and follow-up testing are usually recommended. If biopsy of cells from the
affected area shows CIN2 or more severe abnormality, then a Loop Electrosurgical
Excision Procedure (LEEP), cryotherapy, laser therapy, or conization is performed.

1.5 Gaps in Knowledge
Although wide research on etiology of cervical cancer has been conducted
recently, there have been few population-based studies on prevalence of HPV among
pregnant women in the United States and on the possible adverse health outcomes,
especially with regard to active HPV infections and adverse pregnancy outcomes. U.S.
studies have shown that the HPV infection rates among adolescent girls and
nonpregnant women range from 8.8% to 42.7% among women 14-59 years.79,119-122
However, the prevalence of HPV among pregnant women since the introduction of
vaccines is still unknown. It is also important to note that previous research studies
among pregnant women were mostly conducted before the introduction of the HPV
vaccine, which should already have a measurable impact on the current population. It is
essential to estimate the current prevalence of HPV among pregnant women in the postvaccination era and to further study the effect of HPV on current pregnancies or later
pregnancies.
Recent studies indicate that the prevalence of HPV infection increases drastically
among pregnant women, because of the immune suppression that occurs during
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pregnancy. Additionally, the role of other sexually transmitted diseases such as
chlamydia and gonorrhea in causing adverse pregnancy outcomes is well documented.
However, there is little knowledge about the role of HPV infection in adverse pregnancy
outcomes. It is crucial to understand that role, because HPV affects nearly 80% of
sexually active women.
Another major gap in knowledge is related to the impact of Gardasil 9 vaccine on
Northern Plains American Indian women. To date, no study has projected the impact of
HPV vaccine specifically on Northern Plains American Indians. As mentioned in section
1.2.6, the prevalence of certain types of HPV is higher among American Indian women
than among white women. It is crucial to know the significance of using Gardasil 9
compared to the established Gardasil (4-valent) vaccine among Northern Plains
American Indians, because Gardasil 9 is more expensive.
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OBJECTIVE OF DISSERTATION
This dissertation is focused on two high-risk populations: pregnant women and
Northern Plains American Indian women. The long-term goal of this dissertation is to
reduce adverse consequences of HPV infection in high-risk population groups. The
dissertation has three specific aims.
Aim 1: To examine the association of HPV infection with adverse pregnancy outcomes
by using hospital data from 2012 to 2014.
Aim 2: To examine HPV infection prevalence and its association with perinatal outcomes
among singleton mothers, by using Pregnancy Risk Assessment Monitoring System
(PRAMS) data from 2004 to 2010.
Aim 3: To project the potential public health impact of the Gardasil 9 vaccine on cervical
cancer cases in Northern Plains American Indians.
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Chapter 2
Does HPV affect pregnancy outcomes?

2.1 HPV and Adverse Pregnancy Outcomes Overview
HPV is a huge health problem because of its high prevalence and
transmissibility.123 Studies conducted in the United States and other countries indicate
that pregnant women are at higher risk of acquiring HPV infection.124 During pregnancy,
major physiological and immunological changes take place that regulate the functioning
of the immune system and may cause alteration in HPV replication.125 These changes
make clearance of HPV much more difficult. 78 Extravillious or invasive trophoblast cells
facilitate placental attachment to the maternal uterine wall and are responsible for
establishing a high-flow, low-resistance maternal circulation supplying the placenta and
the fetus.90 HPV infection can impair extravillious trophoblast invasion into the uterine
wall by increasing the rate of trophoblast cell deaths, causing placental dysfunction. As a
consequence of this placental dysfunction, adverse pregnancy outcomes may occur.

90

Preeclampsia is one potential adverse pregnancy outcome. It is a main cause of
maternal and fetal morbidity and mortality. In the last two decades, the rate of
preeclampsia has increased by 25%.126 Although, age, obesity, and history of
preeclampsia are some of the known risk factors, the underlying cause of preeclampsia
is not well understood. However, a study conducted by Redman and Sargent suggests
that the probability of developing preeclampsia increases when the level of systemic
inflammatory burden, which is an integral part of pregnancy, transcends the maternal
capability to compensate for this added stress.127 The researchers believe if this is true,
then it is possible to hypothesize that infections that increase systemic inflammatory
burden could result in increased risk of preeclampsia.127 In the past, various
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epidemiological studies have examined the association between maternal infection and
preeclampsia,128-131 but few focused on its association with HPV.78 A recent study
report by McDonnold et al. noted that risk of developing preeclampsia was nearly twofold
among women infected with HR-HPV.78 However, these findings were contrary to the
study findings of Cho et al., which showed no significant association between HPV and
preeclampsia.89 These inconsistent results suggest a need to further investigate this
association.
Another adverse pregnancy outcome is preterm birth. An estimated 12% to 13%
of pregnancies in the United States are preterm.100 Nearly 25% to 40% of these preterm
births are due to intrauterine infections that activate the inflammatory pathways;
however, this may be an underestimate, because intrauterine infections are not easily
detected with conventional culture techniques.132,133 To date, few studies have examined
the relation of cervical cytology during pregnancy and HPV infection.134-136 Also, previous
study results were inconclusive regarding the impact of HPV on pregnancy outcomes,
highlighting the importance of our study. In addition to preterm birth, intrauterine
infections can affect fetal development and cause intrauterine growth restriction that
results in low birth weight.137 Though the association of bacterial infections, including
gonorrhea and chlamydia, with adverse pregnancy outcomes has been studied before,
no previous studies have focused on their association with HPV.
Premature rupture of membrane (PROM), before the onset of labor, is another
probable adverse pregnancy outcome.138 PROM is a multifactorial condition, with
infection being one of the major causes of membrane damage.139 One possible
mechanism suggested by previous researchers is that cytokines such as
metalloproteases secreted by various organisms degrade the collagen and weaken the
fetal membrane, causing the membrane to rupture.132 Specifically, MMP-2 degrades the
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extracellular matrix of the fetal membrane, resulting in PROM. Interestingly, the increase
in MMP-2 is associated with the presence of HPV in human invasive cervical carcinoma
cell lines, suggesting the possible role of HPV in regulation of MMP.98 Recent
epidemiological research has found an association between PROM and colonization of
the genital tract with Chlamydia trachomatis, Neisseria gonorrhoeae, and group B
streptococci.140,141 However, the relationship between HPV and PROM remains
ambiguous. Bopegamage et al. reported no association between viral genomes and
preterm rupture of membrane (rupturing before 37 weeks),142 whereas another study
showed that the risk of PROM among women with HR-HPV infection was twofold the
risk for noninfected women.89
The ambiguity in the results of the previous studies may be due to confounding
factors such as smoking or co-infection with chlamydia or gonorrhea that were not
controlled for in some studies. In the present study, we controlled for the necessary
confounders to examine whether the association would still be significant. The objective
was to determine if HPV infection is associated with adverse pregnancy outcomes,
including preeclampsia, preterm birth, low birth weight, and PROM.

2.2 Material and Methods
In this study, hospital data on adult women (18 years and older) who delivered a
live birth at Nebraska Medical Center between 2012 and 2014 was analyzed.143 The
potential subjects were identified based from a query of the hospital patient database,
and analysis was restricted to women who had a Pap test during pregnancy. Because
the data were unidentifiable, this study was exempted from Institutional Review Board
approval.143 Women with multipara were included, with each pregnancy considered
individually. However, women with multiple births (e.g. twins, triplets, etc) were excluded
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from our study, because multiple births are more likely to have adverse pregnancy
outcomes.100,144 This resulted in a total of 4,824 women (5,022 births) in the sample.
Patients with low/high-grade squamous intraepithelial lesions or atypical
squamous cells of undetermined significance (ASCUS) on Pap smear were considered
to be HPV-positive. The outcomes studied in this study were preterm birth, PROM, low
birth weight, and preeclampsia. Preterm birth was defined as birth before 37 weeks of
gestation. PROM was defined as rupture of the membrane prior to the onset of labor.
Low birth weight was characterized as infant weight of less than 2500 gram at the time
of birth. Preeclampsia was defined by a systolic blood pressure ≥140 mm Hg and/or
diastolic blood pressure ≥90 mm Hg on two occasions at least 6 hours apart, along with
proteinuria (an abnormal amount of protein in urine).
Bivariate analysis was conducted to assess the relationship between HPV
infection and demographic and clinical variables. Additionally, logistic regression was
performed to determine the association between HPV infection and each of following
pregnancy outcomes, after adjustment for demographic and clinical variables: preterm
birth, PROM, low birth weight, and preeclampsia. The demographic and clinical variables
were those that were significantly different between the infected and noninfected groups
or were based on prior knowledge of their association with both HPV infection and the
outcome. These variables included age, race, smoking, mode of delivery, previous
preterm birth, infection with chlamydia and gonorrhea, obesity prior to pregnancy and
previous abortions.
A two-sided p value of less than 0.05 was considered significant.
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2.3 Results
Of the total sample of 5,022 observations, 221 (4.4%) tested positive for HPV.
Significant differences in demographic and clinical characteristics between HPV-infected
and noninfected groups are shown in Table1.143 Over 40% of HPV-infected women were
in the age group of 20 to 24 years, compared to only 23.3% of uninfected women in that
age category.143 About 30% of women with HPV infection were black, compared to 16%
of women who were not infected. Close to 20% of HPV-infected women were smokers,
compared to 6.9% of uninfected women. HPV-infected women were also at higher risk of
chlamydia and gonorrhea, compared to noninfected women. The HPV-infected group
had a statistically higher percentage of vaginal delivery than did the noninfected group
(87.8% vs. 81.9%; p = 0.025). Finally, the percentages of women with previous preterm
delivery and previous abortion were higher in the HPV-infected group than in the
noninfected group (13.8% vs. 8.1% for preterm delivery; 28.6% vs. 22.5% for
abortion).143
Pregnancy outcomes and odds ratios (ORs) are shown in Table 2. The crude
ORs were significant for preeclampsia (OR: 2.37; 95% confidence interval [CI]: 1.11–
5.06), preterm birth (OR: 1.64; 95% CI: 1.15–2.32), and low birth weight (OR: 2.71; 95%
CI: 1.86–3.94) and remained significant after adjusting for demographic and other
variables that were believed to confound the association, on the basis of prior studies.143
HPV-positive women were 2.83 times more likely to develop preeclampsia, compared to
HPV-negative women (adjusted OR: 2.83; 95% CI: 1.28–6.26), after adjustment for age,
race, previous preterm birth, gestational age, infection with chlamydia and gonorrhea,
previous abortions, and delivery type. Women with HPV infection were 1.8 times more
likely to deliver preterm (adjusted OR: 1.81; 95% CI: 1.15–2.83) and 2.58 times more
likely to deliver low-birth-weight infants (adjusted OR: 2.58; 95% CI: 1.56–4.27) than
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were uninfected women, after adjustment for other covariates. Although the odds of
developing PROM were higher among infected women than among uninfected women,
the association was not statistically significant (OR: 1.39; 95% CI: 0.54–3.52).143

Table 1. Demographic characteristics according to maternal human papillomavirus
(HPV) status143
Characteristics

Infected (%)

Uninfected (%)

P value

Total

221 (4.4)

4801 (95.6)

-

Age

<0.001

≤19

12 (5.4)

392 (8.2)

20–24

91 (41.2)

1119 (23.3)

25–29

57 (25.8)

1536 (31.9)

30–34

35 (15.8)

1215 (25.3)

≥35

26 (11.8)

539 (11.2)

Race/Ethnicity

<0.001

White/Caucasian

113 (51.6)

3140 (67.1)

Black/African American

69 (31.5)

751 (16.0)

AI/AN/PI

11 (5.0)

84 (1.8)

Hispanic

4 (1.8)

139 (2.9)

Other

21 (9.6)

435 (9.3)

Unknown

1 (0.5)

133 (2.8)

Smoking

<0.001

Yes

39 (17.7)

332 (6.9)

No

182 (82.4)

4469 (93.1)

Obese

0.462

Yes

95 (7.5)

1165 (92.5)

No

67 (6.5)

963 (93.5)
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Chlamydia and Gonorrhea

0.002

Yes

8 (15.7)

43 (84.3)

No

213 (4.3)

4758 (95.7)

Mode of delivery

0.025

Vaginal

194 (4.7)

3930 (95.3)

Cesarean (C-section)

27 (3.0)

871 (96.9)

Previous preterm delivery

0.008

Yes

30 (7.2)

383 (92.7)

No

188 (4.1)

4370 (95.9)

Previous abortion

0.047

Yes

57 (5.5)

989 (94.5)

No

142 (4.0)

3400 (95.9)

Table 2. Prenatal outcomes among HPV-positive pregnant women143

δ

Outcomes

Total
Sample size

Prevalence
of HPV (%)

Crude
OR

95% CI

Adjusted
ORδ

95% CI

PROM

94

5.3

0.94

0.38–
2.34

1.39

0.54–3.52

Preeclampsia

66

12.1

2.37

1.11–
5.06

2.83*

1.28–6.26

Preterm birth

626

4.1

1.64

1.15–
2.32

1.81 τ

1.15–2.83

Low birth
weight

357

10.1

2.71

1.86–
3.94

2.58

1.56–4.27

Adjusted for age, race, smoking, previous preterm, gestational age, infection with
Chlamydia and Gonorrhea, previous abortions, delivery type, gestational diabetes and
chronic hypertension
τ
Preterm birth was not adjusted for gestational age
* Except for preeclampsia all other outcomes were additionally adjusted for
preeclampsia
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2.4 Discussion
This study investigated the association of HPV infection with adverse pregnancy
outcomes. The overall prevalence of HPV among pregnant women in this study was
4.4%, remarkably lower than in previous studies conducted in United States.145,146 One
reason could be that previous studies that showed a higher prevalence of HPV among
pregnant women were conducted before the inception of HPV vaccination. Additionally,
there is no recommended screening for HPV among pregnant women.111 Another
possible factor is the difference in HPV prevalence by geographic regions. For example,
a study conducted in Austria showed HPV in 24.6% of pregnant women, whereas a
study conducted in Spain showed a lower HPV infection rate, of 6.5%.147 Interestingly, in
this study, the prevalence of HPV among whites was higher than among other
ethnic/racial groups, contrary to the national rates (51.6% vs. 31.5%). A study conducted
by Dinh et al. indicated that there is a higher prevalence of genital warts among whites
than among blacks.148 Because most genital warts are the result of HPV, the presence
of these in pregnant women would likely prompt healthcare professionals to test them for
HPV. This might be the reason for the higher prevalence of HPV infection among whites
in our study data.
Our study results indicate that HPV infection is significantly associated with
adverse pregnancy outcomes, including preeclampsia, preterm birth, and low birth
weight, but not with premature rupture of membrane. After controlling for demographic
and clinical variables, we observed that HPV-positive women were 2.83 times more
likely to develop preeclampsia, compared to HPV-negative women. The association
remained significant after adjusting for confounding factors. Our study results were
consistent with those of other studies that revealed HPV as a risk factor for
preeclampsia.78,149 A study conducted by McDonnold et al. 78 was scrutinized for not
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adjusting for co-infections, leading to concern that HPV may not be the main cause of
the adverse outcome, but rather a contributing factor to other infections.150 In our study,
we adjusted for co-infection with chlamydia and gonorrhea and still observed a
significant association. However, our study results were contradictory to the results of a
case-control study that found no difference in the detection of HR-HPV from placentas of
women with preterm severe preeclampsia and controls.90 This could be possible if HPV
infection present in uterine decidua can still affect uteroplacental function.78
In addition, we found that HPV-positive women were 1.8 times more likely to
deliver preterm than were HPV-negative women. Our study results were consistent with
the results of a previous study conducted by Zhuang Zuo that revealed a significant
association between HPV and preterm birth.151 Though the pathophysiology of preterm
birth is not well understood, systemic and/or local inflammation has been suggested as
an independent etiological risk factor for preterm birth. According to a study conducted
by Gomez et al., HPV can infect and replicate in invasive trophoblast cells, and that
infection by HPV induces pathological sequelae that are associated with placental
dysfunction and spontaneous preterm delivery. 90 Additionally, some in vitro studies have
shown that HPV can infect a fetus through transplacental transmission.

152,153

Trophoblasts are integral cell types of the placenta. It is believed that trophoblasts
infected with HPV may alter the cellular characteristics and lead to compromised
gestation.154 Racicot et al. proposed that preterm birth is a polymicrobial disease and
demonstrated that a viral infection of the cervix during pregnancy reduces the ability of
the lower reproductive tract to prevent bacterial infection of the pregnant uterus. In the
study model, pregnancy and sex hormones are responsible for increasing the
susceptibility of the cervix to the viral infection. As a consequence of viral infection, the
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protection against ascending bacteria is decreased. This decrease in protection in turn
leads to intrauterine inflammation, in response to bacteria, and preterm birth (Figure 5 ).

Figure 5. Model of polymicrobial disease during pregnancy. Racicot et al., 2013.155
Furthermore, our results indicate that HPV-infected women were 2.58 times more
likely to deliver low-birth-weight infants than were women not infected with HPV.
Although low birth weight has been associated with other sexually transmitted
diseases,156,157 to our knowledge no other study has examined the association of HPV
and low birth weight. HPV infection could occur by ascending from the maternal birth
canal, 152 or it may cross the placenta and cause infection in the fetus. If HPV infection
occurs at a crucial moment during the development of the fetus, it may affect the fetal
cells and cause intrauterine growth retardation. In our study, we did not find any
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significant association between HPV and PROM, even after controlling for other
covariates. Our study results were contrary to those of a study conducted by Cho et al.,
who reported a significant association between HR-HPV and PROM. One reason for this
disagreement with results could be that the other study was conducted in Korea, and the
study sample had a high prevalence of HR-HPV compared to our study (14.1% vs.
4.4%) The difference in prevalence could also be because of the difference in the HPV
test detection methods. Additionally, the study does not mention what HR-HPV types
were included. Furthermore, the study did not adjust for smoking, which has been
reported to be a strong risk factor for both PROM and HPV.158-160
Our study findings are important because currently there is no vaccination or
recommended screening for HPV among pregnant women. Our study results indicate
that the presence of HPV during pregnancy may cause adverse pregnancy outcomes,
suggesting the need for understanding the impact of HPV vaccination on pregnant
women. A number of limitations should be considered when interpreting the results of
this study. First, in this findings of ASCUS were assumed to be a result of HPV infection,
though they could be a result of other factors such as bacterial infection. This may have
caused misclassification of cases, resulting in overestimation. Second, although we had
information on current smoking status, we did not know the smoking status prior to
pregnancy; that missing information may have concealed the true exposure to tobacco.
Previous researchers have found that the prevalence of HPV varies by
gestational age. 27,161 Lee et al. detected HPV DNA in 14% of pregnant women in the
first trimester, 18% in the second trimester, and 10% in the third trimester.27 This
indicates that the HPV infection may be triggered by hormonal or other effects of
pregnancy, such as immunosuppression.161 Although our study was unable to account
for gestational age of infection, future studies might take into account the time point of
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HPV infection. Despite these limitations, the study has a number of strengths. Because
the exposure and outcome status were based on obstetric records/ laboratory tests, this
information was more reliable than self-reported data.

2.5 Conclusion
The data from this study suggest that HPV infection is associated with adverse
pregnancy outcomes, including preeclampsia, preterm birth, and low birth weight. From
a clinical standpoint, this may highlight the health benefits of HPV vaccination for young
girls and adolescent females prior to pregnancy as well as for young boys and men.
Also, one priority should be to improve HPV vaccination rates through better education
and awareness campaigns among the patient population. In addition, policymakers
should consider mandating HPV testing of pregnant women. Concurrently, there should
be a close follow-up of HPV-positive women and their fetuses. However, it appears that
mandating HPV vaccination may be challenging, in light of the experience in Texas.
Although Governor Rick Perry mandated HPV vaccination for young girls, Texas
legislators passed H.B. 1098 to override the executive order. Future studies should
involve larger, more diverse samples of women to enable us to understand the impact of
HPV infection.
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Chapter 3
Examining the Relationship between HPV and Adverse Pregnancy
Outcomes at the Population Level

3.1 Introduction
HPV infection is the most common sexually transmitted disease in the United
States.162 Some of the known risk factors for HPV infection include early first sexual
intercourse, multiple sex partners, co-infection with other sexually transmitted diseases,
and smoking or any form of immune suppression.119 In addition, pregnancy is a risk
factor for new or recurrent HPV infections.89 During pregnancy, the immune system is
suppressed, which decreases the ability to resist infections.163, 78 In addition, the level of
HPV DNA replication is increased in pregnancy because of elevated levels of pregnancy
hormones such as progesterone. Because of these factors, pregnant women may be
more susceptible to HPV infection than nonpregnant women.
There is a lack of population-based data on HPV infection prevalence among
pregnant women in the United States and on the possible adverse health outcomes
related to active HPV infections, especially adverse pregnancy outcomes. U.S. studies
have shown HPV infection rates among adolescent girls and nonpregnant women
ranging from 8.8% to 42.7% among women in the age group of 18-59 years.79,119-122 It is
also important to note that previous research on pregnant women was mostly conducted
before introduction of the HPV vaccine, which may already have a measurable impact
on the current population. It is essential to estimate the current prevalence of HPV
among pregnant women in the post-vaccination era and to further examine its effect on
pregnancy.
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HPV causes genital warts, cervical cancer, head and neck cancer, anal cancer,
juvenile-onset recurrent respiratory papillomatosis, and laryngeal papillomatosis.28
However, little is known about the potential link between HPV infection and adverse
pregnancy outcomes such as preterm birth, low birth weight, preeclampsia, and PROM.
The etiology of such outcomes is still unclear, and the literature on their association with
HPV infection is contradictory.78,89 It is important to research and learn more about the
association between HPV infection and adverse pregnancy outcomes, since the little
information available now is not conclusive. The inconsistencies in the results of the
previous studies regarding adverse pregnancy outcomes and their association with HPV
infection necessitate further research.78,89
Previous studies were based on small sample sizes, which may have caused
underestimation of the results. Use of the Pregnancy Risk Assessment Monitoring
System (PRAMS) is the standardized data collection methodology. It includes a
questionnaire completed by mothers that can provide population-based prevalence
estimates of HPV infection. Additionally, along with information from birth certificates, the
PRAMS database can allow us to elucidate the association of HPV with adverse
pregnancy outcomes. The primary purpose of this study was to estimate the prevalence
of HPV infection among pregnant women, with use of the most recent data available.
The secondary purpose was to examine the association of HPV with adverse pregnancy
outcomes, including preeclampsia, preterm birth, low birth weight, and PROM.

3.2 Methods
This study used data from the 2004–2011 multi-state PRAMS. The current study
used PRAMS data from multiple states: Delaware, Florida, Missouri, Mississippi, New
York, Tennessee, and Utah.
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3.2.1 PRAMS
PRAMS is a state-specific population-based surveillance system that collects
data from women who delivered live-born infants about their experiences before, during,
and after pregnancy.164 This database uses a multistage, complex sampling strategy and
is a mixed-mode surveillance system with standardized data collection methodology.
Each month, a list of mothers who delivered a live infant in the past 2 to 4 months is
randomly generated from a file of birth certificate records. Mothers are sent a 14-page
self-administered questionnaire. Each mother’s response is linked to extracted items
from the birth certificate file, such as infant’s birth weight, type of delivery, and mother’s
marital status, race, age, education, and smoking status. The response rate of PRAMS
is nearly 70%.
The PRAMS database includes core questions for all states’ surveys and
optional standard and state-developed questions. In the present study, only states that
had questions on HPV infection were included.
3.2.2 Study Definitions
HPV Infection: The question used to assess HPV infection among pregnant women
was “During your most recent pregnancy, did a doctor, nurse, or other health care
worker tell you that you had any of the following diseases?” HPV was defined by a ‘yes’
in the Genital warts (HPV) category.
Perinatal Outcomes: Preeclampsia is a disease characterized by high blood pressure
during pregnancy and signs of damage to other organ systems and is a major cause of
maternal and fetal mortality and morbidity.91 Preeclampsia generally begins after 20
weeks of pregnancy in a woman whose blood pressure had been normal. For this study,
it was measured by response to the question “Did you have any of the following
problems during your most recent pregnancy?” Preeclampsia was defined by a ‘yes’
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response in the preeclampsia category. Preterm birth was based on the gestational age
variable available in the birth certificate file. It was defined as the birth of an infant before
37 weeks of pregnancy. Low birth weight was defined as a weight less than 2500 grams
at the time of birth. PROM was defined as the rupture of membrane before the onset of
labor. Both low birth weight and PROM were obtained from birth certificate files.
Covariates: Candidate covariates for the statistical models derived from PRAMS
questionnaire included the following: mother’s age at delivery, mother’s race/ethnicity,
mother’s education level, marital status, smoking, gestational age, body mass index
(BMI) prior to pregnancy, gestational diabetes, high blood pressure before pregnancy
and co-infection with gonorrhea and chlamydia, and previous preterm deliveries. Race
was divided into three categories: white, black, and other. BMI prior to pregnancy was
classified as underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese
(≥30). Mother’s smoking status was categorized as ‘yes’ or ‘no.’

3.3 Data analysis
We limited our study to singleton births since multiples are more likely to have an
adverse outcome such as low birth weight or preterm birth.100,144 To account for the
complex sampling design of the PRAMS, analyses were completed with SAS Survey
procedures, software version 9.3. Data were weighted with sampling weights to produce
population-based estimates. Bivariate analyses were performed to assess the
relationship between each perinatal outcome and HPV infection. Logistic regression was
performed to assess the relationship between each perinatal outcome (PROM, preterm
birth, low birth weight, and preeclampsia) and HPV infection. Multivariable models for
each of the primary independent variables were built to adjust for confounding variables
based on the previous literature.
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Multiple imputation technique was used to impute observations missing at
random for HPV exposure (n = 200) since HPV information was not missing completely
at random. This Monte Carlo process involves repeated imputation of each missing
value and then averaging over imputations. Multiple imputation assumes that data is
missing at random (MAR), and it creates several copies of the data set, each containing
different imputed values. A separate analysis was carried out on each dataset that
yielded multiple sets of parameter estimates and standard errors. For this study, we
used five multiple imputed datasets to combine into a single set as a result. Multiple
imputation was conducted in three phases: imputation, analysis, and pooling. The
multiple imputation process was performed with SAS 9.3. Statistical significance was
assessed at α = 0.05. Multiple imputation was performed on the database with the
PROC MI procedure in SAS. To impute HPV status, variables such as smoking status,
education level, age, bleeding of the mother, and preterm birth were used.

3.4 Results
Table 3 exhibits the demographic and obstetric characteristics of pregnant
women infected with HPV. HPV was present in 1.4% of the PRAMS survey participants
(N = 26,085). The prevalence of HPV was significantly higher among women ≤19 years
old (2.7%) than in all other age groups. Additionally, the prevalence was notably higher
among these groups: smokers (3.5%) versus nonsmokers (1.2%), women who had high
blood pressure before pregnancy (2.5%) versus those who did not (1.3%), and those
who were not married (2.5%) versus those who were (0.8%). Furthermore, the
prevalence of HPV was significantly higher among women who were co-infected with
chlamydia or gonorrhea (6.4%) than among women with no such co-infection (1.3%). No
significant differences in age, pre-pregnancy BMI, previous preterm delivery, or
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gestational diabetes were observed between women with HPV infection and those
without.
Additional analysis was conducted to examine the prevalence of other sexually
transmitted infections by HPV status. As shown in Table 4, we found that there were
significant differences in the prevalence of other sexually transmitted infections by HPV
status. For instance, the prevalence of chlamydia was 9.2% among HPV-positive
women, compared to 2.1% among HPV-negative women. Similarly, the prevalence of
Group B streptococci was 21.7% among HPV-positive women, compared to only 10%
among HPV-negative women.
Table 5 shows the weighted prevalence, ORs, and 95% CIs for the perinatal
outcomes among pregnant women. The overall weighted prevalence of low birth weight
among women who delivered was 7.3%. In the crude analysis, no association was
found between HPV infection and low birth weight. After adjustment for demographic
and obstetric characteristics, low birth weight was not significantly associated with HPV
infection (adjusted OR: 1.00; 95% CI: 0.83–1.21). However, low birth weight was
significantly associated with HPV in the nonimputed data (OR: 1.91; 95% CI: 1.13–3.24).
As shown in Table 6, no significant association was found between HPV infection and
PROM, pre-eclampsia, or preterm birth in the nonimputed data. In addition, the weighted
prevalence among women who delivered preterm was 9.4%. The crude OR and
adjusted OR were not significant for the association between HPV infection and preterm
birth (OR: 0.98; 95% CI: 0.81–1.19). Furthermore, the weighted prevalence among
women who had premature rupture of membrane was 2.9%. Although the odds of
having PROM was higher among HPV-positive versus HPV-negative women, this was
not statistically significant after adjustment for confounding variables (adjusted OR: 1.46,
95% CI: 0.53–4.01). The weighted prevalence of preeclampsia among pregnant women
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was 6.2%. Similar to PROM, the adjusted OR for preeclampsia was higher among those
infected with HPV versus the uninfected; this was not statistically significant (OR: 1.31;
95% CI: 0.95–1.80)
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Table3. Demographic and obstetric characteristics of pregnant women who selfreported HPV exposure status
Characteristics
Total
Age
≤19
20–24
25–34
35+
Race/Ethnicity
Non-Hispanic white
Non-Hispanic black
Non-Hispanic American
Indian/Alaskan Native
Hispanic
Non-Hispanic other
Married
Yes
No
Education, years
≤11
12
13–15
≥16
Smoking
Yes
No
Pre-pregnancy BMI
Underweight
Normal
Overweight
Obese
Pre-high blood pressure
Yes
No
Previous preterm
delivery
Yes
No
Co-infection (chlamydia
and/or gonorrhea)

Unweighted Sample
Size
26085

Weighted Prevalence of
HPV (%, SE)a
1.44 (0.07)

2772
7107
13194
3011

2.7 (0.10)
2.3 (0.09)
0.9 (0.05)
0.8 (0.05)

P valueb

<.001

0.19
16688
3866
160

1.6 (0.07)
1.3 (0.08)
2.2 (0.09)

4230
997

0.9 (0.06)
1.6 (0.07)

16395
9686

0.8 (0.05)
2.5 (0.10)

<.001

.13
5560
7589
6243
6235

1.7 (0.09)
1.9 (0.09)
1.5 (0.08)
0.7 (0.05)

3122
22768

3.5 (0.19)
1.2 (0.06)

<.001

.48
1523
12433
5489
4889

1.9 (0.10)
1.3 (0.06)
1.6 (0.07)
1.5 (0.07)
.019

926
8255

2.5 (0.58)
1.3 (0.08)
.31

488
12245

2.4 (0.59)
1.4 (0.07)
<.001
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Yes
No
Gestational diabetes
Yes
No
a Based

639
25446

6.4 (0.15)
1.3 (0.07)

755
8378

1.5 (0.33)
1.4 (0.07)

.57

on imputed data
test was used to compute the p value. P value of <0.05 was considered significant.

b Chi-square

Table 4. Type of infection by HPV status
Type of Infection
Chlamydia
Herpes
Syphilis
Gonorrhea
Group B
streptococci
Trichomonas
Yeast
a Chi-square

HPV+ (n = 380)

HPV- (n = 25704)

P valuea

33 (9.23%)
33 (7.17%)
11 (2.95%)
15 (5.54%)
64 (21.7%)

556 (2.12%)
229 (1.07%)
13 (0.04%)
93 (0.31%)
2451 (10.04%)

<.0001
<.0001
<.0001
<.0001
<.0001

10 (2.34%)

190 (0.69%)

.011

87 (26.21%)

2006 (7.76%)

<.0001

test was used to compute the p value.
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Table 5. Weighted prevalence (%), ORs, and 95% CIs of perinatal outcomes among
pregnant women by HPV exposure, PRAMS, 2004–2011 (based on imputed data)
Outcomes

Weighted
Prevalence (SE)

Crude ORd

95% CId

AORa,d

95% CI

Low birth weight b

7.27 (0.03)

1.09

0.95–1.24

1.08

0.74–1.57

Preeclampsia c

6.20 (0.21)

0.90

0.67–1.21

1.31

0.95–1.80

PROM b

2.91 (0.15)

1.12

0.79–1.59

1.08

0.74–1.57

Preterm birth

9.36 (0.20)

0.96

0.80–1.16

1.01

0.84–1.20

a Adjusted

for age, race, co-infection (with chlamydia or gonorrhea), BMI, smoking, gestational
age (preterm birth not adjusted for gestational age), married, gestational diabetes.
b In addition to above confounders, preterm birth, PROM, and low birth weight were adjusted for
previous preterm birth and preeclampsia.
c In addition to above confounders, preeclampsia was also adjusted for hypertension before
pregnancy.
d Based on imputed database.

Table 6. ORs and 95% CIs of perinatal outcomes among pregnant women by HPV
exposure, PRAMS, 2004–2011 (based on nonimputed data)
Crude OR

95% CI

AORa

95% CI

Low birth weight b

1.18

0.90–1.54

1.91

1.13–3.24

Preeclampsia c

0.82

0.45–1.48

0.58

0.19–1.71

PROM b

1.25

0.62–2.55

1.46

0.53–4.01

Preterm birth

1.08

0.75–1.56

0.54

0.31–0.95

Outcomes

a Adjusted

for age, race, co-infection (with chlamydia or gonorrhea), BMI, smoking, gestational
age (preterm birth not adjusted for gestational age), married, gestational diabetes.
b In addition to above confounders, preterm birth, PROM, and low birth weight were adjusted for
previous preterm birth and preeclampsia.
c In addition to above confounders, preeclampsia was also adjusted for hypertension before
pregnancy.
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3.5 Discussion
To our knowledge, this is the first study to utilize a multi-state PRAMS database
to study the prevalence of HPV and its impact on pregnancy outcomes. The prevalence
of HPV exposure in our study sample was only 1.4%, which varies drastically from a
meta-analysis that revealed a much higher prevalence of 16.8% among pregnant
women.124 One of the reasons could be that our study was based on self-reported HPV
exposure status. Because HPV testing is not recommended for pregnant women,165
most women may be unaware of their status. This may have underestimated the true
prevalence of HPV among these women. Additionally, lower prevalence could be due to
the impact of HPV vaccination.
In the present study, we found that HPV-positive women had higher prevalence of other
sexually transmitted infections. Because this is a cross-sectional study, we cannot infer
that HPV infection predisposes women to other sexually transmitted infections. However,
Racicot et al. reported that viral infection of the cervix during pregnancy decreases the
ability of the lower reproductive tract to prevent bacterial infections.155 In the future,
prospective studies may explore the relation of HPV infection with other sexually
transmitted diseases. Also, it would be interesting to know if specific types of HPV may
be responsible for putting pregnant women at risk for other sexually transmitted
infections.
On the basis of nonimputed data, women with HPV infection were 1.91 times
more likely to have a low-birth-weight infant (Table 4). Although low birth weight has
been associated with other sexually transmitted diseases,166,167 no studies have
examined the association of HPV and low birth weight. It is believed that some infections
can affect fetal cells and restrict intrauterine growth if they occur at a critical moment in
fetal development.137 If infection occurs during the first trimester, then the consequences
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of the infection on pregnancy are more serious.137 Future studies should consider the
time of infection to better understand the role of HPV in adverse outcomes.
In this study, we did not find any significant association between HPV infection
and pregnancy outcomes, which is contrary to the findings of previous studies. One
possible explanation is that in our study the prevalence of HPV infection was low among
pregnant women (1.4%), in comparison with its prevalence in previous studies that
examined the association of HPV with pregnancy outcomes such as low birth weight,
PROM, preeclampsia, and preterm birth.78,89,90,168 Additionally, one study that showed a
significant association between HPV infection and preterm birth did not control for
smoking, which can confound the association.90 Although there is no clear process by
which HPV infection can result in these adverse pregnancy outcomes, some
mechanisms have been proposed. It is thought that infection with HPV can result in
chronic cervicovaginal inflammation that may put the pregnancy at higher risk of an
adverse outcome.169 Additionally, HPV releases cytokines and metalloprotease
(specifically MMP-2), which can degrade collagen and also weaken the fetal membrane,
resulting in membrane damage. 98,170,171
This study has a few limitations, such as those that apply to PRAMS as a whole.
Because the study was cross-sectional, we cannot infer causality of the relationship
between self-reported HPV and perinatal outcomes. Also, the infection information
available through PRAMS was limited to seven states that included questions related to
HPV infection in their state questionnaire. Additionally, selection bias could have
occurred if women who were educated or had an infant of normal birth weight were more
likely to respond to the PRAMS survey. Furthermore, the question used to assess HPV
infection among pregnant women is non-specific that might be difficult to

comprehend. In the PRAMS survey questionnaire, HPV infection was measured on the
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basis of a single multicategorical question: “What disease or infection were you told you
had?” One of the response options for this question is “Genital Warts (HPV),” which
may not be comprehensive for all women. Except for the above question, there is no
other question related to high-risk HPV or low-risk HPV. Genital warts are the result of
low-risk HPV such as types 6 or 11 and not the cancer-causing HPV types such as HPV
16 or 18. So it might be that some women with high-risk HPV did not report their status.

Despite these limitations, this study has a number of strengths. First, the data
come from a large population-based survey of maternal attitudes and experiences
before, during, and shortly after pregnancy. Second, the PRAMS survey has a high
response rate of 70%, reducing the potential for biased estimates. Third, all of the
outcomes (except for preeclampsia) for this study were derived from birth certificate files,
which are based on medical information (not self-reported).
To the best of our knowledge, this is the first study to utilize PRAMS data to
analyze the prevalence of HPV infection and its relationship with pregnancy outcomes.
On the basis of this multi-state population-based survey, the prevalence of HPV infection
was found to be 1.4%. The low prevalence of HPV infection among PRAMS participants
may be due to the lack of consistent HPV testing among pregnant women. The low
prevalence of HPV infection may have skewed the results significantly. Although we did
not find significant associations between HPV and perinatal outcomes, further research
with use of a large population database is needed. So far, only 7 of 40 states in the
PRAMS database collect information on HPV. We recommend that other states consider
including questions on HPV, which would allow researchers to study HPV among
pregnant women in large population-based investigations and would provide data that
are more representative of the population. In the future, researchers should also
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consider conducting longitudinal studies of HPV among pregnant women that would
allow them to take into account the time of infection.
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Chapter 4
Projecting the potential impact of 9-valent vaccine among Northern Plains
American Indian women and white women

4.1 Introduction
Cervical cancer is the second most common cancer in women worldwide. In
2015, approximately 12,900 women were diagnosed with invasive cervical cancer in the
United States, and 4,100 died from it.172 With widespread use of an effective screening
test (i.e., Pap smear), there was a large decline in incidence rates over the last 30 years;
however, the decline gradually tapered off in the past decade, especially among younger
women.173 Also, after decades of rapid declines, mortality rates have leveled off, and no
significant decline was observed for both women younger than 50 years and those 50
years and older.173
In addition to the lack of progress in decreasing the burden of cervical cancer in
the overall population, another concern is a persisting disparity among certain population
groups in the United States. One group at particularly high risk of developing and dying
from cervical cancer is American Indians/Alaska Natives in the Northern and Southern
Plains regions. For instance, the incidence rate among Northern Plains American
Indians/Alaska Natives was 12.5 per 100,000, which put them at 1.7 times higher risk of
developing cervical cancer than non-Hispanic white women in the same region.81 Other
publications have documented an incidence rate of cervical cancer among American
Indian/Alaska Native women in South Dakota as high as 16.2 per 100,000, compared to
6.1 per 100,000 among non-Hispanic white women in the state, and an age-adjusted
cervical cancer mortality in the Dakotas of 4.5 per 100,000.174
HPV is a primary cause of cervical cancer and is responsible for anal,
oropharyngeal, and vulvar cancer.162 More than 40 types of HPV are considered to be
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high-risk or can cause cancer. Together, HPV 16 and 18 account for 70% of cervical
cancer in the United States.13 Five additional high-risk types, HPV 31, 33, 45, 52, and
58, are believed to account for nearly 20% or more of cervical cancer cases.118 In 2006,
Gardasil was introduced in the United States as the first prophylactic HPV vaccine.
Gardasil, a quadrivalent vaccine, protects against HPV 16, 18, 6, and 11 and is licensed
for administration to individuals between ages 13 and 26. Cervarix, a bivalent vaccine
subsequently licensed in 2009, protects against HPV 16 and 18 only. Both vaccines are
90% to 100% effective against the respective HPV types.116,117,175
In December 2014, Gardasil 9, a 9-valent vaccine including HPV types 16, 18, 6,
11, 31, 33, 45, 52, and 58, was launched. The 9 types included in the vaccine are
considered responsible for 90% of cervical cancers worldwide.118,176 A recent study by
Velde predicted that changing from quadrivalent to a 9-valent vaccine will reduce the
cumulative number of episodes of anogenital warts by an additional 6.6% over 70 years.
In addition, the study showed that switching to 9-valent vaccine could further reduce
precancerous lesions and cervical cancer.177
Previous research indicated variation in the HPV type distribution among
population groups within the United States.121 Because of the differences in HPV
infection, varying degrees of impact are expected from HPV vaccination. Mathematical
modeling, which incorporates results from epidemiological and clinical studies, has been
used in public health to project potential benefits of population-level interventions.177-179
Previously, modelling has been employed to investigate HPV vaccine effectiveness and
cost effectiveness.178-180 However, none of the published studies have examined the
potential impact of 9-valent vaccine in high-risk population such as Northern Plains
American Indians. In addition, of particular interest is the effect that varying vaccination
rates have in decreasing cervical cancer incidence and mortality. The HPV vaccination
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completion rate remains low, around 39.7% as of 2014, among female adolescents in
the United States.181 Given the considerable effort and time it will take to increase the
vaccine completion rate; it is of interest to estimate with a mathematical model the
potential benefit of increasing vaccine coverage.
The purpose of the present study was to estimate the potential impact of 9-valent
vaccine on cervical cancer cases in the American Indian population. Two specific
questions were explored: (1) Among American Indian compared with white women, how
many cases of invasive cervical cancer and cervical dysplasia (CIN2/CIN3) would be
prevented because of the 5 additional types (HPV 31, 33, 45, 52, and 58) incorporated in
the 9-valent vaccine? (2) If the 4-valent vaccine coverage rate of three doses among
Northern Plains American Indian women increased from about 23% currently to 80%,
how many cases of invasive cervical cancer and cervical dysplasia could be prevented
in that population? To our knowledge, this is the first study to use mathematical
modeling to assess the impact of 9-valent vaccine in this high-risk population of Northern
Plains American Indian women.

4.2 Materials and Methods
We developed a deterministic compartmental model to evaluate the effects of 9valent versus 4-valent vaccine on cervical cancer cases. We modeled 4-valent vaccine
(not bivalent) because 4-valent vaccine was the sole vaccine from 2006 to late 2009 in
US.113 Also, it contains HPV types 16 and 18 that are covered by bivalent HPV vaccine.
The model depicted an open population that begins in 2005, a year before the start of
HPV vaccination, and ends after 70 years from the start. Because HPV 6 and 11 are
low-risk viruses that cause genital warts and do not lead to cervical cancer, these were
not included in any of our models. The population of susceptible women in the Northern
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Plains (Iowa, Nebraska, Minnesota, South Dakota, and North Dakota) was based on the
2010 U.S. census. Because the CDC recommends that females aged 12–26 be
vaccinated, the model population was categorized into three groups: <12 years old, 12–
26 years and 27 years and above. There were 37,836 American Indians and 976,958
whites in the 12–26 age group and 99,205 American Indians and 3,458,063 whites in the
age group 27 and above.182
In our study, susceptible women were defined as nonvaccinated women at risk of
getting infected with HPV. HPV-infected women were defined as women who contracted
HPV infection from their male sex partners. Although in many individuals the HPV
infection clears naturally, HPV can also avoid attack by the immune system183 and in
some cases can regress to any of the initial stages. In the absence of regression,
persistent HPV infection progresses from precancerous lesions (CIN1, CIN2, and CIN3)
to cervical cancer.184,185 We did not model males in our study, in order to reduce the
complexity of the model. However, the contact and transmission rate parameter was
based on heterosexual contact rates.
4.2.1 Mathematical Model
On the basis of the biology of HPV and cervical cancer, we developed a system
of differential equations that captures the dynamics of HPV and cervical cancer (see
Appendix for model equations). Figure 1 displays the natural history model flow diagram
as well as the measures taken to mitigate the progression. This epidemiologic model
begins with 12-year-old females entering the susceptible category. Once HPV
transmission occurs, susceptible females enter the category of infected females. In
accordance with mathematical epidemiology convention, the hazard rate at which these
women contract infection is termed the force of infection. Individuals leave this category
when the infectious period for HPV ends, and they start entering the cervical
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intraepithelial neoplasia (CIN) stages. CIN, also known as cervical dysplasia, is the
premalignant transformation and abnormal growth of squamous cells on the surface of
the cervix. In a fraction of females, the infection clears naturally, and they will be immune
for 5 years from the infection. After 5 years, these women will return to the susceptible
stage, while the rest will either suffer mortality move to the CIN2 stage. Similar to CIN1,
in some women at CIN2 and CIN3, the infection will clear, and in others it will regress
back to CIN1 and CIN2, respectively. In addition, some females in these three stages
undergoing treatment will leave their categories, become immune for 5 years, and then
be susceptible after the immunity wanes. Some at the CIN3 stage will acquire cervical
cancer. To reduce the complexity of the model, we assumed that women treated for
cervical cancer will become immune and not susceptible to HPV infection.
A fraction of susceptible females in the age group of 12–26 years will be
vaccinated and thus moved to the vaccination category, and nearly 90% will later be
immune. However, females in any age group can also acquire other high-risk HPVs, and
a proportion of them become infected with HPV 31/33/45/52/58, which all follow the
same natural history as HPV 16/18.
Specifically, within each population, the model tracks the changing number of
susceptible, HPV infected, CIN1, CIN2, CIN3, cervical cancer, treatment, vaccinated,
and immune females. In light of the lower mixing rates between populations, each
population was stimulated separately. Additionally, within each population model, a
different model used for HPV types 16/18 and 5-additional types. Population-level
vaccine-efficacy predictions are presented for the primary outcome: cervical cancer and
CIN over time. Outcomes were modeled over 70 years post vaccination because this
horizon allows enough time to reach a stable post-vaccination equilibrium and shows
maximum differences in efficacy between the different vaccines.
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However, the results
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were reported after 15 and 30 years of vaccination in order to highlight the medium-term
impact of the vaccine.

Figure 6. Model Flow Diagram
4.2.3 Model Assumptions
We assumed homogeneous mixing between the age groups within each
population and used parameter estimates based on the literature. Rates of progression
and regression to HPV and cancer were assumed to be independent of age.35,186,187 We
followed 186 in assuming lifelong immunity in those vaccinated against the infection and
no therapeutic effect of current vaccines (i.e., it cannot cure the virus or related
infection). Additionally, we took into account neither cross-protectivity (in which
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immunization with a certain vaccine type provides clinically significant protection against
infection or disease, or both, due to another HPV type188) nor cross-neutralization (in
which antibodies elicited by vaccination with an HPV type neutralize virions of another
HPV type at a variable degree in vitro). One reason for not taking cross-protectivity into
account was that a comparison of two clinical trials—Females United to Unilaterally
Reduce Endo/Ectocervical Disease (FUTURE) I and II of the quadrivalent vaccine and
Papilloma Trial Against Cancer in Young Adults (PATRICIA) of the bivalent vaccine—
suggested that estimates of cross-protectivity of vaccines against infections and lesions
associated with HPV 31, 33, and 45 were usually higher for the bivalent vaccine than the
quadrivalent vaccine. 189
4.2.4 Model Parameters
Table 1 summarizes the parameter estimates and references. A comprehensive
search of the literature was performed to find parameter estimates. Prevalence rates for
both American Indian women (HPV 16/18: 11.3%; HPV 16/18/31/33/45/52:14.8%) and
white women (HPV 16/18: 5.9%; HPV 16/18/31/33/45/52: 8.3%) were based on
unpublished data collected among Northern Plains American Indians and whites.
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Progression rate, eradication with treatment rate, clearance rate, sensitivity, and vaccine
efficacy for HPV were derived from several published studies. 186,191-193 Because of the
lack of race-specific rates, all the above rates were assumed to be the same for both the
American Indian and the white population (except for the calibrated values). Screening
rates for the year 2010 were obtained from CDC. 194 A sensitivity analysis was
performed for various parameters in the model because different values were noted in
the literature. 186,195,196 Sensitivity and elasticity analysis was conducted on multiple
parameters to determine the most influential inputs (Table 10). The baseline parameters
were increased by 10% to determine the percent change in the baseline values for
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susceptible, HPV infected, CIN3, and cumulative cervical cancer cases. To determine
the sensitivity, the outcomes were measured at year 2035 (after 30 years from the start
of the model).

Table 7. Parameter estimates for HPV disease categories
Parameters in the model
American
Whites
Indians
Number of susceptible
12–26
38,736
976,958
27 and above
67313
3,438,989
Ratio of males to females
0.96
0.98
Infected with oncogenic HPV
13,945
205,161
types
Transmission probability
0.7 (0.4)*
0.7 (0.4)*
Progression hazards per year
HPV Infected to CIN1
0.09 (0.16)*
0.09
CIN1 to CIN2
0.13 (0.24)*
0.13
CIN2 to CIN3
0.14
0.14
CIN3 to cervical cancer
0.42
0.42
Fraction of eradications of
infection with treatment
CIN1
0.96
0.96
CIN2
0.92
0.92
CIN3
0.92
0.92
Localized cervical cancer
0.92
0.92
Clearance hazards rate
CIN1 to Normal
0.32 (0.46)*
0.32 (0.48)*
CIN2 to Normal
0.21
0.21
CIN3 to Normal
0.11
0.11
Regression
CIN2 to CIN1
0.133
0.133
CIN3 to CIN2
0.03
0.03
CIN3 to CIN1
0.03
0.03
Fraction of women screened each 0.73
0.72
year
Sensitivity
CIN1
0.28
0.28
CIN2 and CIN3
0.59
0.59
Vaccine efficacy
0.90
0.90
Current vaccination hazard
0.03
0.05
* The values in parentheses () are calibrated values.

References

177,182

182

195

186
186
186
186

186
186
186
186

186
186
186

186
186
186
194

197
197
198

(IHS, unpublished
data, 2015)
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Table 8. Empirical values
Parameter
Prevalence of any oncogenic
types
Prevalence of HPV 16/18 among
ages 12–26 years
Prevalence of HPV 16/18 among
ages 27 and above
Prevalence of HPV 16, 18, 31,
33, 45, 52, or 58
Prevalence of HPV 31, 33, 45,
52, or 58 among ages 12–26
years
Prevalence of HPV 31, 33, 45,
52, or 58 among 27 and above
Fraction of women vaccinated
(vaccination coverage rate)

American
Indians
36%

Whites

Reference

11.5%

8.9%

5.3%

8.2%

190

14.8%

8.3%

190

23.5%

9.8%

190

6.3%

0.94%

190

0.23

0.40

IHS and South
Dakota Health
Department

21%
190

4.3 Results
4.3.1 Sensitivity and Elasticity Analysis
The baseline parameters were increased by 10% to determine the percent change in the
baseline values for susceptible, HPV infected, CIN3, and cumulative cervical cancer
cases. For instance, a 10% increase in transmission rate resulted in a 6.49% increase in
cumulative cervical cancer cases. Similar results for sensitivity and elasticity analysis
were obtained for American Indian women (data not shown). Overall, the 10% change in
transmission rate, screening rate, CIN 1 to CIN2 hazard rate, and CIN2 to CIN3 caused
the parameter values to deflect more than 5% from the original value.
The baseline parameters were increased by 10% to determine the percent change in the
baseline values for susceptible, HPV infected, CIN3, and cumulative cervical cancer
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cases. For instance, a 10% increase in transmission rate resulted in a 6.49% increase in
cumulative cervical cancer cases. Similar results for sensitivity and elasticity analysis
were obtained for American Indian women (data not shown). Overall, the 10% change in
transmission rate, screening rate, CIN 1 to CIN2 hazard rate, and CIN2 to CIN3 caused
the parameter values to deflect more than 5% from the original value.
Table 9. Sensitivity and elasticity analysis on parameters for white women with HPV 16/18
Percent change (Elasticity)* in:
Parameter

Susceptible
White Women

HPV infected

CIN3

Cumulative
Cervical Cancer

Transmission rate
Screening rate
CIN1 to CIN2 hazard
rate
CIN2 to CIN3 hazard
rate
CIN3 to cervical
cancer hazard rate
Vaccination rate
Rate of regression,
CIN2 to CIN1
Rate of regression,
CIN3 to CIN2
Fraction of CIN1
cured
Fraction of CIN2
cured
Fraction of CIN3
cured

-6.57 (0.6)
0.14 (1.4)
-0.26 (0.02)

15.6 (1.5)
-2.7 (0.2)
-1.64 (0.1)

12.49 (1.2)
-12.5 (1.2)
7.95 (0.7)

6.49 (0.6)
-9.87 (0.9)
8.41 (0.8)

-0.26 (0.02)

-1.63 (0.1)

7.87 (0.7)

8.34 (0.8)

-0.25 (0.02)

1.68 (0.1)

-4.60 (0.4)

5.88 (0.5)

-0.61 (0.06)
-0.26 (0.02)

-3.25 (0.3)
-1.66 (0.01)

-0.68 (0.06)
-1.45 (0.1)

-0.10 (0.01)
-1.18 (0.1)

-0.26 (0.02)

-1.65 (0.1)

-0.26 (0.02)

-0.19 (0.01)

0.12 (0.01)

-2.40 (0.2)

-3.56 (0.3)

-2.51 (0.2)

0.09 (0.009)

-1.91 (0.1)

-5.24 (0.5)

-4.11 (0.4)

-0.25 (0.02)

-1.72 (0.1)

-4.35 (0.4)

-3.56 (0.3)

*After 30 years of vaccination

4.3.2 Model Fit and Validation
The predictive validity of the model was evaluated by comparing model results with
epidemiologic data from populations in the United States. Table 11 shows the
comparison of our model predictions with the reference model. Predictions of the model
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were similar to the values reported in the literature. The prediction for HPV prevalence of
five additional types among white women 27 years old and above is different from the
epidemiological data because the prevalence obtained from the real data seems too low
to be true. Based on the other population studies in the literature it seems plausible to
have prevalence of 0.06 instead of 0.0094.
Table 10 Model validation
Parameter
Fraction of American Indian women 12 to
26 who have been vaccinated

Fraction of White women 12 to 26 who
have been vaccinated
HPV 16/18 prevalence among American
Indian women 12–26 years old
HPV 16/18 prevalence among American
Indian women 27 years old and above
HPV prevalence of five additional types
among American Indian women 12–26
years old
HPV prevalence of five additional types
among American Indian women 27 years
old and above
HPV 16/18 prevalence among white
women 12–26 years old
HPV prevalence of five additional types
among white women 12–26 years old
HPV 16/18 prevalence among white
women 27 years old and above
HPV prevalence of five additional types
among white women 27 years old and
above

Base model
Value
0.224

Reference
Value
0.23

Reference

0.39

0.40

178

0.1144

0.115

190

0.07

0.053

190

0.209

0.235

190

0.078

0.063

190

0.09

0.089

190

0.095

0.098

190

0.094

0.082

190

0.06

0.0094

190

Unpublished
data from
Indian Health
Services

4.3.3 Model Scenarios
In this study we examined two different scenarios. The first scenario examined the
number of CIN3 cases reduced by 9-valent versus 4-valent vaccine among American
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Indian and White women in the Northern Plains. Table 11 shows the estimated number
of CIN2/3 cases reduced per 100,000 by vaccine type since the reference year (2014,
when the 9-valent vaccine was introduced), assuming 20% of cervical cancer cases are
attributable to the 5 additional types of HPV included in the 9-valent vaccine. The model
projects that after 30 years of vaccination, 371.4 per 100,000 CIN2 prevalent cases will
be reduced at that time due to 4-valent vaccine among American Indian women,
compared to 536 per 100,000 CIN 2 prevalent cases reduced at that time due to the 9valent vaccine. Similarly, 132 per 100,000 cases among white women will be reduced by
4-valent vaccine compared to 284.1 per 100,000 cases that will be reduced by the 9valent vaccine. Overall, there is a higher reduction in absolute terms in prevalent cases
of CIN2 and CIN3 due to 4-valent and 9-valent vaccine among American Indian women
compared to White women. Table 11 shows similar results for CIN3. Because the
prevalent cases of CIN3 are much smaller than CIN2, this highlights that the magnitude
of the impact of HPV vaccines to reduce CIN3 cases will be smaller.
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Table 11. CIN2/3 cases reduced per 100,000 by 9-valent vs 4-valent vaccine among
American Indians and whites
4-Valent

¥

American Indians

Whites

Year¥

15

30

15

CIN2

249.67

371.4

CIN3

71.6

112.5

9-Valent
American Indians

Whites

30

15

30

15

30

74.4

132.0

323.82

536.3

166.5

284.1

13.5

27.6

88.9

153.1

35.1

63.9

Years since the reference year of vaccination

As shown in Table 12, the model further projects that after 30 years from the reference
year, 16.34 cumulative cervical cancer cases per 100,000 life years lived will be avoided
by the 4-valent vaccine among American Indian women, while 18.41 cumulative cervical
cancer cases per 100,000 life years lived will be avoided by the 9-valent vaccine among
American Indian women. Similarly, the model predicts that 3.64 per 100,000 life years
lived cumulative cervical cancer cases per 100,000 life years lived will be avoided by 4valent vaccine among white women while 5.53 cumulative cervical cancer cases per
100,000 life years lived will be avoided by the 9-valent vaccine.
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Table 12. Cumulative Cervical Cancer Cases avoided per 100,000 life years lived among
American Indian women and White women
4-valent

9-valent

AI

White

AI

White

Year since the reference
15

30

15

30

15

30

15

30

9.05

18.41

2.25

5.53

year of vaccination
Cumulative cervical
8.51

16.34

1.74

3.64

cancer cases avoided per
100,000 life years lived

Figures 7 and 8 represent the CIN3 cases reduced per 100,000 by vaccine type
among American Indian women and white women. In absolute terms, the switch to 9valent vaccine from 4-valent vaccine further reduced the occurrence of CIN3, from a
reduction of 112.5 per 100,000 women to a reduction of 153.1 per 100,000 women. This
is an absolute difference of 40.6 per 100,000 women among American Indian. Among
whites, the switch to 9-valent from 4-valent vaccine further reduced the occurrence of
CIN3, from a reduction of 27.6 per 100,000 people to a reduction of 63.9 per 100,000
women. This is an absolute difference of 36.3 per 100,000 women. From the above
results, it is clear that American Indian women benefit more from the 9-valent vaccine
compared to the 4-valent vaccine.
Figures 9 and 10 represent the cumulative cervical cancer cases averted over time, by
vaccine status, among American Indian and white women. Caution should be taken in
interpreting the results; the scales of the graphs are different because of the large
difference in population size of American Indians and whites and thus are not
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comparable. However, it does provide a picture of cumulative cervical cancer cases that
would result per vaccination status.
The second scenario noted the number of cervical cancer cases averted by the 4valent vaccine when the vaccination coverage is increased to 80%. The model predicts
that after 30 years, with an increase in the current vaccination coverage from 23% to
80%, there will be a 25% decrease in the cumulative cervical cancer cases (Figure 11).
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Model Scenarios
Fig 7. CIN3 Cases reduced per 100,000 American Indians, by vaccine type
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Fig 8. CIN3 cases reduced per 100,000 white women, by vaccine type
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Fig 9 Cumulative Cervical Cancer Cases averted among American Indians, by
9-valent vs 4-valent vaccine
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Fig 10. Cumulative Cervical Cancer Cases averted among white women by
vaccine type
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Fig 11 Cumulative Cervical Cancer Cases Averted among American Indians
(AI), by increase in vaccination coverage of 4-valent vaccine
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4.4 Discussion
The main aim of this study was to investigate the potential impact of the 9-valent
vaccine in a high-risk population, using Northern Plain American Indians as an example.
We used a mathematical model and considered two different scenarios. The first
scenario examined the cervical cancer cases averted by 4-valent and 9-valent vaccine
among American Indian and white women in the Northern Plains. The second scenario
examined the cervical cancer cases reduced among American Indian women if the
vaccination coverage was increased from 23% to 80%.
Our study result indicates that incremental gains from introducing 9-valent
vaccine are higher among American Indian versus white women. The larger gains from
9-valent vaccination compared to 4-valent vaccination extends to both CIN3 and cervical
cancer. We believe that these results could still be an underestimate because we were
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unable to account for certain risk factors, such as the smoking rate.199 Previous studies
have indicated that persistent HPV infection is strongly associated with higher risk of
cervical cancer.200 Persistent HPV infection results in inactivation of p53 and pRb tumor
suppressor genes by the E6 and E7 proteins on the HPV genome. This, in turn, leads
gradually to severe intraepithelial neoplasia and ultimately to cervical cancer.191
Because smoking is a major risk factor for HPV persistence, it may be causing the 5
additional types to persist longer among American Indian women compared to white
women, resulting in a higher number of cervical cancer cases due to these types.
Additionally, another factor that needs to be taken into consideration is that there are still
certain types of HPV that are not included in the 9-valent vaccine (such as HPV 59, 39,
and 73) that are more prevalent in the American Indian population, 201 which raises an
important concern about whether the implementation of universal vaccine is the best
method in managing HPV infection and cervical cancer in specific populations such as
American Indians. Geographic variation in the HPV distribution can play an important
role in the effectiveness of the vaccination programs and policy development. On the
other hand, if future studies after taking into account all the above factors find significant
reduction in cervical cancer cases among American Indian women, then revaccinating
the American Indian women with the 9-valent vaccine should be taken into
consideration. Revaccinating might be more cost-effective, considering the small
population size.
Another interesting finding of our study was that with the increase in the current
vaccination coverage of 4-valent vaccine among American Indian women to 80% (a
Healthy People 2020 goal), we would be able to reduce 25% of the cumulative cervical
cancer cases after 30 years of vaccination. This is not a dramatic reduction in cumulative
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cervical cancer cases, indicating that vaccinating against HPV 16 and 18 alone may not
be sufficient, thus highlighting the benefit of 9-valent vaccine.
4.4.1 Strengths and Limitations
One of the major challenges we faced in conducting this study was lack of data
on certain parameters (e.g., transmission rate, progression rate, and regression rate),
specifically for the American Indian population. However, we did use calibrated values
for certain parameters, as predicted by the model. Another impediment in modelling
infectious disease is that it is difficult to include all relevant factors. For instance, we
were unable to take smoking into account. Smoking is a major risk factor for HPV
persistence and may be responsible for the higher rate of cervical cancer among
American Indian women. Tobacco smoking is believed to facilitate the acquisition or
persistence of an HPV infection through a reduced number of Langerhans cells and CD4
lymphocytes,62,63 which are markers of local immune response in the cervix.64,205
Although we were unable to account for this in our current study, future studies should
include smoking in their model to make the predictions closer to the reality. Second, we
assumed no cross-protection in our study, which may have affected the predicted
results. However, this may not be true, since recent studies on HPV vaccine have
demonstrated cross-protection against related HPV strains.189,202 Third, we did not
account for HIV in our model, which is a potential modifier of the HPV natural history. We
believe that since these factors were not taken into account, the results might be
underestimated. Fourth, the model was not stratified by HPV types and ethnicity but
instead done separately. This imposed several limitations including the omission of
mixing between ethnic groups, inability to quantify death over time, unable to take into
account multiple infections in an individual. Additionally, we were unable to understand
the effects of death due to one HPV type on the prevalence of the other HPV type. In
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addition, imprecise biological and behavioral measurements and the extreme sensitivity
of the systems to small changes in the parameter values are frequently challenging for
accurate quantitative predictions. Vaccination against HPV not only reduces the
incidence of the disease in those immunized but also indirectly protects nonvaccinated
susceptible persons against infection (called herd immunity). However, due to the static
nature of this model, we could not take herd immunity into account. Our model is based
on assumption of life-long immunity from the vaccine, which may not be the case in
reality. If the immunity against the infection is lost, HPV-infected women may move back
into the susceptible class, and the epidemiology of the HPV infection would be very
different; high observed prevalence and sero-prevalence would be possible, with much
lower basic reproductive number and transmission probability. This may further result in
reduced vaccine efficacy and coverage required for elimination with a vaccine that did
generate immune protection.203
We believe that our modeling approach has several strengths. First, this is the
first study to project the impact of HPV vaccine on American Indian women. Second, for
the validation, model results were compared to the data specific to American Indian
women and white women in the Northern Plains. Third, the vaccination coverage rate
used in this study was obtained from Indian Health Services and the Department of
Health, South Dakota, which makes the results more reliable. Finally, the model is
available to facilitate replication of findings and independent review of the model.

4.5 Conclusion
In summary, our model shows that 9-valent vaccine will substantially reduce the
cumulative cervical cancer cases among both American Indian and white women, with
larger gains among American Indian women. Currently, there is need for more specific
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data for the American Indian population to have more robust results. Future studies
should be conducted to collect more data on the Northern Plains American Indian
population, and a stochastic model should be developed that would allow random
variation in the inputs over time.
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Chapter 5
DISCUSSION

5.1 Current Research
The burden and cost of HPV-associated diseases and cancer remain a major
public health problem.162 The total medical cost of HPV infection for both men and
women aged 15-24 is estimated to be $2.9 billion, making HPV the second most
expensive STI after HIV.204 To reduce this burden, we identified two vulnerable
populations for our study: pregnant women and Northern Plain American Indian women,
both high-risk groups. Two aims of this project were centered on understanding the role
of HPV infection among pregnant women, as they are at higher risk of getting infected
than nonpregnant women. The third aim was focused on projecting the impact of 9valent HPV vaccine compared to 4-valent vaccine among American Indian women, since
the prevalence of certain HPV types is much higher among this group.
5.1.1 HPV infection and its role in pregnancy
There is limited research on HPV infection and its association with adverse
pregnancy outcomes. Recent research indicates that during pregnancy, the immune
system is suppressed and major physiological changes take place that may result in
increased HPV DNA replication.125 In an animal model study, a murine form of herpes
virus, MHV68, induced significant changes in the capacity of the trophoblast to respond
to additional danger signals. When lipopolysaccharide (at a dose level that has no effect
on pregnancy outcome) was injected into pregnant mice that were pre-exposed to
MHV68, the study demonstrated that viral infection modulates the capacity of the
trophoblast to cause increased inflammatory mediators in response to
lipopolysaccharides such as MCP-1, G-CSF, and IL-6.150 It is believed that HPV infection
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impairs the extravillious trophoblast invasion into the uterine wall by increasing the rate
of trophoblast cell deaths and causes placental dysfunction. As a consequence of this
placental dysfunction, adverse pregnancy outcomes may occur. To understand the role
of HPV infection in adverse pregnancy outcomes, the two main objectives of this project
were (1) to examine the HPV infection prevalence and its association with perinatal
outcomes among singleton mothers, with use of PRAMS data, and (2) to examine the
association of HPV infection with adverse pregnancy outcomes, with use of hospital
data. The results from these objectives will add to the existing body of HPV infection
knowledge, aid in the development of better future studies, and help to identify adverse
pregnancy outcomes that may be caused by HPV infection.
Overall, in both the PRAMS and hospital database studies, we found the
prevalence of HPV infection among pregnant women was lower than what has been
previously reported. However, the prevalence of HPV infection was even lower in the
PRAMS study (1.4%). This might be an underestimate because of certain limitations
associated with the data collection. This study was based on self-reported HPV
exposure status, whereas the other studies that have reported higher prevalence of HPV
infection were based on laboratory test results. Self-reported data are subject to recall
bias or may be under-reported or over-reported. Another factor that should be taken into
consideration is that out of 40 states that collect PRAMS data, only seven ask for HPV
information. HPV prevalence varies geographically, so it could be that the prevalence in
those seven states is lower than in some other states. Additionally, in the PRAMS survey
questionnaire, HPV infection is measured on the basis of a single multicategorical
question: “What disease or infection were you told you had?” One of the response
options for this question is “Genital Warts (HPV),” which may not be comprehensive for
all women. Except for the above question, there is no other question related to high-risk
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HPV or low-risk HPV. Genital warts are the result of low-risk HPV such as types 6 or 11
and not the cancer-causing HPV types such as HPV 16 or 18. So it might be that some
women with high-risk HPV did not report their status.
On the contrary, our hospital-based study involved laboratory-tested HPV
infection. The prevalence was found to be 4.4% in the total sample of 5,022 women.
Although the prevalence in this study was also lower than in previous studies (where it
ranges from 5.5% to 65%),205 it was still higher than what we found in the PRAMS
database. This suggests that further exploration is needed. The previous studies that
reported higher prevalence were conducted in the pre-vaccination era, so the decline in
the HPV prevalence noted in our study could be the result of vaccination program
effectiveness. Furthermore, we found that the prevalence of HPV among whites was
higher than in other ethnic/racial groups (including Black, American Indian, and
Hispanic), contrary to the national rates (51.6% vs. 31.5%). A study conducted by Dinh
et al. indicated that there is a higher prevalence of genital warts among whites compared
to blacks. 148 Because most genital warts are the result of HPV, the presence of these in
pregnant women would likely prompt healthcare professionals to perform HPV testing on
these women. This might be the reason for the higher prevalence of HPV infection
among white women in our study data.
Another component of both these studies was to examine the relationship
between HPV infection and adverse pregnancy outcomes, including preterm birth,
preeclampsia, low birth weight, and PROM. Our study based on the PRAMS database
did not find any significant association between HPV infection and adverse pregnancy
outcomes. However, in our hospital based study, we did find significant association
between HPV infection and adverse pregnancy outcomes, including preeclampsia,
preterm birth, and low birth weight. After controlling for demographic and clinical
variables, we observed that HPV-positive women were 2.80 times more likely to develop
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preeclampsia, 1.80 times more likely to have a preterm birth, and 2.58 times more likely
to deliver a low-birth-weight infant. In these studies, we controlled for co-infection with
chlamydia and gonorrhea, which wasn’t adjusted for in some of the previous studies,
raising some concerns related to the reliability of those results.
Our study findings also indicate that there is a significant difference in the
prevalence of other sexually transmitted infections by HPV status. For instance, the
prevalence of chlamydia was 9.2% among HPV-positive women, compared to 2.1%
among HPV-negative women. Similarly, prevalence of Group B streptococci was 21.7%
among HPV-positive women, compared to only 10% among HPV-negative women.
Although the specific role of these sexually transmitted infections in the natural history of
HPV is not clear, several mechanisms have been suggested. The most likely
mechanism is the initiation of cervical inflammation that may lead to genotoxic damage
through oxidative metabolites.206 Previous studies have found an association between
chlamydia and HPV.207 Some studies have suggested that co-infection with chlamydia
reduces the ability of the host to clear HPV infection. The chronic cervical inflammation
influences HPV persistence through increased production of free radicals and a
reduction of host-cell-mediated immunity.208,209 Chlamydia is believed to induce a shift in
the immune response, and the unresolved infections have been associated with a
humoral immune response, while clearance of HPV lesions have been associated with
cellular immune response. Thus, modulation of cervical immune response by chlamydia
may influence the clearance of HPV lesions.209 Because both HPV and chlamydia are
related to sexual behaviors, they may synergize in inducing cervical epithelium
alterations.18,210
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Although this study did not examine the relationship between HPV and chlamydia
among pregnant women, we believe that it is beneficial to understand the association
and its direction (casual inference) among pregnant women in future studies.
5.1.2 Impact of 9-valent HPV vaccine on Cervical Cancer
To our knowledge, this is the first published study to project the impact of 9valent HPV vaccine among Northern Plains American Indian women. The reason for
examining the impact on an American Indian population was that Northern Plains
American Indian/Alaska Native women are at 1.7 times greater risk of developing
cervical cancer than Non-Hispanic white women in the same region.81 Because the
prevalence of HPV differs among population groups in the United States, varying degree
of impact of HPV vaccine is expected. Gardasil 9, a 9-valent vaccine, was introduced in
December 2014. This vaccine seems to have greater potential to reduce cervical cancer
cases because it provides immunity against five additional types of HPV: 31, 33, 45, 52,
and 58.
Our study indicates that the incremental gains from introducing 9-valent vaccine are
higher among American Indian women compared to White women. The larger gains
from 9-valent vaccine compared to 4-valent vaccine extends to both CIN3 and cervical
cancer. The model predicted that after 30 years from the reference year, 16.34
cumulative cervical cancer cases per 100,000 life year lived will be avoided by the 4valent vaccine among American Indian women, while 18.41 cumulative cervical cancer
cases per 100,000 life year lived will be avoided by the 9-valent vaccine among
American Indian women. Similarly, the model predicts that 3.64 per 100,000 cumulative
cervical cancer cases per 100,000 life years lived will be avoided by 4-valent vaccine
among white women while 5.53 cumulative cervical cancer cases per 100,000 life years
lived will be avoided by the 9-valent vaccine. Additionally, the model predicted that in
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absolute terms the switch to 9-valent vaccine from 4-valent vaccine would further reduce
the occurrence of CIN3, from a reduction of 112.5 per 100,000 women to a reduction of
153.1 per 100,000 women, an absolute difference of 40.6 per 100,000 women among
American Indian. Among whites, the switch to 9-valent from 4-valent vaccine further
reduces the occurrence of CIN3, from a reduction of 27.6 per 100,000 people to a
reduction of 63.9 per 100,000 women. This is an absolute difference of 36.3 per 100,000
women.
In this study we also estimated the percent decrease in the cumulative cervical
cancer cases if the vaccination coverage is increased. The vaccination coverage of HPV
vaccine is much lower compared to other vaccines such as Tdap and meningococcal
conjugate vaccine.181 Some of the barriers to vaccination are higher cost of the
vaccine,211 parent’s negative perception about vaccine,212 health care providers not
strongly recommending HPV vaccine for young adolescents,213,214 and low vaccine
acceptance among adolescents.212 Parents are usually influenced by denial of risk
(believing that their child is not sexually active and therefore is not at risk of HPV212),
concerns about vaccine safety, and feeling that a vaccine is too new if it was approved
less than 10 years ago. 213 Moreover, currently only 21 states and D.C. have laws that
either require HPV vaccination for school entry, provide funding to cover the cost of
vaccines or support public education about HPV and vaccine (as shown in figure 12).215
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Figure 12.HPV Vaccination Policies- Mandates, Education, and Funding. Adapted from
The Henry J. Kaiser Family Foundation, 2015.215
Because of the low coverage of the HPV vaccine, it is one of the goals of Healthy
People 2020 to increase the HPV vaccination coverage to 80%. This study finding
shows that if the vaccination coverage among American Indian women with 4-valent
vaccine is increased from 23% to 80%, then after 30 years there will be a 25% decrease
in the cumulative cervical cancer cases.
Our study results show that 9-valent vaccine will have a greater impact in the
American Indian population. However, there are few things that need to be taken into
consideration when interpreting the results of the study. Our model was challenged by
the lack of parameter values specific to the American Indian population. For our study,
we had to assume that the parameter values for American Indian women were the same
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as for white women, which in reality may not be true, considering the environment as
well as genetic and behavioral differences. For instance, the smoking rates are much
higher in the American Indian population. Tobacco smoking is believed to facilitate the
acquisition or persistence of an HPV infection through a reduced number of Langerhans
cells and CD4 lymphocytes,62,63 which are markers of local immune response in the
cervix.64,205
Additionally, the activity of natural killer cells can be affected by tobacco
smoking, which may affect the innate immune response. 64 Thus, the progression rate,
regression rate, and clearance rate might vary drastically from what we see in the white
population. For the treatment rate we also had to rely on data for the white population.
However, to reduce the error, we conducted sensitivity analysis and validated our model
by comparing our model values to historical values. Additionally, in our study, we were
not able to account for smoking and HIV, which can modify the natural history of HPV
infection. Furthermore, we did not consider the effect of circumcision among males in the
model which may have an effect on the transmission probability of HPV infection from
males to females. Circumcision has been associated with a reduced prevalence and
persistence of oncogenic HPV infections.216 Since circumcision rates are much lower in
American Indian women compared to Whites, the transmission rate of HPV infection is
expected to be very different in the two populations.217 Because we were unable to
consider these factors in our model, we believe that our results might be
underestimated, especially among American Indian women. Another key limitation of this
study was that the model was not stratified by HPV types and ethnicity, but instead done
separately. This imposed several limitations including omission of mixing between ethnic
groups, inability to quantify death over time, unable to take into account multiple

82
infections in an individual. Additionally, we were unable to understand the effects of
death due to one type of HPV on prevalence of the other type of HPV.

5.2 Future Directions
5.2.1 Future Directions Based On Research of HPV among Pregnant Women
We found that there is a relationship between HPV infection and adverse
pregnancy outcomes, including preterm birth, low birth weight, and preeclampsia.
However, there is a need for future prospective studies to study these relationships in
more depth. For instance, a cohort of women who are planning to get pregnant within the
next 2 years can be selected randomly from the community. The cohort then can be
divided into two groups: women who have been exposed to HPV and those who have not
been exposed. These women could be followed up until their delivery. This type of study
would allow us to analyze behavioral factors along with other factors before and during
the pregnancy. This would be helpful because women tend to change certain behaviors
(e.g., smoking, alcohol consumption, physical activity) during pregnancy, which may
influence their self-reported responses. Additionally, there is a need for a populationbased database that collects HPV information on pregnant women. We recommend that
other states collecting PRAMS data should include HPV-related questions in their
questionnaire that would allow researchers to explore the relationship at a population
level. Also, new questions related to HPV infection should be included in the
questionnaire, since currently there is only one question, which is very narrow. To get a
clear picture of HPV infection among pregnant women questions like: “Were you ever
told by a physician that you have HPV?” or “Were you ever diagnosed with genital
warts?” or a more specific question like: “When you were pregnant, were you informed by
your healthcare provider that you have HPV?” might be useful.
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In addition, our study identified factors that should be considered when conducting
similar research. First, we recommend future studies exclude ASCUS specimens.
Although 50% of ASCUS specimens demonstrate HR-HPV, 218 other infections can also
result in ASCUS. Second, gestational age of infection is an important factor that we think
should be considered. Previous studies have reported that HPV prevalence varies by
gestational age. Third, vaccination status should be considered since it could confound
the association between HPV and adverse obstetrics outcomes. Fourth, in addition to
chlamydia and gonorrhea, bacterial vaginosis should be taken into consideration, as it is
associated with poor pregnancy outcomes.
5.2.2 Future Directions Based On HPV Modelling Research
We found that the 9-valent HPV vaccine will have a larger impact on American
Indian women women than white. However, our study identified gaps in knowledge that
may have caused underestimation of cervical cancer cases among American Indian
women in the Northern Plains. Further epidemiological studies should be conducted in
the Northern Plain American Indian population to collect information on the sexual
behaviors, screening rate, cervical intraepithelial neoplasia treatment rate, transmission
rate of HPV from men to women and vice versa, progression rate, regression rate, and
clearance rate of HPV among these women. Information on sexual behaviors can be
collected with the help of surveys, and for certain parameters such as
progression/regression/clearance rate, it might be useful to conduct a prospective study.
This could be done by recruiting a randomly selected cohort of women with HPV
infection. The cohort can then be divided into two groups (HR-HPV type and LR-HPV
type), since the rates of progression, regression, and clearance may vary by HPV type.
Then these women could be followed over time, for 5 years, a time period that would
allow us to see the necessary changes. Women receiving treatment should also be
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recorded. Although, this would be the best approach to gather all the necessary
information, it might be difficult considering the challenges associated with conducting
research among American Indian populations. Acknowledging this fact, the other
approach is to conduct a mixed method research. A random sample of women receiving
care at Indian Health Services should be obtained. All those women who provides their
consent to participate in the study should be given surveys to gather information on their
sexual behavior. This information should be later linked to the past health records of an
individual from the clinic.
It was challenging for us to conduct a study without population-specific parameters, and
we believe that this is a void that should be filled for better understanding of HPV
vaccination. For example, it would be beneficial to study sexual behaviors and calculate
the transmission rate, based on the sexual activity level. Because not every person has
the same level of sexual activity, the transmission rate would not be the same across the
population. Additionally, we recommend that future studies should include smoking as
one of the parameters because it is known to cause modification in the natural history of
HPV. Another important factor that should be considered is waning immunity. Given the
significance of the duration of protection on the effectiveness of HPV vaccination, it
would be essential to conduct post-vaccination surveillance. If the vaccine immunity
does wane, then from the health policy standpoint it would be essential to consider
booster shots, which would help in maintaining vaccine-induced immunity. For simplicity
of the model and based on previous literature, we assumed life-long immunity after
vaccination and assumed that after clearance of HPV infection the immunity wanes after
5 years in both American Indian and white population. However, this assumption may
not be valid in reality. It could be possible that due to gene-environment interaction the
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immunity wanes sooner in American Indian than white women. Hence, more studies are
needed to explore this research area.
Furthermore, future studies are recommended to stratify the model by HPV
types and ethnicity instead of creating a separate model. By doing so, various limitations
associated with the current model such as the omission of mixing between ethnic
groups, inability to quantify death over time, inability to account for multiple infections in
an individual could be avoided.
5.3 Conclusion
Overall, this dissertation fills gaps in knowledge about the impact of HPV on
two vulnerable populations; pregnant women and Northern Plains American Indian
women. This is the first population based study that estimated HPV prevalence among
pregnant women and examined its role in adverse pregnancy outcomes. In addition, this
project identified the need for consistent HPV testing among pregnant women. In regard
to American Indian population, this project emphasized the need of epidemiological data
that would help in making future predictions using mathematical modeling techniques.
These modeling techniques could also be applied to other vulnerable populations such
as Black and Hispanics. Because of limitations, the findings of this study cannot be used
to provide clinical recommendations, but they do provide knowledge that will be useful to
the advancement of future research.
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APPENDIX
HPV Model Equations for American Indian Population
 "Cancer cases lived per year per 100,000 with five additional types"=Cancer cases
lived per year five additional types*100000
 "Cancer cases lived per life year per 100,000 nona"= "Cancer Cases lived per life
year (nona)"*100000
 Cancer cases lived per life year per 100000= "Cancer cases lived per year
(quad)"*100000
 "vacc rate (FiveAdditionalTypes)"= IF THEN ELSE (Time < 8, 0 , Prospective nona
vaccination rate)
 Prospective nona vaccination rate=0.03
 total population of women nona=total population of women quadrivalent
 Cumulative count cancer cases nona= Cumulative cervical cancer cases 12 to 26
FiveAdditionalTypes+Cumulative cervical cancer cases 12 to 26 quad +Cumulative
Cervical Cancer cases 27 and above FiveAdditionalTypes+"cumulative cervical
cancer cases quad 27&above"
 cumulative count of cervical cancer cases five additional types= Cumulative cervical
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 27
and above FiveAdditionalTypes
 Cumulative count of cervical cancer cases quad= Cumulative cervical cancer cases
12 to 26 quad+" cumulative cervical cancer cases quad 27&above"
 Cancer cases lived per year five additional types= zidz(cumulative count of cervical
cancer cases five additional types,life years lived five additional types)
 "Cancer Cases lived per life year (nona)"= zidz(cumulative count cancer cases
nona,Life years lived nona)
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 "Cancer cases lived per year (quad)"= zidz(cumulative count of cervical cancer
cases quad,life years lived quad)
 Life years lived nona= INTEG (total population of women nona,0)
 total population of women quad= total population of women quadrivalent
 Total population of five additonal types= total population of women 12 to 26
quadrivalent+ total population of women 27 and above FiveAdditionalTypesvalent
 total population of women five additional types= Total population of five additional
types
 life years lived quad= INTEG (total population of women quad,1)
 life years lived five additional types= INTEG (total population of women five
additional types,0)
 Ref rate of clearance of HPV infected quad 27 and above= 0.5922
 reg1 12 to 26FiveAdditionalTypes= Rate of regression CIN2 to CIN1 five additional
types*CIN2 12to 26 FiveAdditionalTypes
 clearance2 FiveAdditionalTypes= "Rate of clearance of CIN2 five additional types
27&above"*CIN2 27 and above FiveAdditionalTypes
 "reg1 27&above FiveAdditionalTypes"= Rate of regression CIN2 to CIN1 five
additional types*CIN2 27 and above FiveAdditionalTypes
 clearance3 among 12 to 26 quad= Ref Rate of clearance of CIN3 quad 12 to
26*CIN3 12 to 26 quad*Coefficient of clearance for quad
 clearance3 FiveAdditionalTypes= Rate of clearance of CIN3 five additional types 27
and above*CIN3 27 and above FiveAdditionalTypes
 "reg2 27 &above FiveAdditionalTypes"= Rate of Regression CIN3 to CIN2 five
additional types*CIN3 27 and above FiveAdditionalTypes
 reg3 12 to 26FiveAdditionalTypes= Rate of regression CIN3 to CIN1 five additional
types*CIN3 12to26 FiveAdditionalTypes
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 Ref rate of clearance of CIN2 quad 27 and above= 0.21
 "reg3 27&above FiveAdditionalTypes"= Rate of regression CIN3 to CIN1 five
additional types*CIN3 27 and above FiveAdditionalTypes
 "clearance1 27&above quad"= Ref rate of clearance of CIN1 quad 27 and
above*CIN1 27 and above quad*Coefficient of clearance for quad
 Rate of regression CIN3 to CIN1 five additional types= 0.03
 Rate of Regression CIN3 to CIN2 five additional types= 0.03
 "clear2 27 & above quad"= Ref rate of clearance of CIN2 quad 27 and above*CIN2
27 and above quad*Coefficient of clearance for quad
 "clear3 27&above quad"= Ref rate of clearance of CIN3 quad 27 and above*CIN3
27 and above quad*Coefficient of clearance for quad
 Rate of clearance of HPV infected five additional types 27 and above= 0.47705
 clearance of HPV infected 27 and above quad= HPV infected 27and above
quad*Ref rate of clearance of HPV infected quad 27 and above *Coefficient of
clearance for quad
 "clearance of infection 27&above FiveAdditionalTypes"= Rate of clearance of HPV
infected five additional types 27 and above*HPV infected 27 and above
FiveAdditionalTypes
 Ref rate of clearance of CIN1 quad 27 and above= 0.4606
 Rate of clearance of CIN1 five additional types 27 and above= 0.329
 Rate of regression CIN2 to CIN1 five additional types= 0.133
 "Rate of clearance of CIN2 five additional types 27&above"= 0.21
 reg2 26no= Rate of Regression CIN3 to CIN2 five additional types*CIN3 12to26
FiveAdditionalTypes
 Rate of clearance of CIN3 five additional types 27 and above= 0.11
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 "clearance1 27 & above FiveAdditionalTypes"= Rate of clearance of CIN1 five
additional types 27 and above*CIN1 27 and above FiveAdditionalTypes
 Ref rate of clearance of CIN3 quad 27 and above= 0.11
 rx1 12to26 FiveAdditionalTypes= Fraction of CIN1 successfully cured*screening
rate FiveAdditionalTypes*sensitivity CIN1 *CIN1 12 to26 FiveAdditionalTypes
 "rx3 27&above quad"= Fraction of CIN3 successfully cured*sensitivity CIN2and
CIN3*screening rate*CIN3 27 and above quad
 "rx2 27&above quad"= screening rate*Fraction of CIN2 successfully
cured*sensitivity CIN2and CIN3*CIN2 27 and above quad
 "rx1 27&above quad"= Fraction of CIN1 successfully cured*screening
rate*sensitivity CIN1*CIN1 27 and above quad
 rx2 12to26 FiveAdditionalTypes= Fraction of CIN2 successfully cured*screening
rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN2 12to 26
FiveAdditionalTypes
 rx3 12to26 FiveAdditionalTypes= Fraction of CIN3 successfully cured*screening
rate FiveAdditionalTypes*sensitivity CIN2and CIN3 *CIN3 12to26
FiveAdditionalTypes
 clearance1 among 12to26 quad= Ref Rate of clearance of CIN1 quad 12 to
26*CIN1 12 to 26 quad*Coefficient of clearance for quad
 clearance2 among 12to26 quad= Ref Rate of clearance of CIN2 quad 12 to
26*CIN2 12 to 26 quad*Coefficient of clearance for quad
 Coefficient of clearance for quad= 0.68
 HPV infected clearance rate 12 to 26 quad= HPV infected 12 to 26 quad*Ref Rate
of clearance of HPV infected quad 12 to 26*Coefficient of clearance for quad
 prog2 12to26FiveAdditionalTypes=CIN1 to CIN2 hazard rate
FiveAdditionalTypes*CIN1 12 to26 FiveAdditionalTypes
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 "prog2 27& above FiveAdditionalTypes"= CIN1 to CIN2 hazard rate
FiveAdditionalTypes*CIN1 27 and above FiveAdditionalTypes
 clearance2 12to 26 FiveAdditionalTypes= Rate of clearance of CIN2
FiveAdditionalTypes 12 to 26*CIN2 12to 26 FiveAdditionalTypes
 prog3 12 to 26FiveAdditionalTypes= CIN2 to CIN3 hazard rate
FiveAdditionalTypes*CIN2 12to 26 FiveAdditionalTypes
 clearance3 12to26 FiveAdditionalTypes= Rate of clearance of CIN3
FiveAdditionalTypes 12 to 26*CIN3 12to26 FiveAdditionalTypes
 "prog1 27 & above FiveAdditionalTypes"= HPV infected to CIN1 hazard rate
FiveAdditionalTypes*HPV infected 27 and above FiveAdditionalTypes
 Rate of clearance of CIN3 FiveAdditionalTypes 12 to 26= 0.11
 clearance hpv infected 12 to 26FiveAdditionalTypes= Rate of clearance of HPV
infected FiveAdditionalTypes 12 to 26*HPV infected 12to26 FiveAdditionalTypes
 Rate of clearance of HPV infected FiveAdditionalTypes 12 to 26= 0.1316
 CIN3 to cervical cancer hazard rate FiveAdditionalTypes= 0.42
 CIN1 12 to26 FiveAdditionalTypes= INTEG (prog1 12 to
26FiveAdditionalTypes+reg1 12 to 26FiveAdditionalTypes+reg3 12 to
26FiveAdditionalTypes-CIN1 12 to 26 FiveAdditionalTypes aging-CIN1 deaths 12to
26FiveAdditionalTypes-clearance1 12to26 FiveAdditionalTypes-prog2
12to26FiveAdditionalTypes-rx1 12to26 FiveAdditionalTypes, Initially HPV infected
12 to 26 women with FiveAdditionalTypes who are at CIN1)
 "prog3 27& above FiveAdditionalTypes"= CIN2 to CIN3 hazard rate
FiveAdditionalTypes*CIN2 27 and above FiveAdditionalTypes
 rate of clearance of CIN1 FiveAdditionalTypes 12 to 26= 0.329
 CIN2 to CIN3 hazard rate FiveAdditionalTypes= 0.14
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 "prog4 27&above FiveAdditionalTypes"= CIN3 to cervical cancer hazard rate
FiveAdditionalTypes*CIN3 27 and above FiveAdditionalTypes
 HPV infected to CIN1 hazard rate FiveAdditionalTypes= 0.094
 CIN1 to CIN2 hazard rate FiveAdditionalTypes=0.136
 progression4 12to26 FiveAdditionalTypes= CIN3 12to26 FiveAdditionalTypes*CIN3
to cervical cancer hazard rate FiveAdditionalTypes
 HPV infected 12to26 FiveAdditionalTypes= INTEG (infection
12to26FiveAdditionalTypes-clearance hpv infected 12 to 26FiveAdditionalTypesdeaths infected 12to 26 FiveAdditionalTypes-hpv infected 12 to
26FiveAdditionalTypes aging-prog1 12 to 26FiveAdditionalTypes initially infected
HPV women 12 to 26 from US census for FiveAdditionalTypes that are not CIN1)
 clearance1 12to26 FiveAdditionalTypes= rate of clearance of CIN1
FiveAdditionalTypes 12 to 26*CIN1 12 to26 FiveAdditionalTypes
 Rate of clearance of CIN2 FiveAdditionalTypes 12 to 26= 0.21
 prog1 12 to 26FiveAdditionalTypes= HPV infected to CIN1 hazard rate
FiveAdditionalTypes*HPV infected 12to26 FiveAdditionalTypes
 total cumulative cervical cancer cases 5 additional types= Cumulative cervical
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 27
and above FiveAdditionalTypes
 total cumulative cervical cancer cases quad= Cumulative cervical cancer cases 12
to 26 quad+"cumulative cervical cancer cases quad 27&above"
 women 27 and above who have been vaccinated quad= INTEG (aging into women
27 and above who have been vaccinated quad-death of women 27 and above who
have been vaccinated quad, 0)
 aging into women 27 and above who have been vaccinated FiveAdditionalTypes=
aging women 12 to 26 who have been vaccinated FiveAdditionalTypes
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 aging into women 27 and above who have been vaccinated quad= aging number of
women 12 to 26 who are vaccinated quad
 death of women 27 and above who have been vaccinated quad= women 27 and
above who have been vaccinated quad*"death rate for 27&above"
 death of number of women 12 to 26 who are vaccinated FiveAdditionalTypes=
women 12 to 26 FiveAdditionalTypes who have been vaccinated*death rate 12 to
26
 new vaccination of 12to 26 FiveAdditionalTypes=total population of women 12 to 26
FiveAdditionalTypesvalent*"vacc rate (FiveAdditionalTypes)"
 death of women 27 and above who have been vaccinated FiveAdditionalTypes=
Women 27 and above who have been vaccinated FiveAdditionalTypes*"death rate
for 27&above"
 Women 27 and above who have been vaccinated FiveAdditionalTypes= INTEG
(aging into women 27 and above who have been vaccinated FiveAdditionalTypesdeath of women 27 and above who have been vaccinated FiveAdditionalTypes, 0)
 fraction of women 12 to 26 who have been vaccinated= women 12 to 26
FiveAdditionalTypes who have been vaccinated/total population of women 12 to 26
FiveAdditionalTypesvalent
 aging women 12 to 26 who have been vaccinated FiveAdditionalTypes= women 12
to 26 FiveAdditionalTypes who have been vaccinated/mean years until aging
 women 12 to 26 FiveAdditionalTypes who have been vaccinated= INTEG (new
vaccination of 12to 26 FiveAdditionalTypes-death of number of women 12 to 26
who are vaccinated FiveAdditionalTypes-aging women 12 to 26 who have been
vaccinated FiveAdditionalTypes,0)
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 Women 12 to 26 who have been vaccinated quad= INTEG (new vaccinations of 12
to 26 women-aging number of women 12 to 26 who are vaccinated quad-death of
number of women 12 to 26 who are vaccinated,0)
 new vaccinations of 12 to 26 women= total population of women 12 to 26
quadrivalent*vacc rate
 aging number of women 12 to 26 who are vaccinated quad= Women 12 to 26 who
have been vaccinated quad/mean years until aging
 death of number of women 12 to 26 who are vaccinated= Women 12 to 26 who
have been vaccinated quad*death rate 12 to 26
 vacc quad= Susceptible12to26 quad*vacc rate*vaccine efficacy
 fraction of women 12 to 26 who have been vaccinated quad= Women 12 to 26 who
have been vaccinated quad/total population of women 12 to 26 quadrivalent
 vacc rate= 0.03
 fraction of susceptible women 27 and above FiveAdditionalTypes= Susceptible
27and above FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent
 Fraction of women susceptible 12 to 26 quad= Susceptible12to26 quad/total
population of women 12 to 26 quadrivalent
 Fraction of women susceptible 12 to 26 FiveAdditionalTypes= susceptible 12 to26
FiveAdditionalTypes/total population of women 12 to 26 FiveAdditionalTypesvalent
 fraction of women that are susceptible for 27 and above quad= Susceptible 27and
above quad/total population of women 27 and above quadrivalent
 Inital 27 and above CIN1 infected women from HPV quad infected= fraction of
women 27 and above who were infected with quad and are CIN1*Initial 27 and
above HPV quad infected women from US census including CIN1
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 HPV infected 27 and above FiveAdditionalTypes= INTEG (aging into hpv infected
FiveAdditionalTypes+"infection 27&above FiveAdditionalTypes"-"clearance of
infection 27&above FiveAdditionalTypes"-infected 27 and above deaths
FiveAdditionalTypes-"prog1 27 & above FiveAdditionalTypes", initially HPV infected
women 27 and above not CIN1 FiveAdditionalTypes)
 fraction of women 27 from US census who are infected with HPV quad strain=
(0.0528*0) +0.1
 initially infected HPV women 12 to 26 from US census for FiveAdditionalTypes that
are not CIN1=Initially infected HPV women 12 to 26 from US census including CIN1
for FiveAdditionalTypes-Initially HPV infected 12 to 26 women with
FiveAdditionalTypes who are at CIN1
 Initially susceptible women 12 to 26 from US census= Total initial population 12 to 26
from US census-(Initially CIN1 infected women from HPV infected women+Initially
HPV infected women from US census for quad not CIN1)
 HPV infected 12 to 26 quad= INTEG (infection rate among 12to26 quad-aging hpv
infected 12 to 26 quad-deaths of infected 12 to 26 quad-HPV infected clearance rate
12 to 26 quad-progression1 among 12 to 26 quad, Initially HPV infected women from
US census for quad not CIN1)
 Initally susceptible women 12 to 26 from US census for FiveAdditionalTypes= Total
initial population 12 to 26 from US census-(Initially HPV infected 12 to 26 women
with FiveAdditionalTypes who are at CIN1+initially infected HPV women 12 to 26
from US census for FiveAdditionalTypes that are not CIN1)
 Initially HPV infected women 27 and above from US census for quad not CIN1=
Initial 27 and above HPV quad infected women from US census including CIN1Inital 27 and above CIN1 infected women from HPV quad infected
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 Initial susceptible women 27 and above from US census FiveAdditionalTypes=
total initial population 27 and above from US census-(initially HPV infected
women 27 and above not CIN1 FiveAdditionalTypes+ Initial 27 and above at
CIN1 from HPV infected women with FiveAdditionalTypes strain)
 total population of women 27 and above quadrivalent= HPV infected 27and
above quad+ Susceptible 27and above quad+CIN1 27 and above quad +CIN2
27 and above quad+CIN3 27 and above quad+Immune via vaccination 27 and
above quad+ Immune after HPV clearance 27 and above quad
 Initially susceptible women 27 and above from US census= total initial population
27 and above from US census-(Initially HPV infected women 27 and above from
US census for quad not CIN1+Initial 27 and above CIN1 infected women from
HPV quad infected)
 Initial 27 and above HPV quad infected women from US census including CIN1=
fraction of women 27 from US census who are infected with HPV quad
strain*total initial population 27 and above from US census
 initially HPV infected women 27 and above not CIN1 FiveAdditionalTypes=
Initially infected 27 and above with HPV FiveAdditionalTypes including CIN1Inital 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes
strain
 total population of women 12 to 26 quadrivalent= HPV infected 12 to 26 quad+
Susceptible12to26 quad+CIN1 12 to 26 quad+ CIN2 12 to 26 quad+CIN3 12 to
26 quad +Immune via vaccination 12to26 quad+Immune after HPV infection
clearance 12 to 26 quad
 total population of women 12 to 26 FiveAdditionalTypesvalent= CIN1 12 to26
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26
FiveAdditionalTypes+ HPV infected 12to26 FiveAdditionalTypes +susceptible 12
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to26 FiveAdditionalTypes+ immune via vacc 12 to 26 FiveAdditionalTypes
+Immune after HPV infection 12 to26 FiveAdditionalTypes
 Initially HPV infected women from US census for quad not CIN1= Initially HPV
infected women from US census for quad including CIN1-Initially CIN1 infected
women from HPV infected women
 total population of women 27 and above FiveAdditionalTypesvalent= CIN1 27
and above FiveAdditionalTypes+CIN2 27 and above FiveAdditionalTypes+CIN3
27 and above FiveAdditionalTypes +HPV infected 27 and above
FiveAdditionalTypes+ Susceptible 27and above FiveAdditionalTypes +immune
via vaccination 27 and above FiveAdditionalTypes +Immune after HPV infection
27and above FiveAdditionalTypes
 HPV infected 27and above quad= INTEG (Aging into HPV infected 27+"infection
27&above quad"-clearance of HPV infected 27 and above quad-"deaths of
infected 27&above quad"-prog1 27and above quad, Initially HPV infected women
27 and above from US census for quad not CIN1)
 Immune after HPV clearance 27 and above quad= INTEG (aging into immune
after HPV clearance 27 and above quad+"clear2 27 & above quad"+"clear3
27&above quad"+ clearance of HPV infected 27 and above quad+"clearance1
27&above quad"+"rx1 27&above quad"+"rx2 27&above quad"+"rx3 27&above
quad"-death of immune after HPV clearance 27 and above-waning immunity after
infection among 27 and above quad,0)
 Susceptible 27and above quad= INTEG (Aging into susceptible 27+waning
immunity after infection among 27 and above quad-"infection 27&above quad"susceptible27 deaths+"waning immunity among 27 and above (quad)”, Initially
susceptible women 27 and above from US census)
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 Immune after HPV infection 27and above FiveAdditionalTypes= INTEG (aging
into immune after HPV infection 27 and above FiveAdditionalTypes+"clearance
of infection 27&above FiveAdditionalTypes"+"clearance1 27 & above
FiveAdditionalTypes"+clearance2 FiveAdditionalTypes+clearance3
FiveAdditionalTypes+"rx1 27& above FiveAdditionalTypes"+"rx2 27& above
FiveAdditionalTypes"+"rx3 27&above FiveAdditionalTypes" -Deaths of immune
after vaccination 27 and above FiveAdditionalTypes-waning immunity after
infection 27 and above nano,0)
 susceptible 12 to26 FiveAdditionalTypes= INTEG ("Aging females <12
FiveAdditionalTypes"+waning immunity after vaccination 12to 26 nano +waning
immunity of 27 and above FiveAdditionalTypes-death of susceptibles 12to 26noinfection 12to26FiveAdditionalTypes-Susceptible 12 to 26 FiveAdditionalTypes
aging-vacc FiveAdditionalTypes, Initally susceptible women 12 to 26 from US
census for FiveAdditionalTypes)
 immune via vacc 12 to 26 FiveAdditionalTypes= INTEG (vacc
FiveAdditionalTypes-aging of immune 12 to 26 FiveAdditionalTypes-deaths of
immune 12 to 26 FiveAdditionalTypes-waning immunity after vaccination 12to 26
nano-waning immunity after vaccination 12to 26 nano,0)
 "rx2 27& above FiveAdditionalTypes"=Fraction of CIN2 successfully
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN2 27
and above FiveAdditionalTypes
 Immune via vaccination 12to26 quad= INTEG (vacc quad-aging immune via
vaccination 12 to 26 quad-deaths of immune 12 to 26 quad-waning immunity
after vaccination among 12to26quad,0)
 Susceptible12to26 quad= INTEG ("Aging of female <12"-aging susceptible 12to
26 quad-deaths of susceptible 12 to 26 quad-infection rate among 12to26 quad-
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vacc quad+ Waning immunity after infection 12 to 26 quad+ waning immunity
after vaccination among 12to26quad, Initially susceptible women 12 to 26 from
US census)
 waning immunity after infection among 27 and above quad=Immune after HPV
clearance 27 and above quad/Time until waning immunity after infection
 Susceptible 27and above FiveAdditionalTypes= INTEG (aging into susceptible
27 and FiveAdditionalTypes+waning immunity after infection 27 and above nano"infection 27&above FiveAdditionalTypes"-susceptible 27 and above
deaths+waning immunity after vaccination 27 and above FiveAdditionalTypes,
Initial susceptible women 27 and above from US census FiveAdditionalTypes)
 time until waning immunity after vaccination=10
 waning immunity after vaccination among 12to26quad= (Immune via vaccination
12to26 quad/time until waning immunity after vaccination)*"enable waning
immunity after vaccination?"
 "enable waning immunity after vaccination?"=0
 waning immunity after vaccination 12to 26 nano=(immune via vacc 12 to 26
FiveAdditionalTypes/time until waning immunity after vaccination)*"enable
waning immunity after vaccination?"
 rx2 12to26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN2
successfully cured*CIN2 12 to 26 quad
 waning immunity after vaccination 27 and above FiveAdditionalTypes= (immune
via vaccination 27 and above FiveAdditionalTypes/time until waning immunity
after vaccination)* "enable waning immunity after vaccination?"
 waning immunity after infection 27 and above nano= Immune after HPV infection
27and above FiveAdditionalTypes/Time until waning immunity after infection
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 "waning immunity among 27 and above (quad)"= (Immune via vaccination 27 and
above quad/time until waning immunity after vaccination) *"enable waning
immunity after vaccination?"
 fraction of women 12to26 immune via vaccination quad= Immune via vaccination
12to26 quad/total population of women 12 to 26 quadrivalent

 waning immunity of 27 and above FiveAdditionalTypes= Immune after HPV
infection 12 to26 FiveAdditionalTypes/Time until waning immunity after infection
 aging of immune after HPV infection 12 to 26 FiveAdditionalTypes=
 Immune after HPV infection 12 to26 FiveAdditionalTypes/mean years until aging
 aging into immune after HPV clearance 27 and above quad= aging of immune
after HPV infection clearance 12 to 26 quad
 Immune after HPV infection 12 to26 FiveAdditionalTypes= INTEG (clearance1
12to26 FiveAdditionalTypes+clearance2 12to 26
FiveAdditionalTypes+clearance3 12to26 FiveAdditionalTypes+rx1 12to26
FiveAdditionalTypes+rx2 12to26 FiveAdditionalTypes+rx3 12to26
FiveAdditionalTypes-deaths of immune after HPV infection 12 to 26
FiveAdditionalTypes-waning immunity of 27 and above FiveAdditionalTypesaging of immune after HPV infection 12 to 26 FiveAdditionalTypes+ clearance
hpv infected 12 to 26FiveAdditionalTypes,0)
 deaths of immune after HPV infection 12 to 26 FiveAdditionalTypes= death rate
12 to 26*Immune after HPV infection 12 to26 FiveAdditionalTypes
 Deaths of immune after vaccination 27 and above FiveAdditionalTypes= "death
rate for 27&above"*Immune after HPV infection 27and above
FiveAdditionalTypes
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 aging into immune after HPV infection 27 and above FiveAdditionalTypes= aging
of immune after HPV infection 12 to 26 FiveAdditionalTypes
 Waning immunity after infection 12 to 26 quad= Immune after HPV infection
clearance 12 to 26 quad/Time until waning immunity after infection
 Time until waning immunity after infection= 5
 incidence of cc per 100000 12to26= (Progression4 among 12 to 26 quad/total
population of women 12 to 26 quadrivalent)*100000
 aging of immune after HPV infection clearance 12 to 26 quad= Immune after
HPV infection clearance 12 to 26 quad/mean years until aging
 deaths of immune after HPV infection clearance= Immune after HPV infection
clearance 12 to 26 quad*death rate 12 to 26
 death of immune after HPV clearance 27 and above= Immune after HPV
clearance 27 and above quad*"death rate for 27&above"
 Immune after HPV infection clearance 12 to 26 quad= INTEG (HPV infected
clearance rate 12 to 26 quad+clearance1 among 12to26 quad+clearance2
among 12to26 quad+clearance3 among 12 to 26 quad+rx1 12to26 quad+rx2
12to26 quad+rx3 12 to 26 quad -Waning immunity after infection 12 to 26 quadaging of immune after HPV infection clearance 12 to 26 quad-deaths of immune
after HPV infection clearance,0)
 force of infection 12to26 quad=mean partner acquisition 12 to 26*(Fraction of
partners of 12 to 26 year old women that are in 12 to 26 year of age* HPV
prevalence 12 to 26 quad+ (1-Fraction of partners of 12 to 26 year old women
that are in 12 to 26 year of age) * HPV prevalence 27 and above quad)
*transmission rate 12to26
 force of infection 12 to 26 FiveAdditionalTypes= mean partner acquistion 12 to
26*(Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of
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age* HPV prevalence 12to26FiveAdditionalTypes+ (1-Fraction of partners of 12
to 26 year old women that are in 12 to 26 year of age) * HPV prevalence 27 and
above FiveAdditionalTypes)* transmission rate 12to26
 transmission rate 12to26= 0.4
 CIN3 27 and above deaths FiveAdditionalTypes= "death rate for
27&above"*CIN3 27 and above FiveAdditionalTypes
 CIN3 12to26 FiveAdditionalTypes= INTEG (prog3 12 to 26FiveAdditionalTypesCIN3 12 to 26 FiveAdditionalTypes aging-CIN3 deaths
12to26FiveAdditionalTypes-clearance3 12to26 FiveAdditionalTypes-reg2 26noreg3 12 to 26FiveAdditionalTypes-rx3 12to26 FiveAdditionalTypes +prog3 12 to
26FiveAdditionalTypes-progression4 12to26 FiveAdditionalTypes,0)
 "CIN3 27 & above death quad"= "death rate for 27&above"*CIN3 27 and above
quad
 CIN3 27 and above FiveAdditionalTypes= INTEG (aging into cin3
FiveAdditionalTypes+"prog3 27& above FiveAdditionalTypes"-CIN3 27 and
above deaths FiveAdditionalTypes-clearance3 FiveAdditionalTypes-"prog4
27&above FiveAdditionalTypes"-"reg2 27 &above FiveAdditionalTypes"-"reg3
27&above FiveAdditionalTypes"-"rx3 27&above FiveAdditionalTypes"+"prog3
27& above FiveAdditionalTypes"-"prog4 27&above FiveAdditionalTypes", 0)
 CIN3 27 and above quad= INTEG ("Aging into CIN3 27&above quad"+prog3
27and above quad-"CIN3 27 & above death quad"-"clear3 27&above quad"-"reg2
27&above quad"-reg3 27 and above quad-"rx3 27&above quad"+prog3 27and
above quad-prog4 27and above quad,0)
 "CIN1 27&above deaths quad"= "death rate for 27&above"*CIN1 27 and above
quad
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 immune via vacc deaths quad= Immune via vaccination 27 and above
quad*"death rate for 27&above"
 Cumulative cervical cancer cases 12 to 26 FiveAdditionalTypes= INTEG
(progression4 12to26 FiveAdditionalTypes,0)
 Cumulative Cervical Cancer cases 27 and above FiveAdditionalTypes= INTEG
("prog4 27&above FiveAdditionalTypes", 0)
 "cumulative cervical cancer cases quad 27&above"= INTEG (prog4 27and above
quad,0)
 infected 27 and above deaths FiveAdditionalTypes= "death rate for
27&above"*HPV infected 27 and above FiveAdditionalTypes
 prog4 27and above quad= CIN3 27 and above quad*CIN3 to cervical cancer
hazard rate quad
 "death rate for 27&above"= 0.005417
 Progression4 among 12 to 26 quad= CIN3 to cervical cancer hazard rate
quad*CIN3 12 to 26 quad
 "CIN1 27 &above deaths FiveAdditionalTypes"= CIN1 27 and above
FiveAdditionalTypes*"death rate for 27&above"
 susceptible27 deaths= Susceptible 27and above quad*"death rate for 27&above"
 "CIN2 27&above deaths FiveAdditionalTypes"= CIN2 27 and above
FiveAdditionalTypes*"death rate for 27&above"
 deaths of immune 27 and above FiveAdditionalTypes="death rate for
27&above"*immune via vaccination 27 and above FiveAdditionalTypes
 susceptible 27 and above deaths="death rate for 27&above"*Susceptible 27and
above FiveAdditionalTypes
 prog4 27 and above quad per 100000= (prog4 27and above quad/total
population of women 27 and above quadrivalent)*100000
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 CIN3 12 to 26 quad= INTEG (-Aging CIN3 12 to 26 FiveAdditionalTypesclearance3 among 12 to 26 quad-deaths of CIN3 12 to 26 quad-regression2
12to26 quad-Regression3 12to26 quad-rx3 12 to 26 quad+progression3 among
12 to 26 quad-Progression4 among 12 to 26 quad,0)
 CIN2 deaths among 27 and above quad= CIN2 27 and above quad*"death rate
for 27&above"
 "deaths of infected 27&above quad"= HPV infected 27and above quad*"death
rate for 27&above"
 Cumulative cervical cancer cases 12 to 26 quad= INTEG (Progression4 among
12 to 26 quad,0)
 total population of men and women FiveAdditionalTypes= total population of
women FiveAdditionalTypesvalent*(1+Ratio of male to female population)
 "Initial susceptible women <12 years FiveAdditionalTypesvalent"= 37112
 "Female <12 FiveAdditionalTypes"= INTEG (birth FiveAdditionalTypes-"Aging
females <12 FiveAdditionalTypes"-"death of females <12 years", "Initial
susceptible women <12 years FiveAdditionalTypesvalent")
 total population of men and women quad= total population of women
quadrivalent*(1+Ratio of male to female population)
 birth FiveAdditionalTypes= birth rate for female babies*total population of men
and women FiveAdditionalTypes
 birth quad= total population of men and women quad*birth rate for female babies
 Ratio of male to female population= 0.96
 rx3 12 to 26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN3
successfully cured*CIN3 12 to 26 quad
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 "rx3 27&above FiveAdditionalTypes"= Fraction of CIN3 successfully
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN3 27
and above FiveAdditionalTypes
 "rx1 27& above FiveAdditionalTypes"= Fraction of CIN1 successfully
cured*screening rate FiveAdditionalTypes*sensitivity CIN1*CIN1 27 and above
FiveAdditionalTypes
 rx1 12to26 quad= sensitivity CIN1*screening rate*Fraction of CIN1 successfully
cured*CIN1 12 to 26 quad
 HPV infected FiveAdditionalTypes per 100000= (HPV infected 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 CIN3 among 12 to 26 per 100000 quad= (CIN3 12 to 26 quad/total population of
women 12 to 26 quadrivalent)*100000
 CIN2 12to26 quad per 100000= (CIN2 12 to 26 quad/total population of women
12 to 26 quadrivalent)*100000
 CIN3 FiveAdditionalTypes per 100000= (CIN3 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 CIN2 27 and above per 100000 quad=(CIN2 27 and above quad/total population
of women 27 and above quadrivalent)*100000
 CIN1 12to26 per 100000 quad= (CIN1 12 to 26 quad/total population of women
12 to 26 quadrivalent)*100000
 CIN1 26FiveAdditionalTypes per 100000= (CIN1 12 to26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
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 hpv infected 27 and above per 100000 quad=(HPV infected 27and above
quad/total population of women 27 and above quadrivalent)*100000
 "CIN1 27& above FiveAdditionalTypes per 100000"= (CIN1 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 CIN3 12 to 26 per 100000 FiveAdditionalTypes= (CIN3 12to26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
 "CIN1 27&above per 100000 quad"= (CIN1 27 and above quad/total population
of women 27 and above quadrivalent)*100000
 CIN3 27 and above per 100000 quad= (CIN3 27 and above quad/total population
of women 27 and above quadrivalent)*100000
 CIN2 12 to 26per 100000 FiveAdditionalTypes= (CIN2 12to 26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
 "total population of women (quad+FiveAdditionalTypes)"= total population of
women 12 to 26 FiveAdditionalTypesvalent+total population of women 12 to 26
quadrivalent +total population of women 27 and above
FiveAdditionalTypesvalent+total population of women 27 and above quadrivalent
 total population="total population of women (quad+FiveAdditionalTypes)"*ratio of
total population to total population of women
 "CIN2 27&above FiveAdditionalTypes per 100000"= (CIN2 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 HPV infected 12 to 26 per 100000 quad=(HPV infected 12 to 26 quad/total
population of women 12 to 26 quadrivalent)*100000
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 hpv infected 12 to 26FiveAdditionalTypes per 100000= (HPV infected 12to26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
 Aging into HPV infected 27= aging hpv infected 12 to 26 quad
 "Females <12 quad"= INTEG (birth quad-"Aging of female <12"-"death of
females< 12 years of age", "Initial susceptible females <12 quad")
 "Initial susceptible females <12 quad"= 37112
 total population of women FiveAdditionalTypesvalent= total population of women
12 to 26 FiveAdditionalTypesvalent+total population of women 27 and above
FiveAdditionalTypesvalent
 "HPV Infection (quad) among 12 to 26 count"= CIN1 12 to 26 quad+CIN2 12 to
26 quad+CIN3 12 to 26 quad+HPV infected 12 to 26 quad
 HPV prevalence 27 and above FiveAdditionalTypes= ("HPV infection among 27
and above (FiveAdditionalTypes) count")/total population of women 27 and
above FiveAdditionalTypesvalen
 HPV prevalence 12 to 26 quad= ("HPV Infection (quad) among 12 to 26
count")/total population of women 12 to 26 quadrivalent
 "HPV infection among 12 to 26 (FiveAdditionalTypes) count"=CIN1 12 to26
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26
FiveAdditionalTypes +HPV infected 12to26 FiveAdditionalTypes
 "HPV infection among 27 and above (FiveAdditionalTypes) count"= HPV infected
27 and above FiveAdditionalTypes+CIN1 27 and above FiveAdditionalTypes+
CIN2 27 and above FiveAdditionalTypes+CIN3 27 and above
FiveAdditionalTypes
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 "HPV infection among 27 and above (quad) count"= CIN1 27 and above
quad+CIN2 27 and above quad+CIN3 27 and above quad+HPV infected 27and
above quad
 HPV prevalence 12to26FiveAdditionalTypes= ("HPV infection among 12 to 26
(FiveAdditionalTypes) count")/total population of women 12 to 26
FiveAdditionalTypesvalent
 HPV prevalence 27 and above quad= ("HPV infection among 27 and above
(quad) count")/total population of women 27 and above quadrivalent
 CIN1 12 to 26 quad= INTEG (progression1 among 12 to 26 quad+regression1
12to26 quad+Regression3 12to26 quad-aging CIN1 12to26 quad-clearance1
among 12to26 quad-deaths of CIN1 12to26 quad-progression2 among 12 to 26
quad-rx1 12to26 quad, Initially CIN1 infected women from HPV infected women)
 CIN1 27 and above FiveAdditionalTypes= INTEG (aging into CIN1
FiveAdditionalTypes+"prog1 27 & above FiveAdditionalTypes"+"reg1 27&above
FiveAdditionalTypes"+"reg3 27&above FiveAdditionalTypes"-"CIN1 27 &above
deaths FiveAdditionalTypes"-"clearance1 27 & above FiveAdditionalTypes""prog2 27& above FiveAdditionalTypes"-"rx1 27& above FiveAdditionalTypes",
Initial 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes
strain)
 total population of women quadrivalent= total population of women 12 to 26
quadrivalent+total population of women 27 and above quadrivalent
 deaths of immune 12 to 26 FiveAdditionalTypes= death rate 12 to 26*immune via
vacc 12 to 26 FiveAdditionalTypes
 aging into immune via vaccination 27 and above quad= aging immune via
vaccination 12 to 26 quad
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 deaths of immune 12to 26 FiveAdditionalTypes= death rate 12 to 26*immune via
vacc 12 to 26 FiveAdditionalTypes
 aging immune via vaccination 12 to 26 quad= Immune via vaccination 12to26
quad/mean years until aging
 aging into immune via vacc 27 and above FiveAdditionalTypes= aging of immune
12 to 26 FiveAdditionalTypes
 immune via vaccination 27 and above FiveAdditionalTypes= INTEG (aging into
immune via vacc 27 and above FiveAdditionalTypes-deaths of immune 27 and
above FiveAdditionalTypes-waning immunity after vaccination 27 and above
FiveAdditionalTypes,0)
 Immune via vaccination 27 and above quad= INTEG (aging into immune via
vaccination 27 and above quad-"waning immunity among 27 and above (quad)"immune via vacc deaths quad,0)
 aging of immune 12 to 26 FiveAdditionalTypes= immune via vacc 12 to 26
FiveAdditionalTypes/mean years until aging
 vacc FiveAdditionalTypes= susceptible 12 to26 FiveAdditionalTypes*"vacc rate
(FiveAdditionalTypes)"*vaccine efficacy
 HPV prevalence 27 and above per 100 quad= HPV prevalence 27 and above
quad*100
 HPV prevalence 12 to 26 per 100 FiveAdditionalTypes= HPV prevalence
12to26FiveAdditionalTypes*100
 HPV prevalence 27 and above FiveAdditionalTypes per 100= HPV prevalence 27
and above FiveAdditionalTypes*100
 HPV prevalence 12 to 26 quad per 100= HPV prevalence 12 to 26 quad*100
 CIN1 27 and above quad= INTEG ("Aging into CIN1 27&above quad"+prog1
27and above quad+reg1 27 and above quad+reg3 27 and above quad-"CIN1
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27&above deaths quad"-"clearance1 27&above quad"-prog2 27and above quad"rx1 27&above quad", Initial 27 and above CIN1 infected women from HPV quad
infected)
 fraction of women 27 and above who were infected with quad and are CIN1=
0.09
 Total initial population 12 to 26 from US census= 38736
 total initial population 27 and above from US census=67313
 Initially HPV infected 12 to 26 women with FiveAdditionalTypes who are at CIN1=
Initially infected HPV women 12 to 26 from US census including CIN1 for
FiveAdditionalTypes*Fraction of 12 to 26 years who are initially infected with
HPV FiveAdditionalTypes who have CIN1
 Initially HPV infected women from US census for quad including CIN1=Total
initial population 12 to 26 from US census*Fraction of women 12 to 26 from US
cenus who are HPV infected for quad strain
 Initially infected HPV women 12 to 26 from US census including CIN1 for
FiveAdditionalTypes = Fraction of US 12 to 26 census population that is initially
infected with FiveAdditionalTypes strain of HPV *Total initial population 12 to 26
from US census

 Fraction of women 27 and above from HPV FiveAdditionalTypes infected that are
CIN1= 0.1184

 fraction of women 27 and above from susceptible that are infected with HPV
FiveAdditionalTypes=0.08
 Fraction of 12 to 26 years old who are initially infected with quad strains of HPV
who have CIN1=0.09
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 Initially CIN1 infected women from HPV infected women= Initially HPV infected
women from US census for quad including CIN1*Fraction of 12 to 26 years old
who are initially infected with quad strains of HPV who have CIN1

 Initially infected 27 and above with HPV FiveAdditionalTypes including CIN1=
fraction of women 27 and above from susceptible that are infected with HPV
FiveAdditionalTypes*total initial population 27 and above from US census
 Inital 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes
strain= Fraction of women 27 and above from HPV FiveAdditionalTypes infected
that are CIN1*Initally infected 27 and above with HPV FiveAdditionalTypes
including CIN1
 Fraction of women 12 to 26 from US cenus who are HPV infected for quad
strain= 0.15
 Fraction of 12 to 26 years who are intially infected with HPV FiveAdditionalTypes
who have CIN1=0.09
 Fraction of US 12 to 26 census population that is initially infected with
FiveAdditionalTypes strain of HPV= 0.27
 death of susceptible 12to 26no= susceptible 12 to26 FiveAdditionalTypes*death
rate 12 to 26
 CIN1 deaths 12to 26FiveAdditionalTypes= CIN1 12 to26
FiveAdditionalTypes*death rate 12 to 26
 deaths of CIN3 12 to 26 quad= death rate 12 to 26*CIN3 12 to 26 quad
 deaths of immune 12 to 26 quad= Immune via vaccination 12to26 quad*death
rate 12 to 26
 deaths of infected 12 to 26 quad= death rate 12 to 26*HPV infected 12 to 26
quad
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 CIN3 deaths 12to26FiveAdditionalTypes= CIN3 12to26
FiveAdditionalTypes*death rate 12 to 26
 CIN2 deaths 12to 26 FiveAdditionalTypes= CIN2 12to 26
FiveAdditionalTypes*death rate 12 to 26
 CIN2 27 and above quad= INTEG (Aging into CIN2 27 and above quad-"clear2
27 & above quad"+prog2 27and above quad-prog3 27and above quad +"reg2
27&above quad"-CIN2 deaths among 27 and above quad-reg1 27 and above
quad-"rx2 27&above quad",0)
 deaths infected 12to 26 FiveAdditionalTypes= HPV infected 12to26
FiveAdditionalTypes*death rate 12 to 26
 deaths of CIN2 12 to 26 quad= death rate 12 to 26*CIN2 12 to 26 quad
 CIN2 27 and above FiveAdditionalTypes= INTEG (aging into cin2
FiveAdditionalTypes+"prog2 27& above FiveAdditionalTypes"+"reg2 27 &above
FiveAdditionalTypes"-"CIN2 27&above deaths FiveAdditionalTypes"-clearance2
FiveAdditionalTypes-"prog3 27& above FiveAdditionalTypes"-"reg1 27&above
FiveAdditionalTypes"-"rx2 27& above FiveAdditionalTypes",0)
 deaths of CIN1 12to26 quad= CIN1 12 to 26 quad*death rate 12 to 26
 deaths of susceptible 12 to 26 quad= Susceptible12to26 quad*death rate 12 to
26
 Ref Rate of clearance of CIN1 quad 12 to 26= 0.4606
 Ref Rate of clearance of CIN2 quad 12 to 26= 0.21
 Ref Rate of clearance of CIN3 quad 12 to 26= 0.11
 vaccine efficacy= 0.9
 "death of females< 12 years of age"= "death rate of females <12
years"*"Females <12 quad"
 "death rate of females <12 years"= 0.0002195
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 "death of females <12 years"= "death rate of females <12 years"*"Female <12
FiveAdditionalTypes"
 force of infection 27 and above quad= mean partner acquisition rate 27 and
above*(fraction of partners 27 years and older women that are in 27 years and
older *HPV prevalence 27 and above quad +(1-fraction of partners 27 years and
older women that are in 27 years and older)* HPV prevalence 12 to 26
quad)*transmission rate 27 and above
 force of infection 27 and above FiveAdditionalTypes= mean partner acquisition
rate 27 and above * (fraction of partners 27 years and older women that are in 27
years and older * HPV prevalence 27 and above FiveAdditionalTypes + (1fraction of partners 27 years and older women that are in 27 years and older) *
HPV prevalence 12to26FiveAdditionalTypes)*transmission rate 27 and above
 fraction of partners 27 years and older women that are in 27 years and older=
0.915
 Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of age=
0.33
 "Aging females <12 FiveAdditionalTypes"= "Female <12
FiveAdditionalTypes"/"mean years of aging for <12 years old"
 "Aging of female <12"= "Females <12 quad"/"mean years of aging for <12 years
old"
 "mean years of aging for <12 years old"= 12
 reg3 27 and above quad= CIN3 27 and above quad*Rate of Reg CIN3 to CIN1
quad
 Fraction of CIN1 successfully cured= 0.96
 "reg2 27&above quad"= Rate of Reg CIN3 to CIN2 quad*CIN3 27 and above
quad
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 regression2 12to26 quad= Rate of Reg CIN3 to CIN2 quad*CIN3 12 to 26 quad
 Regression3 12to26 quad= Rate of Reg CIN3 to CIN1 quad*CIN3 12 to 26 quad
 Rate of Reg CIN3 to CIN2 quad= 0.03
 regression1 12to26 quad= Rate of regression CIN2 to CIN1 quad*CIN2 12 to 26
quad
 reg1 27 and above quad= CIN2 27 and above quad*Rate of regression CIN2 to
CIN1 quad
 Rate of Reg CIN3 to CIN1 quad= 0.03
 Fraction of CIN3 successfully cured= 0.92
 Rate of regression CIN2 to CIN1 quad= 0.133
 Fraction of CIN2 successfully cured= 0.92
 CIN3 to cervical cancer hazard rate quad= 0.546
 progression1 among 12 to 26 quad= HPV infected to CIN1 hazard rate
quad*HPV infected 12 to 26 quad
 progression2 among 12 to 26 quad= CIN1 to CIN2 hazard rate quad*CIN1 12 to
26 quad
 progression3 among 12 to 26 quad= CIN2 to CIN3 hazard rate quad*CIN2 12 to
26 quad
 HPV infected to CIN1 hazard rate quad= 0.1692
 prog2 27and above quad= CIN1 to CIN2 hazard rate quad*CIN1 27 and above
quad
 prog3 27and above quad= CIN2 to CIN3 hazard rate quad*CIN2 27 and above
quad
 CIN2 to CIN3 hazard rate quad=0.252
 prog1 27and above quad= HPV infected to CIN1 hazard rate quad*HPV infected
27and above quad
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 CIN1 to CIN2 hazard rate quad= 0.2448
 "Aging into CIN1 27&above quad"= aging CIN1 12to26 quad
 aging into CIN1 FiveAdditionalTypes= CIN1 12 to 26 FiveAdditionalTypes aging
 Aging into CIN2 27 and above quad= aging CIN2 12to 26 quad
 aging into cin2 FiveAdditionalTypes= CIN2 12to26 FiveAdditionalTypes aging
 "Aging into CIN3 27&above quad"= Aging CIN3 12 to 26 FiveAdditionalTypes
 aging into cin3 FiveAdditionalTypes= CIN3 12 to 26 FiveAdditionalTypes aging
 aging into hpv infected FiveAdditionalTypes= hpv infected 12 to
26FiveAdditionalTypes aging
 Aging into susceptible 27= aging susceptible 12to 26 quad
 aging into susceptible 27 and FiveAdditionalTypes= Susceptible 12 to 26
FiveAdditionalTypes aging
 CIN1 12 to 26 FiveAdditionalTypes aging= CIN1 12 to26
FiveAdditionalTypes/mean years until aging
 ratio of total population to total population of women=2
 mean partner acquistion 12 to 26= 1.64
 aging CIN1 12to26 quad= CIN1 12 to 26 quad/mean years until aging
 aging CIN2 12to 26 quad= CIN2 12 to 26 quad/mean years until aging
 aging hpv infected 12 to 26 quad= HPV infected 12 to 26 quad/mean years until
aging
 aging susceptible 12to 26 quad=Susceptible12to26 quad/mean years until aging
 Susceptible 12 to 26 FiveAdditionalTypes aging= susceptible 12 to26
FiveAdditionalTypes/mean years until aging
 CIN2 12to 26 FiveAdditionalTypes= INTEG (prog2
12to26FiveAdditionalTypes+reg2 26no-CIN2 deaths 12to 26
FiveAdditionalTypes-clearance2 12to 26 FiveAdditionalTypes-prog3 12 to
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26FiveAdditionalTypes-reg1 12 to 26FiveAdditionalTypes-rx2 12to26
FiveAdditionalTypes-CIN2 12to26 FiveAdditionalTypes aging,0)
 CIN2 12to26 FiveAdditionalTypes aging= CIN2 12to 26
FiveAdditionalTypes/mean years until aging
 hpv infected 12 to 26FiveAdditionalTypes aging= HPV infected 12to26
FiveAdditionalTypes/mean years until aging
 CIN3 12 to 26 FiveAdditionalTypes aging= CIN3 12to26
FiveAdditionalTypes/mean years until aging
 CIN2 12 to 26 quad= INTEG (+progression2 among 12 to 26 quad+regression2
12to26 quad-clearance2 among 12to26 quad-progression3 among 12 to 26
quad-regression1 12to26 quad-rx2 12to26 quad-aging CIN2 12to 26 quad-deaths
of CIN2 12 to 26 quad,0)
 Aging CIN3 12 to 26 FiveAdditionalTypes= CIN3 12 to 26 quad/mean years until
aging
 mean years until aging= 15
 birth rate for female babies= (0.0124 / 2)
 death rate 12 to 26= 0.000647
 "total infected HPV 16 &18"= HPV infected 12 to 26 per 100000 quad+hpv
infected 27 and above per 100000 quad
 "total infected (5 additional types)"= hpv infected 12 to 26FiveAdditionalTypes per
100000+HPV infected FiveAdditionalTypes per 100000
 "total CIN1 HPV 16&18"= CIN1 12to26 per 100000 quad+"CIN1 27&above per
100000 quad"
 "total CIN1 (5 additional types)"= CIN1 26FiveAdditionalTypes per 100000+"CIN1
27& above FiveAdditionalTypes per 100000"
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 "total CIN2 HPV 16 &18"= CIN2 12to26 quad per 100000+CIN2 27 and above
per 100000 quad
 "total CIN2 (5 additional types)"= CIN2 12 to 26per 100000
FiveAdditionalTypes+"CIN2 27&above FiveAdditionalTypes per 100000"
 "total CIN3 HPV 16&18"= CIN3 among 12 to 26 per 100000 quad+CIN3 27 and
above per 100000 quad
 "total CIN3 (5 additional types)"= CIN3 12 to 26 per 100000
FiveAdditionalTypes+CIN3 FiveAdditionalTypes per 100000
 total infected= HPV infected FiveAdditionalTypes per 100000+HPV infected 12 to
26 per 100000 quad+ hpv infected 12 to 26FiveAdditionalTypes per 100000+hpv
infected 27 and above per 100000 quad
 total CIN 1= CIN1 12to26 per 100000 quad+"CIN1 27& above
FiveAdditionalTypes per 100000"+CIN1 26FiveAdditionalTypes per
100000+"CIN1 27&above per 100000 quad"
 "infection 27&above quad"= force of infection 27 and above quad*Susceptible
27and above quad
 infection 12to26FiveAdditionalTypes= force of infection 12 to 26
FiveAdditionalTypes*susceptible 12 to26 FiveAdditionalTypes
 total CIN2= "CIN2 27&above FiveAdditionalTypes per 100000"+CIN2 12to26
quad per 100000+CIN2 12 to 26per 100000 FiveAdditionalTypes+CIN2 27 and
above per 100000 quad
 total CIN3= CIN3 FiveAdditionalTypes per 100000+CIN3 among 12 to 26 per
100000 quad+CIN3 12 to 26 per 100000 FiveAdditionalTypes+CIN3 27 and
above per 100000 quad
 screening rate FiveAdditionalTypes= 0.73
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 "infection 27&above FiveAdditionalTypes"= force of infection 27 and above
FiveAdditionalTypes*Susceptible 27and above FiveAdditionalTypes
 infection rate among 12to26 quad= force of infection 12to26
quad*Susceptible12to26 quad
 Ref Rate of clearance of HPV infected quad 12 to 26= 0.3619
 mean partner acquisition rate 27 and above= 1.19
 screening rate= 0.73
 sensitivity CIN1= 0.28
 sensitivity CIN2and CIN3= 0.59
 transmission rate 27 and above= 0.4

HPV Model Equations for White Population
 cumulative count of cancer cases nonavalent= Cumulative cervical cancer cases
12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 27 and above
FiveAdditionalTypes+Cumulative cervical cancer cases 12 to 26
quad+"cumulative cervical cancer cases quad 27&above"
 "Cancer cases lived per life year per 100000(five adiditional types)"= cancer
cases lived per life year five additional types*100000
 "Cancer cases lived per life year per 100,000 (nona)"= cancer cases lived per life
year nonavalent*100000
 "Cancer cases lived per life year per 100,000 quad"= Cancer cases lived per life
year quad*100000
 prospective nona vaccination rate= 0.053
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 "vacc rate (FiveAdditionalTypes)"= IF THEN ELSE(Time <8, 0 , prospective nona
vaccination rate )
 cumulative life years lived five additional types= INTEG (total population five
additional types,0)
 cumulative cervical cancer cases count five additional types= Cumulative cervical
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases
27 and above FiveAdditionalTypes
 cancer cases lived per life year five additional types= zidz(cumulative cervical
cancer cases count five additional types,cumulative life years lived five additional
types)
 total population of women quad= total population of women quadrivalent
 cumulative count of cervical cancer cases of quad= Cumulative cervical cancer
cases 12 to 26 quad+"cumulative cervical cancer cases quad 27&above"
 total population nona= total population nonavalent
 cumulative life years lived nonavalent= INTEG (total population nona, 0)
 cumulative life years lived quad= INTEG (total population of women quad,0)
 Cancer cases lived per life year quad=zidz(cumulative count of cervical cancer
cases of quad, cumulative life years lived quad)
 total population five additional types=total population of women
FiveAdditionalTypesvalent
 total population nonavalent= total population of women 12 to 26
FiveAdditionalTypesvalent+ total population of women 27 and above
FiveAdditionalTypesvalent
 cancer cases lived per life year nonavalent= zidz(cumulative count of cancer
cases nonavalent,cumulative life years lived nonavalent)
 Ref Rate of clearance of HPV infected quad 27 and above= 0.483
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 clearance3 FiveAdditionalTypes= Rate of clearance of CIN3 five additional types
27 and above*CIN3 27 and above FiveAdditionalTypes
 "clearance of infection 27&above FiveAdditionalTypes"= Rate of clearance of
HPV infected five additional types 27 and above*HPV infected 27 and above
FiveAdditionalTypes
 clearance2 FiveAdditionalTypes= Rate of clearance of CIN2five additional types
27 and above*CIN2 27 and above FiveAdditionalTypes
 Rate of clearance of CIN3 five additional types 27 and above= 0.11
 Ref rate of clearance of CIN1 quad 27 and above= 0.483
 clearance of HPV infected 27 and above quad=HPV infected 27and above
quad*Ref Rate of clearance of HPV infected quad 27 and above*Coefficient of
clearance for quad
 "clearance1 27 & above FiveAdditionalTypes"= Rate of clearance of CIN1 five
additional types 27 and above*CIN1 27 and above FiveAdditionalTypes
 Ref rate of clearance of CIN3 quad 27 and above= 0.11
 Rate of clearance of HPV infected five additional types 27 and above= 0.41125
 Rate of clearance of CIN1 five additional types 27 and above= 0.329
 "clear2 27 & above quad"= Ref rate of clearance of CIN2 quad 27 and
above*CIN2 27 and above quad*Coefficient of clearance for quad
 "clear3 27&above quad"= Ref rate of clearance of CIN3 quad 27 and
above*CIN3 27 and above quad*Coefficient of clearance for quad
 "clearance1 27&above quad"= Ref rate of clearance of CIN1 quad 27 and
above*CIN1 27 and above quad*Coefficient of clearance for quad
 Ref rate of clearance of CIN2 quad 27 and above= 0.21
 Rate of clearance of CIN2five additional types 27 and above= 0.21
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 rx1 12to26 FiveAdditionalTypes= Fraction of CIN1 sucessfully cured*screening
rate FiveAdditionalTypes*sensitivity CIN1 *CIN1 12 to26 FiveAdditionalTypes
 "rx3 27&above quad"= Fraction of CIN3 successfully cured*sensitivity CIN2and
CIN3*screening rate*CIN3 27 and above quad
 "rx2 27&above quad"= screening rate*Fraction of CIN2 successfully
cured*sensitivity CIN2and CIN3*CIN2 27 and above quad
 "rx1 27&above quad"= Fraction of CIN1 sucessfully cured*screening
rate*sensitivity CIN1*CIN1 27 and above quad
 rx2 12to26 FiveAdditionalTypes= Fraction of CIN2 successfully cured*screening
rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN2 12to 26
FiveAdditionalTypes
 rx3 12to26 FiveAdditionalTypes=Fraction of CIN3 successfully cured*screening
rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN3 12to26
FiveAdditionalTypes
 clearance1 among 12to26 quad= Ref Rate of clearance of CIN1 quad 12 to
26*CIN1 12 to 26 quad*Coefficient of clearance for quad
 clearance3 among 12 to 26 quad= Ref Rate of clearance of CIN3 quad 12 to
26*CIN3 12 to 26 quad*Coefficient of clearance for quad
 clearance2 among 12to26 quad= Ref Rate of clearance of CIN2 quad 12 to
26*CIN2 12 to 26 quad*Coefficient of clearance for quad
 Coefficient of clearance for quad= 0.74
 HPV infected clearance rate 12 to 26 quad= HPV infected 12 to 26 quad*Ref
Rate of clearance of HPV infected quad 12 to 26*Coefficient of clearance for
quad
 prog2 12to26FiveAdditionalTypes= CIN1 to CIN2 hazard rate
FiveAdditionalTypes*CIN1 12 to26 FiveAdditionalTypes
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 "prog2 27& above FiveAdditionalTypes"= CIN1 to CIN2 hazard rate
FiveAdditionalTypes*CIN1 27 and above FiveAdditionalTypes
 clearance2 12to 26 FiveAdditionalTypes= Rate of clearance of CIN2
FiveAdditionalTypes 12 to 26*CIN2 12to 26 FiveAdditionalTypes
 prog3 12 to 26FiveAdditionalTypes= CIN2 to CIN3 hazard rate
FiveAdditionalTypes*CIN2 12to 26 FiveAdditionalTypes
 clearance3 12to26 FiveAdditionalTypes= Rate of clearance of CIN3
FiveAdditionalTypes 12 to 26*CIN3 12to26 FiveAdditionalTypes
 "prog1 27 & above FiveAdditionalTypes"= HPV infected to CIN1 hazard rate
FiveAdditionalTypes*HPV infected 27 and above FiveAdditionalTypes
 Rate of clearance of CIN3 FiveAdditionalTypes 12 to 26= 0.11
 clearance hpv infected 12 to 26FiveAdditionalTypes= Rate of clearance of HPV
infected FiveAdditionalTypes 12 to 26*HPV infected 12to26 FiveAdditionalTypes
 Rate of clearance of HPV infected FiveAdditionalTypes 12 to 26= 0.27965
 CIN3 to cervical cancer hazard rate FiveAdditionalTypes= 0.42
 CIN1 12 to26 FiveAdditionalTypes= INTEG (prog1 12 to
26FiveAdditionalTypes+reg1 12 to 26FiveAdditionalTypes+reg3 12 to
26FiveAdditionalTypes-CIN1 12 to 26 FiveAdditionalTypes aging-CIN1 deaths
12to 26FiveAdditionalTypes-clearance1 12to26 FiveAdditionalTypes -prog2
12to26FiveAdditionalTypes-rx1 12to26 FiveAdditionalTypes, Initially HPV
infected 12 to 26 women with FiveAdditionalTypes who are at CIN1)
 "prog3 27& above FiveAdditionalTypes"= CIN2 to CIN3 hazard rate
FiveAdditionalTypes*CIN2 27 and above FiveAdditionalTypes
 Rate of clearance of CIN1 FiveAdditionalTypes 12 to 26=0.329
 CIN2 to CIN3 hazard rate FiveAdditionalTypes= 0.14
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 "prog4 27&above FiveAdditionalTypes"= CIN3 to cervical cancer hazard rate
FiveAdditionalTypes*CIN3 27 and above FiveAdditionalTypes
 HPV infected to CIN1 hazard rate FiveAdditionalTypes= 0.094
 CIN1 to CIN2 hazard rate FiveAdditionalTypes= 0.136
 progression4 12to26 FiveAdditionalTypes= CIN3 12to26
FiveAdditionalTypes*CIN3 to cervical cancer hazard rate FiveAdditionalTypes
 HPV infected 12to26 FiveAdditionalTypes= INTEG (infection
12to26FiveAdditionalTypes-clearance hpv infected 12 to 26FiveAdditionalTypesdeaths infected 12to 26 FiveAdditionalTypes-hpv infected 12 to
26FiveAdditionalTypes aging-prog1 12 to 26FiveAdditionalTypes, initially infected
HPV women 12 to 26 from US census for FiveAdditionalTypes that are not CIN1)
 clearance1 12to26 FiveAdditionalTypes= Rate of clearance of CIN1
FiveAdditionalTypes 12 to 26*CIN1 12 to26 FiveAdditionalTypes
 Rate of clearance of CIN2 FiveAdditionalTypes 12 to 26= 0.21
 prog1 12 to 26FiveAdditionalTypes= HPV infected to CIN1 hazard rate
FiveAdditionalTypes*HPV infected 12to26 FiveAdditionalTypes
 total cumulative cervical cancer cases 5 additional types= Cumulative cervical
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases
27 and above FiveAdditionalTypes
 total cumulative cervical cancer cases quad= Cumulative cervical cancer cases
12 to 26 quad+"cumulative cervical cancer cases quad 27&above"
 Total cumulative cervical cancer nona=Cumulative cervical cancer cases 12 to
26 FiveAdditionalTypes+Cumulative cervical cancer cases 12 to 26
quad+Cumulative Cervical Cancer cases 27 and above
FiveAdditionalTypes+"cumulative cervical cancer cases quad 27&above"
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 women 27 and above who have been vaccinated quad= INTEG (aging into
women 27 and above who have been vaccinated quad-death of women 27 and
above who have been vaccinated quad,0)
 aging into women 27 and above who have been vaccinated
FiveAdditionalTypes= aging women 12 to 26 who have been vaccinated
FiveAdditionalTypes
 aging into women 27 and above who have been vaccinated quad= aging number
of women 12 to 26 who are vaccinated quad
 death of women 27 and above who have been vaccinated quad= women 27 and
above who have been vaccinated quad*"death rate for 27&above"
 death of number of women 12 to 26 who are vaccinated FiveAdditionalTypes=
women 12 to 26 FiveAdditionalTypes who have been vaccinated*death rate 12 to
26
 new vaccination of 12to 26 FiveAdditionalTypes= total population of women 12 to
26 FiveAdditionalTypesvalent*"vacc rate (FiveAdditionalTypes)"
 death of women 27 and above who have been vaccinated FiveAdditionalTypes=
 Women 27 and above who have been vaccinated FiveAdditionalTypes*"death
rate for 27&above"
 Women 27 and above who have been vaccinated FiveAdditionalTypes= INTEG
(aging into women 27 and above who have been vaccinated
FiveAdditionalTypes-death of women 27 and above who have been vaccinated
FiveAdditionalTypes, 0)
 fraction of women 12 to 26 who have been vaccinated = women 12 to 26
FiveAdditionalTypes who have been vaccinated/total population of women 12 to
26 FiveAdditionalTypesvalent
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 aging women 12 to 26 who have been vaccinated FiveAdditionalTypes= women
12 to 26 FiveAdditionalTypes who have been vaccinated/mean years until aging
 women 12 to 26 FiveAdditionalTypes who have been vaccinated= INTEG (new
vaccination of 12to 26 FiveAdditionalTypes-death of number of women 12 to 26
who are vaccinated FiveAdditionalTypes-aging women 12 to 26 who have been
vaccinated FiveAdditionalTypes,0)
 Women 12 to 26 who have been vaccinated quad= INTEG (new vaccinations of
12 to 26 women-aging number of women 12 to 26 who are vaccinated quaddeath of number of women 12 to 26 who are vaccinated, 0)
 new vaccinations of 12 to 26 women= total population of women 12 to 26
quadrivalent*vacc rate
 aging number of women 12 to 26 who are vaccinated quad= Women 12 to 26
who have been vaccinated quad/mean years until aging
 death of number of women 12 to 26 who are vaccinated= Women 12 to 26 who
have been vaccinated quad*death rate 12 to 26
 vacc quad= Susceptible12to26 quad* vacc rate*vaccine efficacy
 fraction of women 12 to 26 who have been vaccinated quad=
 Women 12 to 26 who have been vaccinated quad/total population of women 12
to 26 quadrivalent
 vacc rate= 0.053
 fraction of susceptible women 27 and above FiveAdditionalTypes= Susceptible
27and above FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent
 Fraction of women susceptible 12 to 26 quad= Susceptible12to26 quad/total
population of women 12 to 26 quadrivalent
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 Fraction of women susceptible 12 to 26 FiveAdditionalTypes= susceptible 12
to26 FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent
 fraction of women that are susceptible for 27 and above quad= Susceptible
27and above quad/total population of women 27 and above quadrivalent
 Inital 27 and above CIN1 infected women from HPV quad infected= fraction of
women 27 and above who were infected with quad and are CIN1*Initial 27 and
above HPV quad infected women from US census including CIN1
 HPV infected 27 and above FiveAdditionalTypes= INTEG (aging into hpv infected
FiveAdditionalTypes+"infection 27&above FiveAdditionalTypes"-"clearance of
infection 27&above FiveAdditionalTypes"-infected 27 and above deaths
FiveAdditionalTypes-"prog1 27 & above FiveAdditionalTypes", initially HPV
infected women 27 and above not CIN1 FiveAdditionalTypes)
 fraction of women 27 from US census who are infected with HPV quad strain=
0.24
 initially infected HPV women 12 to 26 from US census for FiveAdditionalTypes
that are not CIN1= Initially infected HPV women 12 to 26 from US census
including CIN1 for FiveAdditionalTypes-Initially HPV infected 12 to 26 women
with FiveAdditionalTypes who are at CIN1
 Initially susceptible women 12 to 26 from US census=Total initial population 12 to
26 from US census-(Initially CIN1 infected women from HPV infected
women+Initially HPV infected women from US census for quad not CIN1)
 HPV infected 12 to 26 quad= INTEG (infection rate among 12to26 quad-aging
hpv infected 12 to 26 quad-deaths of infected 12 to 26 quad-HPV infected
clearance rate 12 to 26 quad-progression1 among 12 to 26 quad, Initially HPV
infected women from US census for quad not CIN1)
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 Initially susceptible women 12 to 26 from US census for FiveAdditionalTypes=
Total initial population 12 to 26 from US census-(Initially HPV infected 12 to 26
women with FiveAdditionalTypes who are at CIN1+initially infected HPV women
12 to 26 from US census for FiveAdditionalTypes that are not CIN1)
 Initially HPV infected women 27 and above from US census for quad not CIN1=
Initial 27 and above HPV quad infected women from US census including CIN1-Inital
27 and above CIN1 infected women from HPV quad infected
 Initial susceptible women 27 and above from US census FiveAdditionalTypes=
total initial population 27 and above from US census-(initially HPV infected
women 27 and above not CIN1 FiveAdditionalTypes +Initial 27 and above at
CIN1 from HPV infected women with FiveAdditionalTypes strain)
 total population of women 27 and above quadrivalent= HPV infected 27and
above quad+ Susceptible 27and above quad+CIN1 27 and above quad +CIN2
27 and above quad+CIN3 27 and above quad+ Immune via vaccination 27 and
above quad+ Immune after HPV clearance 27 and above quad
 Initially susceptible women 27 and above from US census= total initial population
27 and above from US census-(Initially HPV infected women 27 and above from
US census for quad not CIN1+Initial 27 and above CIN1 infected women from
HPV quad infected)
 Initial 27 and above HPV quad infected women from US census including CIN1=
fraction of women 27 from US census who are infected with HPV quad
strain*total initial population 27 and above from US census
 initially HPV infected women 27 and above not CIN1 FiveAdditionalTypes=
Initially infected 27 and above with HPV FiveAdditionalTypes including CIN1Inital 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes
strain
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 total population of women 12 to 26 quadrivalent= HPV infected 12 to 26 quad+
Susceptible12to26 quad+CIN1 12 to 26 quad+ CIN2 12 to 26 quad+CIN3 12 to
26 quad+ Immune via vaccination 12to26 quad+ Immune after HPV infection
clearance 12 to 26 quad
 total population of women 12 to 26 FiveAdditionalTypesvalent= CIN1 12 to26
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26
FiveAdditionalTypes+HPV infected 12to26 FiveAdditionalTypes +susceptible 12
to26 FiveAdditionalTypes+immune via vacc 12 to 26 FiveAdditionalTypes
+Immune after HPV infection 12 to26 FiveAdditionalTypes
 Initially HPV infected women from US census for quad not CIN1= Initially HPV
infected women from US census for quad including CIN1-Initially CIN1 infected
women from HPV infected women
 total population of women 27 and above FiveAdditionalTypesvalent= CIN1 27
and above FiveAdditionalTypes+CIN2 27 and above FiveAdditionalTypes+CIN3
27 and above FiveAdditionalTypes +HPV infected 27 and
aboveFiveAdditionalTypes+ Susceptible 27and above FiveAdditionalTypes
+immune via vaccination 27 and above FiveAdditionalTypes +Immune after HPV
infection 27and above FiveAdditionalTypes
 HPV infected 27and above quad= INTEG (Aging into HPV infected 27+"infection
27&above quad"-clearance of HPV infected 27 and above quad-"deaths of
infected 27&above quad"-prog1 27and above quad, Initially HPV infected women
27 and above from US census for quad not CIN1)
 Immune after HPV clearance 27 and above quad= INTEG (aging into immune
after HPV clearance 27 and above quad+"clear2 27 & above quad"+"clear3
27&above quad"+clearance of HPV infected 27 and above quad+"clearance1
27&above quad"+"rx1 27&above quad"+"rx2 27&above quad"+"rx3 27&above
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quad"-death of immune after HPV clearance 27 and above-waning immunity after
infection among 27 and above quad,0)
 Susceptible 27and above quad= INTEG (Aging into susceptible 27+waning
immunity after infection among 27 and above quad-"infection 27&above quad" susceptible27 deaths+ "waning immunity among 27 and above (quad)", Initially
susceptible women 27 and above from US census)
 Immune after HPV infection 27and above FiveAdditionalTypes= INTEG (aging
into immune after HPV infection 27 and above FiveAdditionalTypes+"clearance
of infection 27&above FiveAdditionalTypes"+"clearance1 27 & above
FiveAdditionalTypes"+clearance2 FiveAdditionalTypes+clearance3
FiveAdditionalTypes+"rx1 27& above FiveAdditionalTypes"+"rx2 27& above
FiveAdditionalTypes"+"rx3 27&above FiveAdditionalTypes"-Deaths of immune
after vaccination 27 and above FiveAdditionalTypes-waning immunity after
infection 27 and above nano, 0)
 susceptible 12 to26 FiveAdditionalTypes= INTEG ("Aging females <12
FiveAdditionalTypes"+waning immunity after vaccination 12to 26 nano +waning
immunity of 27 and above FiveAdditionalTypes-death of susceptible 12to 26noinfection 12to26FiveAdditionalTypes-Susceptible 12 to 26 FiveAdditionalTypes
aging-vacc FiveAdditionalTypes, Initially susceptible women 12 to 26 from US
census for FiveAdditionalTypes)
 immune via vacc 12 to 26 FiveAdditionalTypes= INTEG (vacc
FiveAdditionalTypes-aging of immune 12 to 26 FiveAdditionalTypes-deaths of
immune 12 to 26 FiveAdditionalTypes -waning immunity after vaccination 12to 26
nano-waning immunity after vaccination 12to 26 nano,0)
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 "rx2 27& above FiveAdditionalTypes"= Fraction of CIN2 successfully
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3 *CIN2 27
and above FiveAdditionalTypes
 Immune via vaccination 12to26 quad= INTEG (vacc quad-aging immune via
vaccination 12 to 26 quad-deaths of immune 12 to 26 quad-waning immunity
after vaccination among 12to26quad, 0)
 Susceptible12to26 quad= INTEG ("Aging of female <12"-aging susceptible 12to
26 quad-deaths of susceptible 12 to 26 quad-infection rate among 12to26 quadvacc quad+ Waning immunity after infection 12 to 26 quad +waning immunity
after vaccination among 12to26quad, Initially susceptible women 12 to 26 from
US census)
 waning immunity after infection among 27 and above quad= Immune after HPV
clearance 27 and above quad/Time until waning immunity after infection
 Susceptible 27and above FiveAdditionalTypes= INTEG (aging into susceptible
27 and FiveAdditionalTypes+waning immunity after infection 27 and above nano"infection 27&above FiveAdditionalTypes"-susceptible 27 and above
deaths+waning immunity after vaccination 27 and above FiveAdditionalTypes,
Initial susceptible women 27 and above from US census FiveAdditionalTypes)
 time until waning immunity after vaccination= 10
 waning immunity after vaccination among 12to26quad= (Immune via vaccination
12to26 quad/time until waning immunity after vaccination) *"enable waning
immunity after vaccination?"
 "enable waning immunity after vaccination?"=0
 waning immunity after vaccination 12to 26 nano= (immune via vacc 12 to 26
FiveAdditionalTypes/time until waning immunity after vaccination)*"enable
waning immunity after vaccination?"
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 rx2 12to26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN2
successfully cured*CIN2 12 to 26 quad
 waning immunity after vaccination 27 and above FiveAdditionalTypes= (immune
via vaccination 27 and above FiveAdditionalTypes/time until waning immunity
after vaccination) *"enable waning immunity after vaccination?"
 waning immunity after infection 27 and above nano= Immune after HPV infection
27and above FiveAdditionalTypes/Time until waning immunity after infection
 "waning immunity among 27 and above (quad)"= (Immune via vaccination 27 and
above quad/time until waning immunity after vaccination) *"enable waning
immunity after vaccination?"
 fraction of women 12to26 immune via vaccination quad= Immune via vaccination
12to26 quad/total population of women 12 to 26 quadrivalent
 waning immunity of 27 and above FiveAdditionalTypes= Immune after HPV
infection 12 to26 FiveAdditionalTypes/Time until waning immunity after infection
 aging of immune after HPV infection 12 to 26 FiveAdditionalTypes= Immune after
HPV infection 12 to26 FiveAdditionalTypes/mean years until aging
 aging into immune after HPV clearance 27 and above quad= aging of immune
after HPV infection clearance 12 to 26 quad
 Immune after HPV infection 12 to26 FiveAdditionalTypes= INTEG (clearance1
12to26 FiveAdditionalTypes+clearance2 12to 26FiveAdditionalTypes+clearance3
12to26 FiveAdditionalTypes +rx1 12to26 FiveAdditionalTypes+rx2 12to26
FiveAdditionalTypes+rx3 12to26 FiveAdditionalTypes-deaths of immune after
HPV infection 12 to 26 FiveAdditionalTypes-waning immunity of 27 and above
FiveAdditionalTypes -aging of immune after HPV infection 12 to 26
FiveAdditionalTypes+clearance hpv infected 12 to 26FiveAdditionalTypes,0)
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 deaths of immune after HPV infection 12 to 26 FiveAdditionalTypes= death rate
12 to 26*Immune after HPV infection 12 to26 FiveAdditionalTypes
 Deaths of immune after vaccination 27 and above FiveAdditionalTypes="death
rate for 27&above"*Immune after HPV infection 27and above
FiveAdditionalTypes
 aging into immune after HPV infection 27 and above FiveAdditionalTypes= aging
of immune after HPV infection 12 to 26 FiveAdditionalTypes
 Waning immunity after infection 12 to 26 quad= Immune after HPV infection
clearance 12 to 26 quad/Time until waning immunity after infection
 Time until waning immunity after infection=5
 incidence of cc per 100000 12to26= (Progression4 among 12 to 26 quad/total
population of women 12 to 26 quadrivalent) * 100000
 aging of immune after HPV infection clearance 12 to 26 quad= Immune after
HPV infection clearance 12 to 26 quad/mean years until aging
 deaths of immune after HPV infection clearance= Immune after HPV infection
clearance 12 to 26 quad*death rate 12 to 26
 death of immune after HPV clearance 27 and above= Immune after HPV
clearance 27 and above quad*"death rate for 27&above"
 Immune after HPV infection clearance 12 to 26 quad= INTEG (HPV infected
clearance rate 12 to 26 quad+clearance1 among 12to26 quad+clearance2
among 12to26 quad+clearance3 among 12 to 26 quad+rx1 12to26 quad+rx2
12to26 quad+rx3 12 to 26 quad-Waning immunity after infection 12 to 26 quadaging of immune after HPV infection clearance 12 to 26 quad-deaths of immune
after HPV infection clearance, 0)
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 force of infection 12to26 quad= mean partner acquisition 12 to 26*(Fraction of
partners of 12 to 26 year old women that are in 12 to 26 year of age* HPV
prevalence 12 to 26 quad + (1-Fraction of partners of 12 to 26 year old women
that are in 12 to 26 year of age) * HPV prevalence 27 and above quad)
*transmission rate 12to26
 force of infection 12 to 26 FiveAdditionalTypes= mean partner acquisition 12 to
26*(Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of
age* HPV prevalence 12to26FiveAdditionalTypes + (1-Fraction of partners of 12
to 26 year old women that are in 12 to 26 year of age) * HPV prevalence 27 and
above FiveAdditionalTypes)* transmission rate 12to26
 transmission rate 12to26= 0.4
 CIN3 27 and above deaths FiveAdditionalTypes= "death rate for
27&above"*CIN3 27 and above FiveAdditionalTypes
 CIN3 12to26 FiveAdditionalTypes= INTEG (prog3 12 to 26FiveAdditionalTypesCIN3 12 to 26 FiveAdditionalTypes aging-CIN3 deaths
12to26FiveAdditionalTypes-clearance3 12to26 FiveAdditionalTypes-reg2 26noreg3 12 to 26FiveAdditionalTypes-rx3 12to26 FiveAdditionalTypes+prog3 12 to
26FiveAdditionalTypes-progression4 12to26 FiveAdditionalTypes,0)
 "CIN3 27 & above death quad"= "death rate for 27&above"*CIN3 27 and above
quad
 CIN3 27 and above FiveAdditionalTypes= INTEG (aging into cin3
FiveAdditionalTypes+"prog3 27& above FiveAdditionalTypes"-CIN3 27 and
above deaths FiveAdditionalTypes-clearance3 FiveAdditionalTypes-"prog4
27&above FiveAdditionalTypes"-"reg2 27 &above FiveAdditionalTypes" -"reg3
27&above FiveAdditionalTypes"-"rx3 27&above FiveAdditionalTypes"+"prog3
27& above FiveAdditionalTypes"-"prog4 27&above FiveAdditionalTypes", 0)
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 CIN3 27 and above quad= INTEG ("Aging into CIN3 27&above quad"+prog3
27and above quad-"CIN3 27 & above death quad"- "clear3 27&above quad""reg2 27&above quad"-reg3 27 and above quad-"rx3 27&above quad"+prog3
27and above quad-prog4 27and above quad, 0)
 "CIN1 27&above deaths quad"= "death rate for 27&above"*CIN1 27 and above
quad
 immune via vacc deaths quad= Immune via vaccination 27 and above
quad*"death rate for 27&above"
 Cumulative cervical cancer cases 12 to 26 FiveAdditionalTypes= INTEG
(progression4 12to26 FiveAdditionalTypes,0)
 Cumulative Cervical Cancer cases 27 and above FiveAdditionalTypes= INTEG
("prog4 27&above FiveAdditionalTypes",0)
 "cumulative cervical cancer cases quad 27&above"= INTEG (prog4 27and above
quad,0)
 infected 27 and above deaths FiveAdditionalTypes= "death rate for
27&above"*HPV infected 27 and above FiveAdditionalTypes
 prog4 27and above quad= CIN3 27 and above quad*CIN3 to cervical cancer
hazard rate
 "death rate for 27&above"= 0.00541
 Progression4 among 12 to 26 quad= CIN3 to cervical cancer hazard rate*CIN3
12 to 26 quad
 "CIN1 27 &above deaths FiveAdditionalTypes"=CIN1 27 and above
FiveAdditionalTypes*"death rate for 27&above"
 susceptible27 deaths=Susceptible 27and above quad*"death rate for 27&above"
 "CIN2 27&above deaths FiveAdditionalTypes"=CIN2 27 and above
FiveAdditionalTypes*"death rate for 27&above"
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 deaths of immune 27 and above FiveAdditionalTypes="death rate for
27&above"*immune via vaccination 27 and above FiveAdditionalTypes
 susceptible 27 and above deaths="death rate for 27&above"*Susceptible 27and
above FiveAdditionalTypes
 prog4 27 and above quad per 100000=(prog4 27and above quad/total population
of women 27 and above quadrivalent)*100000
 CIN3 12 to 26 quad= INTEG (-Aging CIN3 12 to 26 FiveAdditionalTypesclearance3 among 12 to 26 quad-deaths of CIN3 12 to 26 quad-regression2
12to26 quad-Regression3 12to26 quad-rx3 12 to 26 quad+progression3 among
12 to 26 quad-Progression4 among 12 to 26 quad,0)
 CIN2 deaths among 27 and above quad= CIN2 27 and above quad*"death rate
for 27&above"
 "deaths of infected 27&above quad"=HPV infected 27and above quad*"death
rate for 27&above"
 Cumulative cervical cancer cases 12 to 26 quad= INTEG (Progression4 among
12 to 26 quad,0)
 total population of men and women FiveAdditionalTypes= total population of
women FiveAdditionalTypesvalent*(1+Ratio of male to female population)
 "Initial susceptible women <12 years FiveAdditionalTypesvalent"= 37112
 "Female <12 FiveAdditionalTypes"= INTEG (birth FiveAdditionalTypes-"Aging
females <12 FiveAdditionalTypes"-"death of females <12 years","Initial
susceptible women <12 years FiveAdditionalTypesvalent")
 total population of men and women quad=total population of women
quadrivalent*(1+Ratio of male to female population)
 birth FiveAdditionalTypes= birth rate for female babies*total population of men
and women FiveAdditionalTypes
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 birth quad= total population of men and women quad*birth rate for female babies
 Ratio of male to female population= 0.98
 rx3 12 to 26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN3
successfully cured*CIN3 12 to 26 quad
 "rx3 27&above FiveAdditionalTypes"= Fraction of CIN3 successfully
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN3 27
and above FiveAdditionalTypes
 "rx1 27& above FiveAdditionalTypes"= Fraction of CIN1 sucessfully
cured*screening rate FiveAdditionalTypes*sensitivity CIN1*CIN1 27 and above
FiveAdditionalTypes
 rx1 12to26 quad= sensitivity CIN1*screening rate*Fraction of CIN1 sucessfully
cured*CIN1 12 to 26 quad
 HPV infected FiveAdditionalTypes per 100000= (HPV infected 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 CIN3 among 12 to 26 per 100000 quad= (CIN3 12 to 26 quad/total population of
women 12 to 26 quadrivalent)*100000
 CIN2 12to26 quad per 100000=(CIN2 12 to 26 quad/total population of women
12 to 26 quadrivalent)*100000
 CIN3 FiveAdditionalTypes per 100000= (CIN3 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 CIN2 27 and above per 100000 quad= (CIN2 27 and above quad/total population
of women 27 and above quadrivalent)*100000
 CIN1 12to26 per 100000 quad= (CIN1 12 to 26 quad/total population of women
12 to 26 quadrivalent)*100000

164
 CIN1 26FiveAdditionalTypes per 100000= (CIN1 12 to26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
 hpv infected 27 and above per 100000 quad= (HPV infected 27and above
quad/total population of women 27 and above quadrivalent)*100000
 "CIN1 27& above FiveAdditionalTypes per 100000"= (CIN1 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 CIN3 12 to 26 per 100000 FiveAdditionalTypes= (CIN3 12to26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
 "CIN1 27&above per 100000 quad"= (CIN1 27 and above quad/total population
of women 27 and above quadrivalent)*100000
 CIN3 27 and above per 100000 quad= (CIN3 27 and above quad/total population
of women 27 and above quadrivalent)*100000
 CIN2 12 to 26per 100000 FiveAdditionalTypes= (CIN2 12to 26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
 "total population of women (quad+FiveAdditionalTypes)"=total population of
women 12 to 26 FiveAdditionalTypesvalent+total population of women 12 to 26
quadrivalent+total population of women 27 and above
FiveAdditionalTypesvalent+total population of women 27 and above quadrivalent

 total population= "total population of women (quad+FiveAdditionalTypes)"*ratio of
total population to total population of women
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 "CIN2 27&above FiveAdditionalTypes per 100000"= (CIN2 27 and above
FiveAdditionalTypes/total population of women 27 and above
FiveAdditionalTypesvalent)*100000
 HPV infected 12 to 26 per 100000 quad= (HPV infected 12 to 26 quad/total
population of women 12 to 26 quadrivalent)*100000
 hpv infected 12 to 26FiveAdditionalTypes per 100000= (HPV infected 12to26
FiveAdditionalTypes/total population of women 12 to 26
FiveAdditionalTypesvalent)*100000
 Aging into HPV infected 27= aging hpv infected 12 to 26 quad
 "Females <12 quad"= INTEG ( birth quad-"Aging of female <12"-"death of
females< 12 years of age", "Initial susceptible females <12 quad")
 "Initial susceptible females <12 quad"= 724633
 total population of women FiveAdditionalTypesvalent= total population of women
12 to 26 FiveAdditionalTypesvalent+total population of women 27 and above
FiveAdditionalTypesvalent
 "HPV Infection (quad) among 12 to 26 count"= CIN1 12 to 26 quad+CIN2 12 to
26 quad+CIN3 12 to 26 quad+HPV infected 12 to 26 quad
 HPV prevalence 27 and above FiveAdditionalTypes= ("HPV infection among 27
and above (FiveAdditionalTypes) count")/total population of women 27 and
above FiveAdditionalTypesvalent
 HPV prevalence 12 to 26 quad=("HPV Infection (quad) among 12 to 26
count")/total population of women 12 to 26 quadrivalent
 "HPV infection among 12 to 26 (FiveAdditionalTypes) count"= CIN1 12 to26
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26
FiveAdditionalTypes+HPV infected 12to26 FiveAdditionalTypes
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 "HPV infection among 27 and above (FiveAdditionalTypes) count"= HPV infected
27 and above FiveAdditionalTypes+CIN1 27 and above FiveAdditionalTypes+
CIN2 27 and above FiveAdditionalTypes+CIN3 27 and above
FiveAdditionalTypes
 "HPV infection among 27 and above (quad) count"= CIN1 27 and above
quad+CIN2 27 and above quad+CIN3 27 and above quad+HPV infected 27and
above quad
 HPV prevalence 12to26FiveAdditionalTypes= ("HPV infection among 12 to 26
(FiveAdditionalTypes) count")/total population of women 12 to 26
FiveAdditionalTypesvalent
 HPV prevalence 27 and above quad= ("HPV infection among 27 and above
(quad) count")/total population of women 27 and above quadrivalent
 CIN1 12 to 26 quad= INTEG (progression1 among 12 to 26 quad+regression1
12to26 quad+Regression3 12to26 quad-aging CIN1 12to26 quad-clearance1
among 12to26 quad-deaths of CIN1 12to26 quad-progression2 among 12 to 26
quad-rx1 12to26 quad, Initially CIN1 infected women from HPV infected women)
 CIN1 27 and above FiveAdditionalTypes= INTEG (aging into CIN1
FiveAdditionalTypes+"prog1 27 & above FiveAdditionalTypes"+"reg1 27&above
FiveAdditionalTypes"+"reg3 27&above FiveAdditionalTypes"-"CIN1 27 &above
deaths FiveAdditionalTypes"-"clearance1 27 & above FiveAdditionalTypes""prog2 27& above FiveAdditionalTypes"-"rx1 27& above FiveAdditionalTypes",
Initial 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes
strain)
 total population of women quadrivalent= total population of women 12 to 26
quadrivalent+total population of women 27 and above quadrivalent
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 deaths of immune 12 to 26 FiveAdditionalTypes= death rate 12 to 26*immune via
vacc 12 to 26 FiveAdditionalTypes
 aging into immune via vaccination 27 and above quad= aging immune via
vaccination 12 to 26 quad
 deaths of immune 12to 26 FiveAdditionalTypes= death rate 12 to 26*immune via
vacc 12 to 26 FiveAdditionalTypes
 aging immune via vaccination 12 to 26 quad=Immune via vaccination 12to26
quad/mean years until aging
 aging into immune via vacc 27 and above FiveAdditionalTypes= aging of immune
12 to 26 FiveAdditionalTypes
 immune via vaccination 27 and above FiveAdditionalTypes= INTEG (aging into
immune via vacc 27 and above FiveAdditionalTypes-deaths of immune 27 and
above FiveAdditionalTypes-waning immunity after vaccination 27 and above
FiveAdditionalTypes, 0)
 Immune via vaccination 27 and above quad= INTEG (aging into immune via
vaccination 27 and above quad-"waning immunity among 27 and above (quad)"immune via vacc deaths quad,0)
 aging of immune 12 to 26 FiveAdditionalTypes= immune via vacc 12 to 26
FiveAdditionalTypes/mean years until aging
 vacc FiveAdditionalTypes= susceptible 12 to26 FiveAdditionalTypes*"vacc rate
(FiveAdditionalTypes)"*vaccine efficacy
 HPV prevalence 27 and above per 100 quad= HPV prevalence 27 and above
quad*100
 HPV prevalence 12 to 26 per 100 FiveAdditionalTypes= HPV prevalence
12to26FiveAdditionalTypes*100
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 HPV prevalence 27 and above FiveAdditionalTypes per 100= HPV prevalence 27
and above FiveAdditionalTypes*100
 HPV prevalence 12 to 26 quad per 100= HPV prevalence 12 to 26 quad*100
 CIN1 27 and above quad= INTEG ("Aging into CIN1 27&above quad"+prog1
27and above quad+reg1 27 and above quad+reg3 27 and above quad-"CIN1
27&above deaths quad"-"clearance1 27&above quad"-prog2 27and above quad"rx1 27&above quad", Initial 27 and above CIN1 infected women from HPV quad
infected)
 fraction of women 27 and above who were infected with quad and are CIN1=0.1
 Total initial population 12 to 26 from US census=976958
 total initial population 27 and above from US census=3.43899e+006
 Initially HPV infected 12 to 26 women with FiveAdditionalTypes who are at CIN1=
Initially infected HPV women 12 to 26 from US census including CIN1
forFiveAdditionalTypes *Fraction of 12 to 26 years who are intially infected with
HPV FiveAdditionalTypes who have CIN1
 Initially HPV infected women from US census for quad including CIN1=Total
initial population 12 to 26 from US census*Fraction of women 12 to 26 from US
census who are HPV infected for quad strain
 Initially infected HPV women 12 to 26 from US census including CIN1 for
FiveAdditionalTypes= Fraction of US 12 to 26 census population that is initially
infected with FiveAdditionalTypes strain of HPV*Total initial population 12 to 26
from US census
 Fraction of women 27 and above from HPV FiveAdditionalTypes infected that are
CIN1=0.1184
 fraction of women 27 and above from susceptible that are infected with HPV
FiveAdditionalTypes= 0.04
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 Fraction of 12 to 26 years old who are initially infected with quad strains of HPV
who have CIN1= 0.09
 Initially CIN1 infected women from HPV infected women= Initially HPV infected
women from US census for quad including CIN1*Fraction of 12 to 26 years old
who are initially infected with quad strains of HPV who have CIN1
 Initally infected 27 and above with HPV FiveAdditionalTypes including CIN1=
fraction of women 27 and above from susceptible that are infected with HPV
FiveAdditionalTypes *total intial population 27 and above from US census
 Initial 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes
strain= Fraction of women 27 and above from HPV FiveAdditionalTypes infected
that are CIN1*Initially infected 27 and above with HPV FiveAdditionalTypes
including CIN1
 Fraction of women 12 to 26 from US cenus who are HPV infected for quad
strain= 0.18
 Fraction of 12 to 26 years who are intially infected with HPV FiveAdditionalTypes
who have CIN1= 0.09
 Fraction of US 12 to 26 census population that is initially infected with
FiveAdditionalTypes strain of HPV=0.12
 death of susceptible 12to 26no= susceptible 12 to26 FiveAdditionalTypes*death
rate 12 to 26
 CIN1 deaths 12to 26FiveAdditionalTypes= CIN1 12 to26
FiveAdditionalTypes*death rate 12 to 26
 deaths of CIN3 12 to 26 quad= death rate 12 to 26*CIN3 12 to 26 quad
 deaths of immune 12 to 26 quad= Immune via vaccination 12to26 quad*death
rate 12 to 26
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 deaths of infected 12 to 26 quad= death rate 12 to 26*HPV infected 12 to 26
quad
 CIN3 deaths 12to26FiveAdditionalTypes= CIN3 12to26
FiveAdditionalTypes*death rate 12 to 26
 CIN2 deaths 12to 26 FiveAdditionalTypes= CIN2 12to 26
FiveAdditionalTypes*death rate 12 to 26
 CIN2 27 and above quad= INTEG (Aging into CIN2 27 and above quad-"clear2
27 & above quad"+prog2 27and above quad-prog3 27and above quad+"reg2
27&above quad"-CIN2 deaths among 27 and above quad-reg1 27 and above
quad-"rx2 27&above quad",0)
 deaths infected 12to 26 FiveAdditionalTypes= HPV infected 12to26
FiveAdditionalTypes*death rate 12 to 26
 deaths of CIN2 12 to 26 quad=death rate 12 to 26*CIN2 12 to 26 quad
 CIN2 27 and above FiveAdditionalTypes= INTEG (aging into cin2
FiveAdditionalTypes+"prog2 27& above FiveAdditionalTypes"+"reg2 27 &above
FiveAdditionalTypes"-"CIN2 27&above deaths FiveAdditionalTypes"-clearance2
FiveAdditionalTypes-"prog3 27& above FiveAdditionalTypes"-"reg1 27&above
FiveAdditionalTypes"-"rx2 27& above FiveAdditionalTypes", 0)
 deaths of CIN1 12to26 quad= CIN1 12 to 26 quad*death rate 12 to 26
 deaths of susceptible 12 to 26 quad=Susceptible12to26 quad*death rate 12 to 26
 Ref Rate of clearance of CIN1 quad 12 to 26= 0.483
 Ref Rate of clearance of CIN2 quad 12 to 26= 0.21
 Ref Rate of clearance of CIN3 quad 12 to 26= 0.11
 vaccine efficacy= 0.9
 "death of females< 12 years of age"= "death rate of females <12
years"*"Females <12 quad"
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 "death rate of females <12 years"= 0.0002195
 "death of females <12 years"= "death rate of females <12 years"*"Female <12
FiveAdditionalTypes"
 force of infection 27 and above quad= mean partner acquisition rate 27 and
above*(fraction of partners 27 years and older women that are in 27 years and
older *HPV prevalence 27 and above quad +(1-fraction of partners 27 years and
older women that are in 27 years and older) *HPV prevalence 12 to 26
quad)*transmission rate 27 and above
 force of infection 27 and above FiveAdditionalTypes= mean partner acquisition
rate 27 and above * (fraction of partners 27 years and older women that are in 27
years and older * HPV prevalence 27 and above FiveAdditionalTypes + (1fraction of partners 27 years and older women that are in 27 years and older) *
HPV prevalence 12to26FiveAdditionalTypes)*transmission rate 27 and above
 fraction of partners 27 years and older women that are in 27 years and older=
0.915
 Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of age=
0.33
 "Aging females <12 FiveAdditionalTypes"= "Female <12
FiveAdditionalTypes"/"mean years of aging for <12 years old”
 "Aging of female <12"= "Females <12 quad"/"mean years of aging for <12 years
old"
 "mean years of aging for <12 years old"= 12
 reg3 27 and above quad= CIN3 27 and above quad*Rate of Reg CIN3 to CIN1
 Fraction of CIN1 sucessfully cured=0.96
 reg1 12 to 26FiveAdditionalTypes= Rate of regression CIN2 to CIN1*CIN2 12to
26 FiveAdditionalTypes
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 reg2 26no= Rate of Reg CIN3 to CIN2*CIN3 12to26 FiveAdditionalTypes
 "reg2 27&above quad"= Rate of Reg CIN3 to CIN2*CIN3 27 and above quad
 "reg2 27 &above FiveAdditionalTypes"= Rate of Reg CIN3 to CIN2*CIN3 27 and
above FiveAdditionalTypes
 reg3 12 to 26FiveAdditionalTypes= Rate of Reg CIN3 to CIN1*CIN3 12to26
FiveAdditionalTypes
 regression2 12to26 quad= Rate of Reg CIN3 to CIN2*CIN3 12 to 26 quad
 Regression3 12to26 quad= Rate of Reg CIN3 to CIN1*CIN3 12 to 26 quad
 Rate of Reg CIN3 to CIN2=0.03
 regression1 12to26 quad= Rate of regression CIN2 to CIN1*CIN2 12 to 26 quad
 "reg1 27&above FiveAdditionalTypes"= Rate of regression CIN2 to CIN1*CIN2
27 and above FiveAdditionalTypes
 reg1 27 and above quad= CIN2 27 and above quad*Rate of regression CIN2 to
CIN1
 Rate of Reg CIN3 to CIN1= 0.03
 Fraction of CIN3 successfully cured= 0.92
 Rate of regression CIN2 to CIN1= 0.133
 "reg3 27&above FiveAdditionalTypes"= Rate of Reg CIN3 to CIN1*CIN3 27 and
above FiveAdditionalTypes
 Fraction of CIN2 successfully cured= 0.92
 CIN3 to cervical cancer hazard rate= 0.42
 progression1 among 12 to 26 quad= HPV infected to CIN1 hazard rate*HPV
infected 12 to 26 quad
 progression2 among 12 to 26 quad= CIN1 to CIN2 hazard rate*CIN1 12 to 26
quad
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 progression3 among 12 to 26 quad= CIN2 to CIN3 hazard rate*CIN2 12 to 26
quad
 HPV infected to CIN1 hazard rate= 0.094
 prog2 27and above quad= CIN1 to CIN2 hazard rate*CIN1 27 and above quad
 prog3 27and above quad= CIN2 to CIN3 hazard rate*CIN2 27 and above quad
 CIN2 to CIN3 hazard rate= 0.154
 prog1 27and above quad=HPV infected to CIN1 hazard rate*HPV infected 27and
above quad
 CIN1 to CIN2 hazard rate= 0.136
 "Aging into CIN1 27&above quad"= aging CIN1 12to26 quad
 aging into CIN1 FiveAdditionalTypes= CIN1 12 to 26 FiveAdditionalTypes aging
 Aging into CIN2 27 and above quad= aging CIN2 12to 26 quad
 aging into cin2 FiveAdditionalTypes= CIN2 12to26 FiveAdditionalTypes aging
 "Aging into CIN3 27&above quad"=Aging CIN3 12 to 26 FiveAdditionalTypes
 aging into cin3 FiveAdditionalTypes= CIN3 12 to 26 FiveAdditionalTypes aging
 aging into hpv infected FiveAdditionalTypes= hpv infected 12 to
26FiveAdditionalTypes aging
 Aging into susceptible 27= aging susceptible 12to 26 quad
 aging into susceptible 27 and FiveAdditionalTypes= Susceptible 12 to 26
FiveAdditionalTypes aging
 CIN1 12 to 26 FiveAdditionalTypes aging= CIN1 12 to26
FiveAdditionalTypes/mean years until aging
 ratio of total population to total population of women= 2
 mean partner acquistion 12 to 26=1.64
 aging CIN1 12to26 quad= CIN1 12 to 26 quad/mean years until aging
 aging CIN2 12to 26 quad= CIN2 12 to 26 quad/mean years until aging

174
 aging hpv infected 12 to 26 quad= HPV infected 12 to 26 quad/mean years until
aging
 aging susceptible 12to 26 quad= Susceptible12to26 quad/mean years until aging
 Susceptible 12 to 26 FiveAdditionalTypes aging= susceptible 12 to26
FiveAdditionalTypes/mean years until aging
 CIN2 12to 26 FiveAdditionalTypes= INTEG (prog2
12to26FiveAdditionalTypes+reg2 26no-CIN2 deaths 12to 26
FiveAdditionalTypes-clearance2 12to 26 FiveAdditionalTypes -prog3 12 to
26FiveAdditionalTypes-reg1 12 to 26FiveAdditionalTypes-rx2 12to26
FiveAdditionalTypes -CIN2 12to26 FiveAdditionalTypes aging, 0)
 CIN2 12to26 FiveAdditionalTypes aging= CIN2 12to 26
FiveAdditionalTypes/mean years until aging
 hpv infected 12 to 26FiveAdditionalTypes aging= HPV infected 12to26
FiveAdditionalTypes/mean years until aging
 CIN3 12 to 26 FiveAdditionalTypes aging= CIN3 12to26
FiveAdditionalTypes/mean years until aging
 CIN2 12 to 26 quad= INTEG (+progression2 among 12 to 26 quad+regression2
12to26 quad-clearance2 among 12to26 quad-progression3 among 12 to 26
quad-regression1 12to26 quad-rx2 12to26 quad-aging CIN2 12to 26 quad-deaths
of CIN2 12 to 26 quad,0)
 Aging CIN3 12 to 26 FiveAdditionalTypes= CIN3 12 to 26 quad/mean years until
aging
 mean years until aging= 15
 birth rate for female babies= (0.0124 / 2)
 death rate 12 to 26= 0.000647
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 "total infected HPV 16 &18"= HPV infected 12 to 26 per 100000 quad+hpv
infected 27 and above per 100000 quad
 "total infected (5 additional types)"= hpv infected 12 to 26FiveAdditionalTypes per
100000+HPV infected FiveAdditionalTypes per 100000
 "total CIN1 HPV 16&18"= CIN1 12to26 per 100000 quad+"CIN1 27&above per
100000 quad"
 "total CIN1 (5 additional types)"= CIN1 26FiveAdditionalTypes per 100000+"CIN1
27& above FiveAdditionalTypes per 100000"
 "total CIN2 HPV 16 &18"= CIN2 12to26 quad per 100000+CIN2 27 and above
per 100000 quad
 "total CIN2 (5 additional types)"= CIN2 12 to 26per 100000
FiveAdditionalTypes+"CIN2 27&above FiveAdditionalTypes per 100000"
 "total CIN3 HPV 16&18"= CIN3 among 12 to 26 per 100000 quad+CIN3 27 and
above per 100000 quad
 "total CIN3 (5 additional types)"= CIN3 12 to 26 per 100000
FiveAdditionalTypes+CIN3 FiveAdditionalTypes per 100000
 total infected= HPV infected FiveAdditionalTypes per 100000+HPV infected 12 to
26 per 100000 quad+hpv infected 12 to 26FiveAdditionalTypes per 100000+hpv
infected 27 and above per 100000 quad
 total CIN 1= CIN1 12to26 per 100000 quad+"CIN1 27& above
FiveAdditionalTypes per 100000"+CIN1 26FiveAdditionalTypes per 100000
+"CIN1 27&above per 100000 quad"
 "infection 27&above quad"= force of infection 27 and above quad*Susceptible
27and above quad
 infection 12to26FiveAdditionalTypes=force of infection 12 to 26
FiveAdditionalTypes*susceptible 12 to26 FiveAdditionalTypes
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 total CIN2= "CIN2 27&above FiveAdditionalTypes per 100000"+CIN2 12to26
quad per 100000+CIN2 12 to 26per 100000 FiveAdditionalTypes+CIN2 27 and
above per 100000 quad
 total CIN3=CIN3 FiveAdditionalTypes per 100000+CIN3 among 12 to 26 per
100000 quad+CIN3 12 to 26 per 100000 FiveAdditionalTypes+CIN3 27 and
above per 100000 quad
 screening rate FiveAdditionalTypes=0.728
 "infection 27&above FiveAdditionalTypes"= force of infection 27 and above
FiveAdditionalTypes*Susceptible 27and above FiveAdditionalTypes
 infection rate among 12to26 quad= force of infection 12to26
quad*Susceptible12to26 quad
 Ref Rate of clearance of HPV infected quad 12 to 26= 0.483
 mean partner acquisition rate 27 and above= 1.19
 screening rate=0.728
 sensitivity CIN1= 0.28
 sensitivity CIN2and CIN3=0.59
 transmission rate 27 and above= 0.4

